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Abstract 
 
The absence of an effective humoral response contributes to the failure of 
controlling HIV-1 infection.  Methods to elicit a potent neutralising antibody 
response is still underway and this thesis explores three aspects that can affect 
neutralisation.  
 
The pseudovirus-based assay is now recommended as the standard assay for 
assessing neutralising antibody response.  However, recent studies have reported 
discrepancies between pseduovirus-based assay and conventional PBMCs or other 
cell-based assays.  The first aim is to investigate possible causes behind this 
difference.  The effect of virus producer cell type and virus platform (pseudovirus 
vs. replication-competent) was examined and both parameters can affect 
neutralisation.  
 
The second aim was to study the the neutralising antibody response in patients 
with primary HIV-1 infection.  A panel of 6 patients were selected from the 
SPARTAC clinical trial.  Pseudoviruses were constructed with the env gene 
derived from patient samples at week 0 (baseline) and week 52.  The evolutionary 
history and the neutralisation sensitivity of these primary isolates against a panel 
of broadly neutralising antibodies and heterologous and autologous sera were 
studied.  The week 52 isolates escaped from antisera neutralisation rapidly, most 
likely at the glycan level.  In addition, viral load was found to correlate directly 
with intra-patient viral diversity and evolutionary divergence over time.   
 
Finally, the effect of Nef on HIV-1 neutralisation was investigated.  Recent 
reports suggest that Nef modifies HIV-1 envelope glycoprotein.  Hence, 
neutralising antibody response might also be modified in the absence of Nef.  
When subjected to neutralisation with a panel of monoclonal antibodies, the Nef-
deleted (ΔNef) HIV-1 was more readily neutralised than the wild-type (WT) 
virus.  Immunoprecipitation assays showed that neutralising antibodies can 
capture ΔNef virus more efficiently than WT virus.  However, the enhanced 
neutralisation of ΔNef virus was neither due to CD4-down regulation nor 
difference in glycosylation.
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1.1 The epidemic 
 
More than 25 million people have died
1
 since the discovery of Acquired 
Immunodeficiency Syndrome (AIDS)
 2
 and its etiological agent, Human 
Immunodeficiency Virus (HIV)
 3
.  As of 2007, an estimated 33 million people are 
infected with HIV, two-thirds of them from sub-Saharan Africa
1
.  Although the 
introduction of antiretroviral therapy (ART) has greatly reduced mortality, only 3 
million people have access to it, accounting for just 31% of the population in need 
of it
1
.  Moreover, an effective vaccine remains beyond reach, despite intensive 
research efforts over the last two decades.  Further studies on the virology and 
immunology of HIV/AIDS are needed to find preventative methods of the 
infection and a cure for this epidemic.  
 
1.2 The  discovery of AIDS 
 
The symptoms of what it is now known as AIDS were first described and reported 
by the Centers for Disease Control and Prevention (CDC) in June 1981 in the 
United States
2
.  The public became aware of this emerging disease when a group 
of homosexual men developed a rare pneumonia infection, Pneumocystis jiroveci, 
and shortly after that, the CDC reported a high occurrence of Kaposi’s sarcoma, a 
rare form of skin cancer, also appearing in homosexual men
4
.  Although the 
infections were first associated with homosexual and bisexual men, other groups 
such as haemophiliacs, intravenous drug users and heterosexual Haitians were 
soon reported as having acquired similar symptoms
5
.  In all cases, patients were 
described with damaged immune systems, characterised by the depletion of T-
helper cells and the development of opportunistic infections and cancers
6
.  By 
September 1982, nearly 600 cases of AIDS had been reported, with a mortality 
rate of 41%, and yet, its cause was still unknown. 
 
1.3 The discovery of HIV 
 
In 1983 AIDS was first considered to be caused by a retrovirus, when Barre-
Sinoussi and associates at the Pasteur Institute (Paris, France) recovered a virus 
from the lymph node tissue of a French patient with Generalised 
12 
 
Lymphadenopathy
3
, a disease signalling the development of AIDS.  At the time, 
the virus was named as a lymphadenopathy-associated virus (LAV).  The LAV 
contained Reverse Transcriptase (RT) activity and displayed some characteristics 
similar to that of human T-cell leukaemia virus (HTLV)
3
.  However, unlike 
HTLV which immortalises CD4-positive (CD4
+
) T-cells in culture
7
, LAV kills 
lymphocytes, showing that it was phenotypically distinct from HTLV.  Later on, 
Gallo and associates reported the isolation of another human retrovirus from the 
peripheral blood mononuclear cells (PBMCs) of AIDS patients, which they 
named HTLV-III (also known as IIIB)
 8,9
.  However, the HTLV-III isolate was 
later confirmed to be the same virus as LAV
10
.  In addition, Levy and associates 
isolated retroviruses, termed AIDS-associated retroviruses (ARVs)
11
, from both 
AIDS patients and healthy individuals at risk of infection.  The report suggested 
that the retrovirus could induce both symptomatic and asymptomatic infections 
and suggested that individuals might experience a latency state prior to the 
appearance of clinical symptoms.  
 
Phenotypic and genotypic characterisation of LAV (HTLV-III/IIIB) and ARV 
categorised the viruses in the Lentivirus genus of the Retroviridae family
12,13
.  As 
was the case with animal lentiviruses, patients infected with the AIDS virus were 
found to have a long latency period prior to disease manifestation and persistent 
infection
14,15
.  Furthermore, the virus was capable of causing immune deficiency 
by depleting both infected and bystander CD4
+
 T-cells
16,17
.  To reflect better these 
properties of the AIDS virus, it was renamed Human Immunodeficiency Virus 
(HIV) in 1986
18
.  
 
A second subtype of HIV was discovered later in 1986 and was categorised as 
Human Immunodeficiency Virus type II (HIV-2)
19
, while the original subtype was 
designated as type I (HIV-1).  The genomic organisation of HIV-1 and HIV-2 is 
similar (Figure 1.1), except that the vpu gene is only present in HIV-1
20
.  In 
addition, vpx, a duplicate of the vpr gene, is found only in HIV-2
21
.  Compared to 
HIV-1, HIV-2 is less pathogenic.  Patients infected with HIV-2 maintain a higher 
level of CD4
+
 cells and progress to AIDS more slowly
22,23
.  Several factors have 
been investigated to explain the reduced pathogenicity of HIV-2.   
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Figure 1.1 – Genomic organisation of HIV-1 and HIV-2 
 
 
 
 
 
 
 
 
Figure 1.1 The genomic organisation of HIV-1 and HIV-2 is similar.  The HIV 
genome is approximately 9749 nucleotides in length and encodes 10 different 
genes
12,13
.  Note viral protein U (vpu) is only present in HIV-1, while viral protein 
X (vpx) is only present in HIV-2.  
14 
 
In the first place, the cytopathicity of HIV-2 is less than that of HIV-1, possibly 
due to reduced immune activation and low titre replication
24,25,26
.  In addition, 
reduced heterogeneity of the envelope glycoprotein (Env) may also contribute to 
the decreased replicative ability observed in HIV-2
27
.  Sequence analysis of the 
V3 loop, the most variable region of Env, revealed that the average intra-patient 
nucleotide variability was 1.4% in HIV-2 patients while the number could be as 
high as 6.1% in HIV-1 patients
27
. 
 
Secondly, the number and function of CD4
+
 T-cells is better preserved in HIV-2 
infection.  The HIV-2 infection induces significantly less T-cell apoptosis (0-
28%), compared to HIV-1 infection (2-78%)
28
 and the proliferation rate of CD4
+
 
T-cells is 3-fold higher in HIV-2 infection than in HIV-1 infection
29
.  
Furthermore, CD4
+
 T-cells from HIV-2 patients produce stronger Interferon 
gamma (INF-γ) and Interlukin-2 (IL-2) responses compared with those of HIV-1 
patients
29
. 
 
Finally, HIV-2 isolates might be intrinsically more sensitive to neutralisation than 
HIV-1 isolates.  A study by Shi et al. (2005) demonstrates that HIV-2 isolates are 
more sensitive to neutralisation by autologous and heterologous sera
30
.  In 
addition, the neutralisation antibody (NAb) response to HIV-2 has higher 
prevalence and broader specificity
31,32
.  Sera from patients infected with HIV-2 
can cross-neutralise HIV-1 isolates, while HIV-1 sera are group-specific and fail 
to neutralise HIV-2 isolates
32
.   
 
1.4 The origin, heterogeneity and prevalence of HIV 
 
The heterogeneity of HIV-1 isolates is perhaps the highest of all known viruses.  
The genetic variation of HIV is driven by the error-prone RT enzyme during 
replication
33,34,35
.  According to the steady-state model purposed by Coffin (1995), 
HIV-1 replicates more than 300 times in a year and single point mutation at each 
nucleotide occurs at an estimated 10
4 
to 10
5
 times per day in an infected patient
36
.  
This high mutation rate gives rise to a pool of genetically diverse HIV-1 isolates 
with varying viral phenotypes.  Phylogenetic analyses are used to classify and 
organise the circulating virus isolates into different groups and subtypes to reflect  
15 
 
 
their genotypic and phenotypic properties.  The classification, or nomenclature 
system, of HIV is discussed below: 
 
HIV-1 
 
HIV-1 is divided into three groups, namely main (M), outliers (O) and non-M/O 
(N) according to their genetic sequence variation (Figure 1.2)
37
.  More than 90% 
of infections are caused by group M viruses, while group N and group O 
infections are very rare
1
.  Group M is further divided into nine clades (or 
subtypes), designated A-D, F-H, J and K, and clades A and F are further divided 
into sub-subtypes 1 and 2
37
.  Between each clade, the amino acid composition 
differs by about 15% in gag and 30% in env
38,39
.  Different clades can also 
undergo recombination to create hybrid strains, termed “circulating recombinant 
forms” (CRFs)40.  Currently, there are 43 recognised mosaic patterns for CRFs, 
with A/E and A/G recombinants being the most predominant
41
.  Although the 
genetic variation of viruses from group O is as extensive as those in group M, 
phylogenetic analyses of the gag and the env genes did not differentiate the 
viruses into distinctive clusters (sub-types) as in group M
42
.  As for group N, very 
few virus isolates have been identified and sequenced
43
 and, therefore, virus 
subtypes have not been defined. 
 
Among all the subtypes within group M, clade C viruses are the most prevalent 
strains, being responsible for about half of the total HIV infection world-wide, and 
are commonly found in East and Southern Africa and India
1
.  Clade A is the 
second leading subtype, found predominately in West and Central Africa, as well 
as in Russia
1
.  Clade B is found mainly in developed regions, such as North 
America, Europe, Australia and Japan
1
.  As for the CRFs, the A/E recombinant is 
the most common subtype in Southeast Asia, while the A/G subtype predominates 
in West and Central Africa
1
.  Since all of the group M subtypes have been found 
in the Congo, it has been suggested that group M viruses originate from Central 
Africa
44
.  The prevalence of group O and group N viruses is very low, with Group 
O viruses being endemic to Cameroon and West-central Africa, accounting for 
only 1% of the infections
45
.  Group N viruses are extremely rare, and only 10  
cases have been reported, all of which have been in Cameroon
43
.   
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Figure 1.2 – Phylogenetic tree showing the evolution of HIVs from SIV 
 
 
 
 
 
 
 
 
 
Figure 1.2 The genetic variation and evolutionary history of the HIVs and SIVs is 
shown.  HIV-1 is most closely related to SIVcpz, while HIV-2 is most closely 
related to SIVsmm.  HIV-1 is divided into 3 groups: M, N and O, and group M 
can be further divided into 9 subtypes (clade K is not shown in the figure).  Figure 
adapted from Knipe and Howley (2001)
46
. 
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It is generally accepted that HIV-1 is a descendant of the Simian 
Immunodeficiency Virus (SIV) found in chimpanzees (SIVcpz)
47
.  The virus is 
non-pathogenic to its natural host in which the infection remains asymptomatic 
and the host does not develop immune deficiency.  However, animal studies 
demonstrate that, when some SIV strains are transmitted cross-species to non-
natural hosts (i.e. from sooty mangabeys to macaques), the infected animals 
became immune deficient and develop an AIDS-like syndrome
48,49,50
.  
Phylogenetic study of the pol and env genes reveals that SIVcpz, isolated from the 
Pan troglodytes troglodyte subspecies of chimpanzees (SIVcpzPtt), is genetically 
closely related to HIV-1 group M and group N
47
.  A recent study by Keele et al. 
(2006) suggests that groups M and N arise from two independent cross-species 
transmissions of SIVcpzPtt from chimpanzees to humans
51
.  Group M viruses 
belong to a viral linkage originating from chimpanzees which inhabit in South 
Eastern Cameroon, while group N viruses belong to a geographically separate 
linkage from South Central Cameroon.  By contrast, HIV-1 group O viruses 
originated from an ancestry independent of SIVcpzPtt.  The primate reservoir 
which harbours them is still unknown
51
.  However, viruses isolated from the 
Western Lowland Gorilla (SIVgor) are genetically more closely related to group O 
viruses than any other known SIV
52
, suggesting that gorillas are involved in the 
transmission of SIV to humans.  Whether SIV is endemic to the gorilla, or if 
animals acquired the virus from chimpanzees before transmitting it to humans, 
requires further investigation. 
 
The biological differences between different HIV-1 groups and subtypes have 
been described.  An in vitro study on virus fitness suggests that the replicative 
capacity of group O viruses is 100-fold less than that of group M viruses
53
.  This 
experimental observation reflects the low transmission rate and prevalence of 
group O viruses in the AIDS pandemic.  Furthermore, clinical studies have 
indicated that disease progression is associated with the virus subtype.  Patients 
infected with clade A viruses have a slower progression to AIDS than patients 
infected with clades C, D and G viruses
54,55
.  On the other hand, when infected 
with clade D viruses, patients progress to AIDS significantly more rapidly and 
have higher mortality compared with other subtypes
56,57,58
.   
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HIV-2 
 
Currently, HIV-2 isolates are classified into eight groups (A-H).  Groups A and B 
have the highest prevalence, while groups C-H are each represented by a single 
infection
59,60,61,62
.  The genetic diversity between each group of HIV-2 is as 
extensive as that of HIV-1, with up to 25% variation in the amino acid 
composition of the gag, pol and env genes
63,64
.  HIV-2 infection has a low 
prevalence and is largely confined to West Africa and other former Portuguese 
colonies, such as Angola, Mozambique and South India
65,66
.  Unlike HIV-1, HIV-
2 is phylogenetically related to the SIV found in sooty mangabeys (SIVsmm) and 
not chimpanzees, with approximately 75% nucleotide similarity
67,68
.  It is clear 
that HIV-2 is less pathogenic than HIV-1 and patients with HIV-2 infection are 
often asymptomatic and have delayed progression to AIDS.  Furthermore, HIV-2 
has a reduced transmission frequency and demonstrates stable prevalence rates, 
compared with HIV-1
69,70
.      
 
1.5 Hypotheses on HIV-1 transmission and emergence 
 
Although there are still discrepancies in the explanation of how HIV-1 first 
infected humans, it is generally believed that HIV-1 infection arose from a 
zoonotic infection of man with SIV
51,71
.  Two hypotheses have been proposed to 
explain the transmission and emergence of HIV-1 into the human population from 
primates, and these are discussed in the following paragraphs.   
 
The first theory suggests that the preparations of the oral polio vaccine in 
chimpanzee kidney cells were contaminated with SIV which evolved into HIV-1 
and infected its human recipients
72
.  This theory is vigorously refuted with 
compelling evidence.  Molecular clock analyses show that HIV-1 has been 
circulating in the human population dated back in 1930s
73,74
, well before the oral 
polio vaccine trial took place in the 1950s
75
.  Moreover, the vaccine was actually 
prepared in kidney cells from macaques
76
, not chimpanzees, and no trace of HIV-
1, SIV, or chimpanzee DNA has been recovered from the original vaccine 
samples
77,78
, indicating that AIDS did not result from SIV-contaminated oral polio  
vaccine.  The second theory, which is more widely accepted, proposes that the 
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virus entered the human population via hunting and consumption of bush meat
79
.  
Hunters bitten or cut by primates were zoonotically infected with SIV.  The 
transmitted SIV subsequently adapted to the human host through serial passage 
and replication in human lymphocytes and, eventually, evolved into the virus 
known as HIV. 
 
Two “ancient” HIV-1 isolates, ZR59 and DRC60, have been recovered from 
preserved human tissues
74, 80
.  The ZR59 virus is the oldest HIV known to date; it 
was obtained from a 1959 blood sample taken from a man in Kinshasa, Congo
80
.  
The second oldest, the DRC60 virus, was isolated recently from a wax-embedded 
lymph node tissue of a woman, who was also from the Kinshasa area
74
.  The 
existence of these ancient HIV isolates clearly indicates that HIV has been spread 
among humans long before it was recognised.  So, why did it take over half a 
century for the epidemic to break out?  Some suggest that the ancient HIV 
infection (or AIDS) was rare and occurred in a geographically isolated region and, 
thus, it took a long time for the pathogen to spread and reach a detectable 
threshold
81,82,83
.  Changes in social behaviour, urbanisation, international human 
trafficking and the use of non-sterile needles in post-colonial Africa (1960s to 
1980s) all contributed to accelerate the rate of virus transmission and 
adaptation
81,84,85
 and lead to the outbreak in the early 1980s.   
 
1.6 Structure and genomic organisation of HIV-1 
 
The structure of HIV-1 has characteristics typical of a lentivirus (Figure 1.3).   
The virion is spherical in shape and approximately 100 to 120nm in diameter
86
.  
The outermost surface of a mature HIV-1 virion is a lipid bilayer membrane 
within which is embedded the trimeric envelope (Env) glycoprotein.  The Env 
protein consists of an external unit, gp120 and a transmembrane unit, gp41, bound 
together by non-covalent interactions
87
.  The integrity of the virion is supported 
by three layers of the group-specific antigen (Gag) protein: matrix (MA, p17) 
capsid (CA, p24) and nucleocapsid (NC, p7)
88
.  The p17 protein constitutes a 
protective shell just inside and below the lipid membrane.  The p24 protein forms 
a conical core, within which is two identical copies of single-stranded RNA, and 
the p7 protein which interacts with the viral genomic RNA is required for the  
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Figure 1.3 – Schematic representation of HIV-1 virion 
 
 
 
 
 
 
 
Figure 1.3 The structure of HIV-1 is shown.  The virion is approximately 100-
120nm in diameter and morphologically similar to other lentiviruses.  The trimeric 
envelope glycoprotein, gp120, and part of the transmembrane glycoprotein, gp41, 
are found on the external surface on the virion.  Within the CA, two identical 
copies of single stranded RNA are found, linked at the 5’ end by the DLS (red 
line). 
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encapsidation of the RNA into nascent virus particles.   
 
The two strands of RNA are linked together at the 5’ end by a dimer linkage 
structure (DLS)
89
.  Recent studies demonstrate that the DLS has a role in virus 
maturation and recombination
90,91
.  Three enzymes are closely associated with the 
RNAs, namely the reverse transcriptase (RT, also known as RNA-dependent 
DNA polymerase) which is essential for transcribing the retroviral genetic 
material from RNA to DNA
92,93
, the protease (PR) which cleaves the pol and gag 
genes into their functional forms and the integrase (IN) which catalyses the 
integration of viral DNA into host cells
94
.  In addition, HIV-1 RNA encodes the 
long terminal repeat (LTR) sequences which flank the genome at the 5’ and 3’ 
ends (Figure 1.4).  Furthermore, there are two regulatory proteins, Tat and Rev, 
which are essential for virus replication and four accessory proteins, Vif, Vpu, 
Vpr and Nef, which are required for efficient virus replication and pathogenesis.  
A detailed description of each gene product follows. 
 
1.7 Group-specific antigen (Gag) 
 
The Gag protein is synthesised as a polyprotein precursor, Pr55
Gag
 which is 
cleaved into its mature forms, namely p24, p17, p7 and p6, by PR shortly after 
budding
95,96
.   The cleavage of the Pr55
Gag
 also generates two spacer peptides, p1 
and p2
97
.  The p1 peptide is situated between p7 and p6, while the p2 peptide is 
located between p24 and p17.  Although the precise function of the spacer 
peptides is unknown, some studies indicate that p1 and p2 regulate the rate and 
the order of the cleavage, thereby affecting virion morphogenesis
98,99,100
.   
 
Matrix (p17) 
 
The MA domain at the N-terminal of the Pr55
Gag
 targets Gag to the plasma 
membrane
101,102
 by interacting with the acidic phospholipids of the lipid 
bilayer
103
.  Mutations in the MA domain block the transportation of the Pr55
Gag
 to 
the plasma membrane and lead to promiscuous viral assembly at intercellular 
sites, such as the endoplasmic reticulum (ER) and the Golgi apparatus
101,102,104
.  
After virus assembly is complete and before the virion is released from the cell, 
Env glycoproteins are incorporated into the nascent virus particle in a MA- 
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Figure 1.4 – Genomic organisation of long terminal repeats (LTR) sequence 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The LTR consists of 3 domains: U3 (green block), R (pink block) and 
U5 (blue block).  The U3 domain is 630bp in size and situated immediately 
downstream of Nef.  It can be divided into 3 functional subunits: the modulatory 
region, enhancer and promoter.  The R domain is a 96bp repeat present at all viral 
mRNA.  The U5 domain is a 86bp region immediate upstream of the Gag leader 
sequence.  The LTR contains binding sites for multiple transcription factors, 
including NF-κB (yellow block). 
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associated process.  Previous studies demonstrate that an interaction between the 
MA and the gp41 cytoplasmic domain is required for the full-length Env to be 
incorporated into the virion
105,106,107
.  Crystallographic analyses of SIV and HIV-1 
MA reveal that the MA trimerises and forms a lattice-like structure, containing 
holes into which the cytoplasmic tail can be inserted.  This event may be 
responsible for embedding Env in the viral membrane
108,109
.  Furthermore, the 
MA is also reported to be associated with the viral core, suggesting a functional 
role in the early post-entry step
110,111,112
.  Although the precise mechanism 
remains unclear, mutations in the MA have been shown to decrease reverse 
transcription efficiency, reduce the stability of the proviral DNA being 
synthesised and increase detainment of the lipid membrane, which results in the 
degradation of the reverse transcription complex
113
.   
Capsid (p24) 
The CA protein consists of two subunits, namely the core domain at the N-
terminal and the dimerisation domain at the C-terminal
114,115,116
.  The core domain 
is responsible for virus maturation and infectivity.  Mutations in the core domain 
block the incorporation of the cellular protein, cyclophilin A, into the virion, 
resulting in lagged virus release and reduced viral infectivity
117,118,119
.  The 
dimerisation domain contains the major homology region (MHR) which displays 
significant amino acid homology between different retrovirus genera
120
.  
Mutations in the MHR disrupt Gag-Gag interaction and impair virus assembly, 
maturation and infectivity
121
.   
 
Nucleocapsid (p7) 
 
The NC protein contains two highly conserved zinc-finger motifs which are 
tightly associated with full-length genomic RNA in the viral core
122
.  Interaction 
between the NC and RNA can be either sequence-specific or not, although 
previous studies indicate that NC displays preferential binding to the packaging 
signal (ψ-site) to confer RNA encapsidation123,124.  Mutations in the zinc-finger 
motifs disrupt RNA splicing and RNA encapsidation, resulting in the production 
of non-infectious virions
125,126
.   
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In addition to the zinc-finger motifs, the N-terminal basic domain of NC is 
believed to have a role in virus assembly and release
127
.  The basic domain is 
responsible for the tight packing of Gag, thereby producing virus particles with a 
high density
127
.  Several other functions of NC have also been reported.  For 
example, the NC displays nucleic acid chaperone activity, in which it catalyses the 
refolding of the nucleic acid into its most thermodynamically stable conformation 
with the maximum number of complementary base pairs (bp)
128
.  Furthermore, it 
appears to enable the production and stability of the newly reverse-transcribed 
viral DNA
129
.  The NC also promotes RNA dimerisation
130
 and protects viral 
DNA from endonuclease cleavage
131
. 
 
In addition to MA, CA and NC, HIV-1 gag encodes the p6 protein which is 
required for efficient virus budding
132
.  In the absence of p6, virus particles 
accumulate at the cell surface and are tethered to the membrane.  In addition, p6 is 
required for the incorporation of the viral protein R (Vpr) into the virion
133
.   
   
1.8 Polymerase (Pol) 
 
Immediately downstream of gag lies the pol gene.  The pol gene is produced 
initially as a 160kD Gag-Pol fusion polypeptide, by frameshift mutation during 
translation of the unspliced Gag
134
.  The precursor peptide is autocleaved by its 
PR region into three mature Pol products: PR, RT and IN
135
. 
 
Protease (PR) 
 
The HIV-1 PR is an aspartate protease that cleaves polyprotein precursors into its 
mature products
136,137
.  Similar to other proteases, HIV-1 PR utilises two highly 
conserved aspartate residues to coordinate water molecules and hydrolyses 
peptide bonds in the target proteins
138
.  X-ray crystallography analyses reveal that 
PR exists as a dimer with two non-identical monomers
139,140
.  The aspartate 
residues are located in the centre of the dimer and substrate binding site is located 
between the cleft of the two monomers.  Since the premature cleavage of Gag and 
Gag-Pol by PR is detrimental to virus assembly, PR is one of the obvious drug 
targets for HIV-1.   
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Reverse Transcriptase (RT) 
 
Retroviruses, such as HIV-1, rely on RT to reverse transcribe their RNA genome 
into DNA which is then integrated into the host genomic DNA.  The RT enzyme 
lacks an exon nucleolytic proofreading activity and is, therefore, error-
prone
33,34,35
.  It has been estimated that reverse transcription in vivo has a mutation 
rate of 3.4x10
-5
 mutation per bp per replication cycle
141
.  In addition, template 
switching between the two RNA strands occurs frequently during reverse 
transcription
142
.  An early study by Robertson et al. (1995) estimated that 5-10% 
of virus isolates sequenced arose from inter-subtype recombination
143
.  This high 
rate of mutation and recombination gives rise to genetic variation among the virus 
population, making the design of a broadly-reactive vaccine highly challenging. 
 
The mature RT molecule is a heterodimer consisting of two subunits, namely p51 
and p66
144,145
.  The p66 sub-unit has two domains, the first of which is an N-
terminal polymerase site with three active aspartate residues, and the second is a 
C-terminal ribonuclease H (RNase H) site which provides the ribonuclease 
activity of RT.  The p51 subunit is a cleavage product of p66 and is completely 
inactive.  Based on its structure topology, RT inhibitors have been developed for 
anti-HIV therapy.  
 
Integrase (IN) 
 
The integration of HIV-1 viral DNA into the host nucleic acid machinery provides 
a template for virus replication and the establishment of a persistent infection.  
The process of retrovirus integration is catalysed by the IN enzyme
146,147
.  The 
HIV-1 IN is composed of three structural domains, namely the N-terminal domain 
with a zinc-finger motif, the catalytic core domain and the C-terminal domain.    
The core domain contains a conserved DD(35)E motif which is responsible for 
catalysing viral integration
148
.  Mutations in any of the three amino acid residues 
of this motif result in a complete loss of function of IN
149
.  The function of the N-
terminal domain is poorly understood, but it is believed to play a role in 
maintaining structural stability by promoting IN tetramerisation
150
.  The C-
terminal domain exhibits strong non-specific binding to both viral and host 
DNA
151,152
.  Mutations in the C-terminal domain result in the loss of DNA binding  
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activity, and consequently, reduce integration efficiency
153
. 
 
1.9 Envelope glycoprotein (Env) 
 
The envelope glycoprotein, initially expressed as a polyprotein precursor, gp160, 
in the rough ER
154,155
, is co-translationally modified by the addition of asparagine 
(N)-linked high mannose sugars
156
, before undergoing rapid oligomerisation
157
.  
The precursor protein is transported to the Golgi apparatus, where a cellular 
enzyme, furin, cleaves it into two non-covalently associated subunits
158
, namely 
the external surface glycoprotein, gp120, and the transmembrane protein, gp41.  
The uncleaved gp160 is transported to the lysosomes where it is degraded, while 
the mature gp120 and gp41 are transported to the cell membrane
159
.  Because the 
association between the two subunits is weak, a fraction of the gp120 is 
spontaneously shed from the mature virion, especially in some laboratory-adapted 
strains
160
.   
 
Structure and conformation 
 
The gp120 domain consists of five variable regions (V1-V5) which are interposed 
with five conserved regions (C1-C5)
161
.  The V1-V4 regions each contain two 
highly conserved cysteine residues which form disulfide bonds that anchor the 
region into a loop
162
.  Three-dimensional structural studies employing X-ray 
crystallography and cyro-electron tomography indicate that functional gp120 is 
assembled as a trimer
163,164
.  The surface of the gp120 is covered by N-linked 
glycans which act as a protective shield to prevent antibody binding
165
.  The 
variable regions are positioned outward so that the “neutralising face” of the 
gp120 is locked within the trimer
166
.  This conformational masking allows gp120-
receptor binding, while constraining the access of antibodies.      
 
As for gp120, the gp41 protein is also assembled as a trimer
167
.  The gp41 domain 
consists of three subdomains, namely an extracellular ectodomain, a membrane-
spanning domain and a long cytoplasmic domain.  The ectodomain contains a 
fusion peptide, a C-terminal heptad repeat helical region and an N-terminal 
leucine zipper helical region
168,169
.  The two helices form a 6-helix bundle and 
mediate fusion between the viral and the cellular membrane.  The membrane-
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spanning domain contains three hydrophobic regions
170
 from residue 1 to 30, 512 
to 541 and 684 to 706.  Mutagenic studies reveal that the third hydrophobic region 
is responsible for anchoring Env on the lipid bilayer and for viral fusion
171,172,173
.  
The cytoplasmic domain contains a tyrosine-based endocytosis motif and two 
alpha helices.  The endocytosis motif mediates the Env trafficking pathway by 
directing unincorporated Env to the clathrin-coated pits to undergo 
internalisation
174,175
, while the two helices facilitate virus entry
176
 and mediate 
Env incorporation into the virion
177,178
.   
  
Receptor binding 
 
Identification of CD4
179
 as the receptor of gp120 binding represents one of the 
first major breakthroughs in the course of HIV-1 research
180,181
.  The CD4 
receptor is expressed on T helper (Th) cells, macrophages and dendritic cells and 
consists of four extracellular N-terminal domains (D1 to D4), a hydrophobic 
membrane-spanning domain and a short cytoplasmic domain
182,183
.  The C4 
region of gp120 is the main CD4-binding region of HIV-1
184,185
.  It specifically 
targets the complementarity-determining region 2 located on the D1 domain of 
CD4
186,187
.   
 
The native conformation of gp120 is essential in initial CD4 binding.  Mutagenic 
studies demonstrate that even a single amino change is sufficient to alter receptor 
binding and cellular tropism
188,189,190
.  Upon virus attachment, conformational 
changes in CD4 promote further binding of gp120 to its co-receptors to facilitate 
membrane fusion and viral entry.  Early studies engineered a soluble form of CD4 
(sCD4) in the hope of an antiviral intervention which could block viral 
infection
191,192
.  Although sCD4 can neutralise some laboratory-adapted virus 
isolates, it fails to neutralise primary isolates effectively 
193
.  In addition, an 
increase in infection of the target cells has been observed in some cases, 
particularly when low sCD4 concentration was used
194,195,196
.  
 
Co-receptor tropism  
  
Binding to CD4 alone, however, is insufficient to cause viral fusion or to induce 
infection.  Not all CD4
+
 cells permit the entry and replication of HIV-1
197
 and the  
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expression of CD4 alone in non-human cells does not render them susceptible to 
HIV-1 infection
198,199,200
.  In addition, different strains of HIV-1 often only infect 
a subset of CD4
+
 cells
201,202
, suggesting that the presence of secondary receptors is 
necessary.  The α-chemokine receptor CXCR4 (X4)203 and the β-chemokine 
receptor CCR5 (R5)
204,205,206
 have been identified as the major co-receptors 
essential for viral fusion and transmission.  Both X4 and R5 are G-protein coupled 
receptors belonging to the 7-transmembrane domain receptor family.  Other 
chemokine receptors, such as CCR2, CCR3, CCR8, etc…, can also serve as co-
receptors for HIV-1 entry
207
, but they appear to account for only a small portion 
of co-receptor activity and their exact roles are unclear.  Hence, most research is 
focused upon the functions and activities of the X4 and R5 receptors.   
 
Different HIV-1 isolates have different preferences for co-receptor usage, which 
are referred to as R5-tropic, X4-tropic or R5X4-tropic if the virus can utilise both 
receptors
208
.  The R5-tropic isolates are found predominantly in early HIV-1 
infection
209
 and are often referred as M-tropic isolates as they tend to infect R5-
expressing macrophages and display a slow replicative phenotype
210
.  The X4-
tropic isolates are found at a later stage of infection
211
 as the virus spreads in X4-
expressing T-cells (thus, also referred as T-tropic) and display a rapid replicative 
phenotype
210,211
.   
 
The V1, V2 and, particularly, the V3 regions of gp120 are important determinants 
of co-receptor binding and tropism
212,213
.  A single mutation in the V1 or the V3 
loop is sufficient to alter cellular tropism and enable M-tropic virus to replicate in 
T-cells
214,215
.  An early study by Shioda et al. (1992) reported that a three-amino 
acid change in the V3 loop can confer M-tropism on T-tropic isolate
216
.  In 
addition, removal of two N-linked glycans through amino acid substitution on the 
V2 loop induces the isolate to switch from T-tropic to M-tropic
217
. 
 
Membrane fusion 
 
Fusion between the viral membrane and the host cellular membrane is one of the 
most critical steps in retroviral infection.  This entry event is mediated both 
directly and indirectly by Env, of which the ectodomain of gp41 plays the major 
role in fusion.  Upon gp120 binding to CD4 and co-receptors, the N- and the C-
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terminal helices of the gp41 ectodomain undergo a conformational change
218
.  
This allows gp41 to unfold and insert its hydrophobic N-terminus fusion peptide 
into the cell membrane
219,220
.  The gp41 then falls back on itself and draws the 
viral membrane into close proximity with the host cellular membrane
167
.  
However, the precise mechanism as to how fusion takes place from this 
apposition remains unknown.  
 
Although gp120 does not interact directly with the viral or cellular membrane 
post-binding, previous studies indicate that several domains of gp120 are required 
for the fusion event.  Mutations in the V1 and V2 loops destabilise the 
gp120:gp41 association and block virus entry
221
.  Antibodies targeted against the 
V3 loop appear to neutralise the virus by disrupting steps in the membrane fusion 
process
222
 and amino acid substitutions in the V3 loop severely decrease viral 
infectivity and fusogenicity
223,224
.  In addition, mutations in the C4 domain 
abrogate receptor binding and moderately reduce fusion activity
225,226
.     
 
Incorporation into the virion 
 
Although the precise mechanism of the Env incorporation into the virion remains 
unclear, some early studies suggest that the presence of the MA protein may be 
necessary for the incorporation of full-length Env
105,106
.  It possibly acts by 
interacting with the gp41 cytoplasmic domain of Env
107,177
.  On the other hand, 
incorporation of pseudotyped Env can occur without the MA requirement
227
.  
Some studies have reported that the truncation of the CT does not affect the Env 
incorporation
227,228
, but this appears to be highly cell type-dependent.  An intact 
gp41 cytoplasmic domain is required for efficient Env incorporation into the 
virion when virus is produced in most T-cell lines, macrophages or PBMCs
229
.   
  
1.10 Long terminal repeat (LTR) 
  
The LTR is a 630bp sequence located at either end of the proviral DNA and it is 
divided into three regions, namely U3, R and U5
230
 (Figure 1.4).  The U3 region is 
further divided into the modulatory region, the enhancer region and the core 
promoter region.  The HIV-1 LTR regulates integration and virus production.  
Early in reverse transcription, the R region of the LTR forms a hybrid bridge 
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between the short single-stranded nascent DNA and the viral RNA template, 
allowing DNA synthesis to continue from the 3’ end of the viral RNA231,232.  The 
enhancer and promoter located at U3 are essential for initiating transcription and 
regulating viral mRNA production
233
.  The U5 region is involved with DNA 
integration and packaging RNA into progeny virions
234,235
.   
 
The LTR contains binding sites for multiple transcription factors
236
 (show in 
Figure 1.4), the most important of which is the nuclear factor-kappa B (NF-κB).  
Upon HIV-1 infection, T-cells are activated and induce NF-κB.  Binding of the 
NF-κB to the LTR activates the virus from its latent state and initiates 
transcription and gene expression
237
.  The number of NF-κB binding sites on the 
LTR varies by subtypes.  HIV-1 clade B has two sites and clade C has three sites, 
while clade E has only one site
238
.  It has been suggested that the increased 
number of binding sites directly correlates with the enhanced transcriptional 
activities of clade C viruses
239,240
. 
 
1.11 Transactivator of transcription (Tat) 
 
Tat is one of the two regulatory proteins encoded by HIV-1.  It is essential for 
virus replication, since no progeny virions can be produced when tat is mutated or 
deleted
241,242
.  A series of transcriptional complexes are recruited upon the binding 
of Tat to the transactivation responsive region (TAR) on the LTR
243
.  These 
cellular factors phosphorylate the C-terminal domain of RNA polymerase II
244
 , 
resulting in an increase of the steady state level of the viral mRNA and 
enhancement of the rate of transcription
245,246,247
.   
 
Other functions of Tat have also been reported.  These include up-regulating co-
receptors (R5 and X4) expression on cell surfaces
248,249
, blocking natural killer 
(NK) cell activities
250
, inducing apoptosis
251,252
 and enhancing the production of 
interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF-α) and beta (β)-
chemokines
253
.  An animal study using SIVmac revealed that Tat-specific 
cytotoxic T-lymphocyte (CTL) responses can control early virus replication and 
select for less pathogenic escape mutants
254
, suggesting a potential role for Tat as 
an antiviral target.  
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1.12 Regulator of virion protein expression (Rev) 
 
Rev is the other regulatory protein which is essential for HIV-1 replication
255
.  It 
is known to display high affinity binding to the cis-acting Rev response element 
(RRE) located on the env gene
256,257
.  Subsequent to the binding or Rev to RRE, 
Rev multimerises
258
 and exerts three main post-transcriptional functions: (1) it 
regulates mRNA splicing
259,260
, (2) stabilises mRNA
261
 and (3) exports viral 
mRNA to the cytoplasm for protein translation
257,261
.  The Rev-mediated 
accumulation of unspliced or partially spliced mRNA in the cytoplasm is 
apparently required for productive HIV-1 infection
262,263
.   
 
1.13 Virus infectivity factor (Vif) 
 
Vif is a highly conserved viral infectivity factor which is present in all 
lentiviruses, with the exception of the Equine Infectious Anaemia Virus 
(EIAV)
264
.  The Vif protein is required for virus infectivity
265
 and cell-to-cell 
transmission
266
.  In addition, Vif-defective HIV-1 virions are abnormal in their 
morphology
267
 and display reduced endogenous RT activity
268
 which results in 
impaired DNA synthesis
269,270
.   
 
The Vif-defective phenotypes, however, are cell-dependent
271
.  Vif is required for 
productive infection in non-permissive cell lines (i.e. HUT78 and CEM) and 
PBMCs, while its presence in permissive cell lines (i.e. MT-4 and Jurkat) is 
dispensable.  When non-permissive cells and permissive cells are fused together, 
the resulting heterokaryons require Vif to produce fully infectious virions, 
indicating that the non-permissive phenotype is dominant
272
.  This observation 
leads to the hypothesis that non-permissive cells may express antiviral factors 
which are inhibited by Vif.  Subsequent studies on non-permissive cells identified 
a unique gene, CEM15, as having antiviral activity which is overcome by Vif
273
.   
 
The CEM15 gene encodes an apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3G (APOBEC3G) which induces G to A hypermutation in 
nascent viral DNA
274,275,276,277
, leading to DNA degradation and/or the production 
of non-infectious virions.   The binding of Vif to APOBEC3G induces 
ubiquitination and rapid degradation of APOBEC3G via a proteasomal-dependent 
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pathway
278,279
, thereby protecting the virus from APOBEC3G-mediated 
inactivation.  In addition, Vif prevents APOBEC3G packaging into progeny 
virions
280
, thereby allowing new infections to proceed without pre-emptive 
hypermutation.   
 
Another member of the APOBEC family, APOBEC3F, displays similar antiviral 
activity as APOBEC3G, although its function is also inhibited by the presence of 
Vif
281
.  It has also been reported that APOBEC3D/E can weakly inhibit HIV-1 in 
a Vif-sensitive manner
282
.  Other APOBEC proteins, such as 3B, 3C and 3H, are 
Vif-independent and display either a weak or non-inhibiting effect on HIV-
1
283,284,285
. 
 
1.14 Viral protein R (Vpr) 
 
Vpr is a 14-kD accessory protein required for efficient HIV-1 infection of 
monocytes and macrophages
286
.  It is incorporated at a high level into the virion 
via interaction with the p6 Gag protein
287,288
.  Vpr prevents proliferation of the 
infected cells by arresting cell cycling at the G2 stage
289
, during which the HIV-1 
LTR is found to be the most active.  Hence, a delay in cell cycling facilitates 
transcription and increases virus production
290
.  A few studies have reported Vpr-
mediated apoptosis and suggested that the event is functionally related to cell 
cycle arrest and transactivation of the LTR
291,292,293
.  In addition, Vpr participates 
in the nuclear importation of the preintegration complex (PIC) via an interaction 
with karyopherin-α294.  Karyopherin-α is a protein responsible for transporting 
macromolecules between the cytoplasm and the nucleus through the nuclear 
pore
295
.  Since PIC is larger than the nuclear pore in size, Vpr induces transient 
rupture to the nuclear envelope to allow the passage of PIC into the nucleus
296
.   
 
1.15 Viral protein U (Vpu) 
 
Vpu is a 16-kD membrane phosphoprotein present only in HIV-1 and SIVcpz
297,298
, 
which is required for efficient virion release
299,300,301
.  In the absence of Vpu, virus 
particles accumulate in the intracellular vesicles or at the cellular membrane.  It 
has been suggested that Vpu enhances virion release by binding to its cellular co-
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factor, the Vpu-binding protein (UBP)
302
.  The Vpu-UBP complex abrogates the 
association between UBP and Gag, thereby allowing the transport of Gag to the 
plasma membrane.  Very recently, Vpu is found to facilitate virion release by 
inhibiting a membrane protein termed tetherin
303,304
.  In the absence of Vpu, 
tetherin co-localises with Gag and induces adherence between the nascent virions 
and the cell membrane, thereby preventing the virions from releasing.   
 
Another important virological function of Vpu is to down-regulate CD4 
expression.  The CD4 receptor forms an intracellular complex with the envelope 
precursor, gp160, blocking its transport to the cell surface
305
.  In order to release 
gp160, Vpu binds to the CT of CD4 and mediates the degradation of it in the 
ER
306,307
.  This down-regulation also enhances HIV-1 particle production, since 
continual expression of CD4 has been shown to inhibit the viral function of 
Vpu
308
. 
 
1.16 Negative factor (Nef) 
 
Although Nef was originally designated as a negative factor for suppressing LTR-
mediated transcription and down-regulation of virus replication
309,310
, it is now 
clear that this accessory protein possesses pleiotropic functions which are 
essential for HIV-1 replication and pathogenesis.   
 
Several distinct functions for Nef have been described and characterised, the most 
important of which is its ability to down-regulate surface expressed receptors, 
such as CD4
311,312
.  The binding of Nef to the dileucine motif of the CD4 CT 
triggers a clathrin-mediated endocytosis pathway, leading to the degradation of 
CD4 in the lysosomes
313
.  Removal of CD4 from the cell surface facilitates Env 
incorporation and virus replication, resulting in an increased production of 
infectious progeny virions
314,315
.  In addition to CD4, Nef is also known to down-
regulate the major histocompatibility complex (MHC) classes I and II to assist 
evasion of the host immune response
316,317
.  Reduced expression of MHC-I may 
protect infected cells from recognition and lysis by CTLs
318
, while the down-
modulation of MHC-II impairs the CD4
+
 T-helper (Th) responses
317
.   
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Furthermore, Nef regulates T-cell function.  Interactions with cellular kinases 
modulate the signal transduction pathway
319,320
, leading to T-cell activation or 
inhibition
321,322
.  The increased activation of T-cells promotes viral 
replication
323,324
 and induces apoptosis in uninfected bystander cells
325
, while the 
decreased activation of T-cells protects infected cells from apoptosis
326,327
, 
allowing an extended period of virus production.   
 
Another important feature of Nef is its ability to enhance HIV-1 
infectivity
324,328,329
.  Although the precise mechanism remains unclear, several 
studies have provided some insight as to how this is achieved: (1) Nef protects the 
virion from post-entry proteasomal degradation and tethers the viral core to its 
cellular transport pathway
330
.  (2) Nef disrupts the host actin cytoskeleton which 
poses as a barrier to intracytoplasmic trafficking of the viral core
331
.  (3) 
Cholesterol incorporation into the virus particle is enhanced by Nef, resulting in 
more efficient virion budding
332
.  (4) Interaction between Nef and cellular factor 
Dynamin-2 (Dyn2) possibly leads to regulation of the signal transduction pathway 
and an interaction with the Pr55
Gag
, thereby facilitating virion assembly
333,334
.   
 
Since Nef is an important determinant of HIV-1 pathogenicity, attempts have been 
made in the past to employ a Nef-deficient attenuated virus as a vaccine 
candidate
335,336
.  Although the vaccine protects monkeys from the challenge of 
fully infectious SIV, the safety aspect of using a live-attenuated vaccine remains a 
major concern
337
, since the deletion of Nef alone may not be sufficient to produce 
fully non-infectious virus. 
 
1.17 The life cycle of HIV-1 
 
In order to establish a productive infection, HIV-1 must be able to enter and 
replicate efficiently in infected cells.  The HIV-1 replicative cycle (Figure 1.5) is a 
complicated process involving a series of molecular events, beginning with the 
attachment of the virion gp120 to the cellular receptor, CD4, on T-cells or 
macrophages
180,181
.  Attachment to the major receptor promotes further binding to 
the co-receptor, such as R5 or X4
203,204,205,206
, resulting in a dramatic 
conformational change which causes the gp41 to unfold and insert its N-terminus  
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Figure 1.5 – The replicative cycle of HIV-1 
 
 
 
 
 
 
 
Figure 1.5 The schematic diagram of the HIV-1 replicative cycle is shown.  The 
replication cycle is a multi-step process: (1) The virus attaches to the CD4 
receptor (green block) and subsequently, to the R5 or X4 co-receptor (orange 
curves). (2) The virus membrane fuses with the host cell membrane, thereby 
allowing the entry of nucleocapsid into the cytoplasm.  (3) The viral RNA is 
reverse transcribed into DNA by RT (green circle) (described in Figure 1.6).  (4) 
The IN (dark blue circle) transfers the viral DNA into the cellular nucleus and 
facilitates the integration of viral DNA into the host chromosome.  (5) Upon 
activation, the proviral DNA is transcribed into mRNA which may or may not 
undergo splicing.  (6) The Env precursor, gp160 (bright blue), is produced by 
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partially spliced mRNA and subsequently, cleaved by PR (orange circle) into its 
mature form.  Non-virion associated gp120s (light blue circle) are sometimes 
released from the cell.  (7) Unspliced mRNA is produced Pr55
Gag
 (purple block) 
and Gag-Pol (purple and orange block) polyproteins, in association with the two 
RNA strands, are transported to the plasma membrane.  (8) Partially or completely 
spliced mRNA is also transcribed into regulatory and accessory HIV proteins 
which assists replication. (9) The viral RNA and the Pr55
Gag
 and Gag-Pol are 
assembled into “buds” at the plasma membrane.  (10) The PR processes the 
polyproteins to yield a fully functional virus particle.  Figure adapted from Knipe 
and Howley (2001)
338
. 
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into the target cell membrane
219,220
.  The virion is then drawn to the cell and 
eventually fused with the cell membrane in a pH-independent process
339
.   
 
The virus particle uncoats after entry and the nucleocapsid gains entry to the host 
cytoplasm
340,341
, releasing the viral RNA and three enzymes, namely RT, IN and  
PR.  The polymerase active site of RT reverse transcribes the viral RNA into 
DNA and creates a RNA-DNA hybrid helix
92,93 
(Figure 1.6).  The RNase H active 
site of RT breaks down the RNA
342
, then the polymerase finishes the transcription 
and produces a DNA double helix.  The IN then cleaves two nucleotides off the 3’ 
ends of the viral DNA, thereby creating two sticky ends
343,344
.  The processed 
viral DNA is then transferred to the cell nucleus by the IN which also catalyzes its 
integration into the host cell genome
146,147
.  Activation of the host cell induces the 
transcription of proviral DNA into mRNA.  The mRNA contains a variety of 
intros which may be unspliced, partially spliced or completely spliced before 
being exported to the cytoplasm
345,346
.  The unspliced mRNA is translated into the 
Gag precursor (Pr55
Gag
) and the Gag-Pol polyprotein, the partially spliced mRNA 
encodes the Env precursor (gp160), Vif, Vpu and Vpr, and the completely spliced 
mRNA is for the synthesis of Tat, Rev and Nef.   
 
The gp160 is subsequently transported from the ER to the Golgi apparatus where 
it is cleaved by furin-like PR into gp120 and gp4
158
.  The mature envelope 
glycoproteins are then transported to the plasma membrane and are later 
assembled onto the surface of the progeny virions
177
.  Simultaneously, the two 
strands of nascent viral RNA, associated with the Pr55
Gag
 and the Gag-Pol 
polyproteins, are transported to the plasma membrane where they form an 
electron-dense “bud” 347 .  The PR cleaves both polyproteins either during, or 
immediately following, virion budding to produce a fully infectious mature virus 
particle
348
.   
 
1.18 The humoral immune response  
 
The development of the antiviral antibody has traditionally been regarded as one 
of the most effective mechanisms in curtailing viral pathogenic infection.  The 
inability of the immune system to produce broadly reactive neutralising antibodies  
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Figure 1.6 – Overview of reverse transcription at the LTR 
 
 
 
 
 
Figure 1.6 The HIV-1 RT contains two functional units, the N-terminus 
polymerase and the C-terminus RNase H, both of which are essential for reverse 
transcription at the LTR level.  (1) Partially unwound tRNA binds to the primer 
binding site of the single stranded viral RNA.  The polymerase extends the short 
single stranded DNA (also known as minus-strand strong-stop DNA, or -sssDNA) 
towards the 5’ end.  (2) The RNase H degrades the RNA portion of the RNA/-
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sssDNA hybrid helix.  (3) The first strand transfer occurs in which –sssDNA 
jumps to the R region at the 3’ end of the RNA genome.  (4) The –sssDNA is then 
used as a primer, and the polymerase resumes its reverse transcription by 
extending the DNA in a 5’ to 3’ direction.  (5) The RNase H degrades all but the 
polypurine tract region of the template RNA.  (6) The polypurine tract region is 
now used as a template for the synthesis of the plus-strand strong stop DNA 
(+sssDNA).  (7) The RNase H removes the tRNA and the polypurine tract RNA 
primers.  The +sssDNA and the minus strand DNA then circularise and the 
polymerase extends the plus strand DNA.  (8) Complementary primer binding 
sites between the plus and minus DNA strands allow a second strand transfer and 
the polymerase completes the extension of the minus strand DNA.  At the end of 
the process, a viral DNA double helix is resulted.  Figure adapted from Coffin et 
al. (1998)
349
. 
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immediately after infection attributes, in a large part, to the failure of the host to 
control HIV-1 infection and poses difficulty in designing an effective 
vaccine
350,351,352
.  Although anti-HIV-1 antibodies can be detected within two 
weeks of infection, most of the early antiviral antibodies are directed against p24 
and are non-neutralising
353
.  The envelope glycoprotein is the only viral antigen 
against which neutralising antibodies are targeted.   
 
Early studies demonstrate that primary isolates are substantially more resistant to 
antibody neutralisation and soluble CD4 than laboratory-adapted isolates or 
recombinant gp120
354 , 355 , 356
, suggesting a possible difference between their 
envelope glycoprotein conformation.    It is believed that the laboratory-adapted 
viruses contain envelope trimers with an “open” conformation where epitopes are 
readily accessible by neutralising antibodies
357
 (Figure 1.7).  This is possibly due 
a lack of selective pressure by neutralising antibodies in vitro, which leads to the 
optimisation of CD4-gp120 interaction, resulting in the exposure of a limited 
numbers of epitopes on gp120 and gp41
358
.  In contrast, primary isolates are under 
the selective pressure of neutralising antibodies presented in serum and their 
epitope accessibility is occluded, possibly due to a more compact gp120-gp41 
and/or gp41-gp41 interaction
357
 (Figure 1.7).   
 
Neutralising antibodies can be either type-specific or group-specific.  Type-
specific antibodies neutralise a particular virus isolate, while group-specific 
antibodies neutralise a range of viral isolates.  In addition, most of the type-
specific antibodies recognise epitopes on the V3 region of gp120
359
, while group-
specific antibodies recognise epitopes on the CD4 binding site of gp120, the 
membrane-proximal external region (MPER) of gp41 and the carbohydrate 
moieties
360
.  Currently, there are four broadly-reactive group-specific monoclonal 
neutralising antibodies, namely b12, 2G12, 2F5 and 4E10, the properties of which 
are discussed below. 
 
b12 
 
The b12 antibody was the first broadly neutralising anti-HIV-1 monoclonal 
antibody ever to be identified.  It was isolated from a phage-display library 
constructed from the bone marrow of a long-term asymptomatic HIV-1  
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Figure 1.7 – HIV-1 envelope glycoprotein conformations 
 
 
 
 
 
Figure 1.7 Laboratory-adapted HIV-1 (top) and primary HIV-1 (bottom) have 
different envelope glycoprotein conformations.  Epitopes for neutralising 
antibodies are well-exposed in laboratory-adapted strains, making them readily 
neutralisable.  In contrast, primary isolates are resistant to neutralisation and their 
epitopes are not well accessible.  Figure adapted from Burton (1997)
357
. 
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seropositive donor
361
.  Epitope mapping indicates that b12 recognises a 
discontinuous epitope (RPVVSTQLLLNGSLAEEEVV) which overlaps the CD4 
binding site of gp120
362,363,364
.  Binding of b12 to the virion blocks the CD4 
attachment and subsequent cell fusion, thereby preventing infection.  Previous 
studies show that b12 can efficiently neutralise HIV-1 primary isolates from 
different clades
365 , 366
 and protect macaques from vaginal challenge with an 
SIV/HIV-1 (SHIV) chimeric virus
367
.   
 
2G12 
 
The carbohydrate moieties on gp120 not only protect the virus from antibody 
neutralisation, but are also essential for the gp120-CD4 interaction, as non-
glycosylated virus envelope cannot bind to the CD4 receptor
368,369
.  The 2G12 
antibody is unique in that it targets a cluster of oligomannose residues on 
gp120
370
.  The precise position of the 2G12 epitope is unclear. However, a study 
by Scanlan et al. (2002) suggests that the most likely epitope is formed by 
mannose residues at position N295 and N332
371
.  The binding of 2G12 to its 
epitope generates a steric interference that prevents gp120 from attaching to the 
CCR5 co-receptor, thereby inhibiting viral entry
372
.  Although 2G12 displays 
strong neutralising activity against HIV-1 from clade B and sporadic activity 
against viruses from clades A, D and A/C, it does not usually neutralise viruses 
from clades C or E
373,374
.   
 
2F5 and 4E10 
 
The MPER domain is situated at the C-terminus of the ectodomain of gp41.  It 
destabilises the viral membrane and is crucial for the fusion step
375
.  Both 2F5
376
 
and 4E10
377
 recognise two adjacent, but distinct, conserved linear epitopes 
(ELDKWAS and NWFDIT, respectively) on MPER.  Unlike b12 and 2G12, 2F5 
and 4E10 do not interfere with receptor binding. Instead, they inhibit envelope-
mediated fusion
378
.  The 2F5 antibody can effectively neutralise a range of 
primary isolates, with the exception of C clade viruses
374
.  The 4E10 antibody, on 
the other hand, is only modestly potent but appears to possess the greatest breadth 
of cross-reactivity among all the neutralising antibodies
379
.  In a comprehensive 
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study by Binley et al. (2004), 4E10 is the only monoclonal antibody that can 
neutralise all 90 geographically distinct viruses being tested
374
.   
 
Because of their ability to neutralise the virus, the potential use of these NAbs as 
vaccine candidates was assessed.  When non-human primates are passively 
administrated with a high dosage of combined neutralising antibodies, most of the 
animals are protected from challenge infection
367,380,381,382,383,384,385,386
.  Based on 
this evidence, the efficacy of employing neutralising antibodies as immunotherapy 
in HIV-1 patients was examined.  Asymptomatic HIV-1 patients who were 
passively immunised with a combination of neutralising antibodies have a reduced 
virus replication, compared to those in the control group
387,388
.  In a meticulous 
study by Trkola et al. (2005), administration of neutralising antibodies after 
cessation of ART has a minimal clinical benefit in chronic HIV-1 patients
389
.  
However, a substantial delay in virus rebound was observed in patients with acute 
infection and a similar observation was made in another independent study
390
.  
These results indicate that, although neutralising antibodies suppresses disease 
progression at an early stage, their potency is limited and cannot replace ART.  Of 
note, 2G12 appears to have the highest neutralising activity, compared to the anti-
gp41 antibodies
389
.  Escape mutants developed resistance to the 2G12 antibody 
but not to 2F5 and 4E10, raising concerns of whether or not anti-gp41 antibodies 
are neutralising and efficacious in vivo.  
 
 
Prior to the production of neutralising antibodies, the host immune response 
produces anti-HIV-1 antibodies (IgG isotype) which can induce antibody-
dependent cellular cytotoxicity (ADCC)
391
.  This occurs when infected or 
uninfected CD4
+
 T-cells, coated with HIV-1 antigen-antibody complex on the cell 
surface, are subsequently eliminated via necrosis or apoptosis upon being bound 
to the Fc receptor on NK cells or macrophages.  The ADCC response is targeted 
against gp120 or gp41
392,393 ,394
, although one study has also reported ADCC 
activity against surface expressing Nef protein
395
.  The precise role of ADCC in 
HIV-1 infection remains to be elucidated.  A few clinical studies have described 
that ADCC activity is inversely associated with CD4
+
 cell count and disease 
progression
396 , 397 , 398
, suggesting that ADCC is beneficial in controlling the 
infection, particularly in the acute phase.  On the other hand, ADCC is attributed 
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to being one of the mechanisms behind the rapid depletion of uninfected CD4
+
 T-
cells (bystander killing)
 399,400
.  Since bystander killing by ADCC depends on the 
presence of shed gp120 absorbed to the cell surface, the low level of free gp120 
detected in plasma in vivo
401 , 402
 might not be physiologically sufficient for 
ADCC-mediated cell deaths to occur.   
 
1.19 The Cellular Immune Response 
 
The adaptive immune response against HIV-1 infection is a complex process 
involving both CD8
+
 and CD4
+
 T-lymphocytes.  The HIV-1-specific, MHC-I 
restricted CD8
+
 cytotoxic T-lymphocytes (CTLs) emerge before sero-conversion 
and have been shown to suppress viraemia through arresting virus 
replication
403,404 ,405 ,406 ,407
.  Clinical studies observe that CD8
+
 CTL inversely 
correlates with disease progression.  In these studies, patients with strong CD8
+
 
CTL response progress slowly in their disease course and vice versa
408,409,410
.  
Furthermore, studies on asymptomatic long-term non-progressors and exposed 
uninfected African sex workers reveal that these individuals possess strong CD8
+
 
CTL activity
411,412,413,414
, suggesting a protective role of CD8
+
 CTL in vaccine 
design strategy.   
 
Unlike the neutralising antibody responses which only target Env, the CD8
+
 CTLs 
target epitopes in Gag, RT, Env and all the accessory/regulatory 
proteins
415,416,417,418,419,420
.  The ability of CD8
+
 CTLs to control viraemia depends 
on the viral epitope recognised.  In a comprehensive cohort study with untreated 
HIV-1 patients, only a Gag-specific response is associated with decreased viral 
load, while Env-specific and accessory/regulatory protein-specific responses are 
associated with increased viral load
421
.  Furthermore, epitope recognition by CD8
+
 
CTLs is governed by the human leukocyte antigen (HLA) type of MHC-I.  
Patients with homozygous HLA alleles have a narrower CD8
+
 CTL reactivity and 
progress more rapidly to AIDS, compared to those with heterozygous alleles
422
.  
In addition, certain HLA genotypes, such as A2, B57, B27 and DR-13, are 
associated with delayed progression to AIDS, while others are associated with 
accelerated disease progression
423
.  These findings suggest a differential viral 
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antigen expression by different HLA alleles, resulting in either increased or 
decreased level of CD8
+
 CTLs recognition and immune response.   
 
The CD8
+
 cells secrete a number of antiviral factors that can inactivate HIV-1.  
These include cell antiviral factor (CAF), β-chemokine, macrophage-derived 
chemokine (MDC) and IL-16.   
 
CAF 
 
The CAF inhibits virus replication by suppressing the Tat-mediated LTR 
transcription
424
.  When the culture supernatant of CD8
+
 T-cells was added to HIV-
1 infected cell culture, virus replication was reduced via a non-MHC restricted 
and non-cytolytic mechanism
425 , 426 , 427
.  An animal study with SIV infected 
macaques indicates that the level of CAF activity directly correlates with CD4
+
 
cell count and viraemia suppression
428
.  In HIV-1 patients, CAF activity is 
associated with disease progression.  Asymptomatic patients display a 
significantly greater extent of CD8
+ 
antiviral activity and CD4 count than AIDS 
patients
429,430
.     
 
β-chemokine 
 
Three β-chemokines, RANTES, macrophage inflammatory protein (MIP)-α and 
MIP-β, are secreted by CD8+ cells and demonstrate potent antiviral activities in 
vitro
431.  These β-chemokines act as antagonists to the R5 co-receptor and block 
viral replication at the entry step.  However, since X4-tropic viruses do not utilise 
the R5 co-receptor, β-chemokines are only effective in containing R5-tropic HIV-
1 isolates
432.  Furthermore, β-chemokines activity fails to show a clear correlation 
with viral load, CD4 counts or disease progression, since asymptomatic patients 
are found to have similar levels of β-chemokines as AIDS patients433,434,435.  
  
MDC 
 
Little is known about MDC and controversial results on its antiviral properties 
were reported by different groups.  In one study, MDC was found to be a potent 
antiviral factor to both M-tropic and T-tropic virus isolates
436
, while another study 
reports selective virus inhibition in macrophages but not in T-cells
437
.  Even more 
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so, MDC is observed to enhance virus replication in macrophages in a third 
study
438
.   
 
IL-16 
 
IL-16 is a chemoattractant to the CD4 receptor
439,440
.  Binding of this cytokine to 
CD4 prevents HIV-1 from infection, inhibits viral replication and preserves the 
proliferation of uninfected CD4
+
 cells
441,442,443
.  A direct correlation between the 
level of IL-16 and disease progression has been described.  Asymptomatic 
patients are found to have a high level of IL-16, compared to those who have 
progressed
444,445
.   
 
However, CD8
+
 CTL-mediated immune response is only effective in the early 
stage of infection as it fails to suppress viral load persistently.  HIV-1 develops 
escape mechanisms to avoid CTL recognition and eventually eliminate the 
immune cells.  Several studies have described the emergence of escape mutants 
where epitopes are mutated to avoid CD8
+
 CTL recognition and lysis
446,447,448,449
.  
In addition, viral proteins, Nef and Tat, can down-regulate MHC-I expression on 
infected cells, thereby reducing antigen presentation and recognition
316, 450
.  
Furthermore, persistent exposure to viral antigen can lead to CD8
+ 
CTL 
exhaustion where the antiviral clonotypes can completely disappear within a 
week
451
.  When CD8
+
 CTLs are eliminated, HIV-1 replication is no longer 
effectively suppressed, thus resulting in a persistent infection. 
 
In addition to CD8
+
 CTLs, adaptive immunity also includes the CD4
+
 T-helper 
(Th) cell response.  The CD4
+
 CTLs are MHC-II restricted and target both 
infected and uninfected cells
452 , 453
.  Upon antigen recognition, CD4
+
 CTLs 
produce a number of cytokines which have antiviral effects.  Depending on their 
function and cytokine production, the CD4
+
 T-cells can be divided into either Th1 
or Th2 subsets
 454
.  The Th1 subset secretes IL-2, IFN-γ and TNF-α and is 
associated with CTL immunity while the Th2 subset secrets IL-4, 5, 6, 10, and 13 
and is associated with humoral responses.  A switch from Th1 to Th2 response 
correlates with disease progression, in which Th1 response is found in patients 
with asymptomatic HIV-1 infection while Th2 response is found in patients in a 
later stage of the disease
455,456,457,458
.  Vigorous CD4
+
 CTL response is associated 
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with suppressed viral load
459
 and is essential in maintaining an effective CD8
+
 
CTL response
460,461
.  Since CD4
+
 cells are targeted and rapidly eliminated by 
HIV-1, administration of ART early in the infection may be beneficial in 
preserving the CD4
+
 cell count and delaying disease progression. 
 
1.20 Vaccine development 
 
Despite intensive research over the past 25 years, a safe and effective HIV-1 
vaccine is still lacking to date.  Multiple design strategies have been undertaken, 
including: (1) live-attenuated virus, (2) inactivated virus, (3) recombinant 
proteins, (4) vector expressing viral proteins and (5) naked DNA.  
 
Live attenuated virus 
 
Live attenuated virus is perhaps the oldest form of vaccine approach, documented 
as far back as the 16
th
 century in China where attenuated smallpox was inoculated 
into human recipients to prevent infection
462
.   This practice was later introduced 
to the West where pioneers like Edward Jenner and Louis Pasteur successfully 
introduced a number of vaccines against smallpox and other infectious 
agents
463,464
.   
 
Early studies on macaques show that vaccines employing whole attenuated SIV 
fail to protect against challenge infection but can prevent early disease 
development
465,466
.  In other studies employing SIVmac with deletion at nef or 
vpr, animals displayed strong neutralising antibody responses
335, 467
 and were 
completely protected from challenge infection
468,469
.  In some cases, however, the 
viral deletion was repaired and the animals developed disease,
470,471
 and this raises 
significant concern in terms of using live attenuated virus as vaccine immunogen.  
Because of its potential risk, it is very unlikely that live attenuated virus will ever 
be administered to human subjects. 
 
Inactivated virus 
 
Whole inactivated virus is another approach commonly employed in vaccine 
design, in which the microorganism is killed thermally and/or chemically
472,473
.  
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This strategy was proven to be very effective in vaccines developed for non-
primate retroviruses, such as feline immunodeficiency virus and equine infectious 
anaemia virus
474,475
.  Immunisation studies with primates produced mixed results.  
Macaques immunised with SIVmac were protected against low dose challenge 
with homologous virus strain
476,477
, but not with heterologous virus strain
478
.  
Because gp120 sheds frequently from virion surface, one concern about an 
inactivating virus is retaining sufficient envelope antigenicity.  A recent study by 
Poon et al. (2005) demonstrated that treatment with formaldehyde prior to thermal 
inactivation can stabilise the envelope trimer and allow better retainment of 
gp120, thereby enhancing immunogenicity
479
. 
 
Viral protein 
 
The use of recombinant viral protein as a vaccine immunogen was a fairly recent 
innovation, and has so far only been used against Hepatitis B
480,481
.  For HIV-1, 
the envelope glycoprotein is the main antigen being investigated.  Soluble gp120, 
gp140 (which contains the external domain of gp41) and gp160 are produced in 
baculovirus or in mammalian cell lines
482
.  Chimpanzees that are immunised with 
recombinant gp120 are found to be protected from challenge infection with either 
homologous or heterologous virus
483,484,485
.  Subsequent studies indicated that the 
protective immunity is enhanced by employing native envelope trimer or by 
partial deletion at the V2 loop, both of which induce weakly cross-reactive 
neutralising antibody responses
486,487
.   
 
Based on encouraging data from animal studies, the VaxGen Pharmaceuticals 
conducted two phase III clinical trials (VAX003 and VAX004) to evaluate the 
potential use of recombinant envelope glycoprotein in human vaccine
488,489
.  The 
VaxGen studies were the first of all HIV vaccines to enter phase III trials and they 
provided significant insights on the use of recombinant glycoproteins as vaccine 
immunogens and the effect of immunisation on the immune system.  The 
VAX004 study recruited 5,417 volunteers in North America and Europe.  Two 
clade B gp120 antigens, MN which is X4-tropic and GNE8 which is R5-tropic 
were used in this study
488,489
.  The VAX003 study recruited 2,545 volunteers in 
Thailand.  Since clades B and E are prevalent subtypes in Thailand, the VAX003 
trial employed gp120 isolates derived from both subtypes: MN (clade B) and 
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A244 (clade E)
 488,489
.  All the recombinant gp120 was produced in Chinese 
hamster ovary cells and intramuscularly administered to the volunteers at months 
0, 1, 6, 12, 18, 24 and 30
488,489
.  In both trials, the vaccines failed to produce a 
protective immunity against HIV-1 infection.  The same percentage of infection 
was found in the vaccinated group and the control group which received a 
placebo
489
.  In addition, there was no difference in viral load or clinical course 
among the infected individuals, whether they were vaccinated or not.  
Nevertheless, the VaxGen studies provide valuable information not only for future 
vaccine design, but also to raise the issues of safety and risk evaluation, social and 
governmental support, as well as trial management
489
.  
 
Vectors expressing viral proteins 
 
In addition to using recombinant proteins alone, another approach to vaccine 
design is to express the viral proteins by non-lentivirus vectors, which better 
mimic natural infection.  One of the most commonly used vectors is poxvirus.  
Chimpanzees and macaques which were immunised with poxvirus (canarypox or 
vaccinia) expressing SIV gp160 developed SIV-specific CD8
+
 cellular immunity 
and were protected from challenge infection
490 ,491 ,492
.  In a further study by 
Barouch et al. (2001), vaccinia virus Ankara vector expressing SIV89.6P Gag-Pol 
and HIV-1 Env induced potent Gag-specific CTLs and Env-specific neutralising 
antibody responses in the immunised macaques
493
.  Although the vaccine failed to 
protect the animals from challenge infection, it helped to preserve CD4+ T-cells, 
suppressed viral load and delayed disease progression. 
 
Another commonly used vector in vaccine design is adenovirus.  Adenovirus 5 
vector expressing SIV89.6P Gag and Env induced potent CD8
+
 CTL response and 
protects the primates from HIV-1 challenge
494,495
.  Based on this data, Merck 
Pharmaceuticals conducted a Phase II “test of concept” trial (also known as the 
STEP trial) investigating the efficacy of adenovirus 5-based HIV-1 vaccine.  The 
study globally recruited 3,000 volunteers who are at high risk of HIV-1 infection 
and participants were vaccinated either once or twice with a combined dose 
containing three adenovirus 5 vectors, each expresses HIV-1 Gag, Pol, or Nef 
496
.  
In the group where the vaccine was administered just once, 24 out of 741 
volunteers contracted HIV-1 infection, compared with 21 out of 762 volunteers in 
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the placebo group.  In the group where the vaccine was administered twice, 19 out 
of 672 volunteers contacted HIV-1, compared to 11 out of 691 volunteers in the 
placebo group
497
.  Not only did the vaccine fail to induce protect immunity, there 
was also a potential increased risk of HIV-1 infection.  For this reason, the trial 
was discontinued.  The failure of the STEP trial indicates that a vaccine which 
aims to elicit CTL immunity alone is not sufficient to prevent HIV-1 infection 
and, thus, a neutralising antibody response must also be elicited for future 
rational
498
.   
 
Naked DNA 
 
A recent strategy in vaccine design is the administration of plasmid DNA 
containing the genes of viral antigens.  These viral genes are then translated into 
proteins by the host machinery and presented on the cell surface by MHC-I or II, 
thereby stimulating CD8
+
 CTL or CD4
+
 helper responses.   
 
Early studies by Weiner and associates (1995 and 1997) demonstrate that the 
inoculation of plasmid DNA encoding gp160 alone, or with other HIV-1 genes, 
can elicit both humoral and cellular immune responses in chimpanzees and protect 
the animals from challenge infection with heterologous virus
499,500
.  A similar 
result was observed in another study where rhesus macaques, immunised with 
plasmid DNA encoding gp120IIIB, displayed potent Th-1 responses
501
.  To amplify 
the immune response, subsequent studies undertake a DNA prime / recombinant 
protein boost strategy.  In two independent studies where rhesus macaques were 
first primed with envelope DNA, followed by boosting with soluble recombinant 
gp120 IIIB or gp160 IIIB, strong neutralising antibody responses were detected and 
the animals were protected from homologous virus challenge
502 ,503
.  Another 
approach to maximising the immune response is by priming with DNA, followed 
by boosting with vector which expresses viral proteins.  In a study by Robinson et 
al. (1999), cellular immune response was detected after the animals were primed 
with SIVmac239 gag and pol and boosted with poxvirus expressing Gag-Pol 
polyprotein and Env (or Nef) 
504
.  A similar result was obtained in several other 
studies in which animals immunised with DNA/poxvirus were either completely 
protected from challenge infection or displayed a reduced viral load
505,506,507,508
.  
A number of DNA vaccines with poxvirus boost or adenovirus boost are now 
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being tested in clinical trials
509
.  Preliminary data from one of the DNA vaccine 
candidates, HVTN-204, indicates that the vaccine is well-tolerated and elicits T 
cell response in approximately 70% of the recipients
510,511
.  Once the trials of 
HVTN-204 and others are completed, detailed information regarding the safety, 
efficacy and the type of immune response being produced by DNA vaccines will 
be known, and this will provide important insights for future vaccine 
development. 
 
Ever since its discovery, the development of an efficacious HIV-1 vaccine has 
been one of the most challenging objectives for the scientific community.  
Because of its extensive genetic variation and its ability to integrate into the host 
genome to create a persistent infection, an ideal HIV-1 vaccine must be cross-
reactive and able to elicit both potent humoral and cell-mediated immunity.  
Increased funding support from both governments and private enterprises (i.e. the 
Gates Foundation) allows investigators to form multi-site collaboration and work 
on initiatives focusing on neutralising antibodies, CTL immunity and diagnostic 
tools.  Any new understanding and discoveries made today will contribute to the 
search for a working vaccine tomorrow.  
 
1.21 Aims of the thesis 
 
This thesis consists of three main aims of investigation; all revolve around HIV-1 
Env and neutralising antibody responses.  We aim to: 
1) Evaluate the results from two standard neutralisation protocols and 
examine parameters that might contribute to the discrepancies between 
different assays. 
2) Study the neutralising antibody responses in six patients with PHI using 
the pseudovirus-based assay and to investigate the concomitant viral 
diversity and evolutionary history. 
3) Examine the effect of Nef on neutralisation and possible causes behind the 
observed phenomenon.   
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Chapter 2: 
 
Materials and Methods 
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2.1  Cell lines and culture 
 
The cell lines used in the study are listed in Table 2.1.  All cells were maintained 
at 37C with 5% CO2 in a humidified atmosphere.   
 
Adherent cells were maintained in a complete medium of Dulbecco’s Modified 
Eagle Medium (DMEM) (GIBCO Invitrogen) containing 10% heat-inactivated (at 
56C for 1 hour) fetal calf serum (FCS) (Scientific Laboratory Services), 250 
U/ml Penicillin and 250μg/ml Streptomycin (1% P/S) (GIBCO Invitrogen).  For 
the NP2 cells stably transfected with the HIV-1 co-receptor CXCR4 (X4) or 
CCR5 (R5), 500g/ml G418 (Sigma-Aldrich) and 1g/ml puromycin (Sigma-
Aldrich) were also added to the complete DMEM for co-receptor selection.   The 
adherent cells were passaged at 85-90% confluence.  The monolayer was washed 
once with phosphate-buffered saline (PBS) (Sigma-Aldrich) before Trypsin-
Ethylenediaminetetra acetic acid (EDTA) (GIBCO Invitrogen) was added.  
Following incubation at 37C for 2 to 5 minutes, when the cells had detached 
from the plastic surface, they were suspended in complete DMEM and pelleted by 
centrifugation (MSE Mistral 3000i) at 400g for 5 minutes.  The cell pellet was 
resuspended in complete DMEM, then diluted in a ratio of 1:10 and transferred to 
a new tissue culture flask (Starstedt).   
 
Non-adherent cells were maintained in complete RPMI 1640 medium (GIBCO 
Invitrogen) containing 10% heat-inactivated FCS and 1% P/S.  Cells in 
suspension were passaged by dilution at a ratio of 1:10 in complete RPMI when 
confluence reached 85-90%. 
 
To monitor cell viability, 10μl of cell suspension were added to an equal volume 
of 0.4% Trypan Blue (Sigma-Aldrich).  The number of viable (clear) and non-
viable (blue) cells were counted in a haemocytometer by light microscopy. 
 
2.2  PBMCs separation and culture 
 
Donor peripheral blood mononuclear cells (PBMCs) were isolated from buffy 
coat residue (National Blood Service, St George’s Hospital, UK).  The buffy coat  
residue was first diluted 4 times with PBS before overlaying an equal amount of 
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Table 2.1 – Cell lines used in the investigation 
 
 
 
 
 
 
Table 2.1 The cell lines used in the study, their provenance and original citation 
in the literature are shown. 
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1X Histopaque solution (Sigma-Aldrich) in 50ml Falcon tubes (BD Biosciences).  
The mixture was centrifuged at 800g for 10mins and the PBMCs were identified 
at the interface of the plasma and Histopaque layers.  The PBMCs were carefully 
removed with a Pasteur pipette and washed 3 times with 50ml PBS, followed by 
centrifugation at 400g for 10mins.  Before the last centrifugation, 10μl of cells 
were added to an equal volume of 0.4% Trypan Blue and the number of viable 
cells were counted in a haemocytometer by light microscopy.  The cell pellet was 
resuspended in complete RMPI containing 10% heat-inactivated FCS, 1% P/S, 
stimulated with 1µg/ml of Phytohaemagglutinin (PHA) (Sigma-Aldrich) and 
cultured at 37°C with 5% CO2 for 2 days.  The PBMCs were washed once with 
medium by centrifugation at 400g for 5 minutes and resuspended in fresh 
complete RPMI supplemented with 1µg/ml of Interleukin-2 (IL-2) (Sigma-
Aldrich).   
 
2.3  Freezing and thawing cells 
 
To freeze, cells lines were grown in a 75cm
2
 flask until they were 90% confluent.  
Adherent cells were first harvested by incubation with Trypsin-EDTA, then 
suspended in 10ml DMEM and the number of viable cells was counted in a 
haemocytometer by light microscopy.  The cells were pelleted by centrifugation at 
400g for 5 minutes in a 15ml Falcon tube (Invitrogen).  The cell pellet was 
resuspended in 4ml ice-cold heat-inactivated FCS and a further 4ml of ice-cold 
DMEM containing 20% dimethyl sulfoxide (DMSO) (Sigma-Aldrich) were 
added.  The cells in freezing mixture were aliquoted on ice in 1ml volumes into 
cryotubes (Merck) and frozen slowly overnight at -80C, at a rate of 1C/minute 
in a cryofreezing container (Jencons) containing isopropanol (Sigma-Aldrich).  
Long-term storage was in liquid nitrogen.  Freezing of non-adherent cells was 
carried out in a similar manner on one 75cm
2
 flask of cells, without the Trypsin-
EDTA harvesting step.  All cells were frozen in aliquots containing 10
6
-10
7
 
cells/ml. 
 
Frozen cells were partially thawed in a 37°C water bath before being quickly 
decanted into a 50ml Falcon centrifuge tube containing 45ml PBS.  The cells were 
pelleted by centrifugation at 400g for 5 minutes and resuspended in 5ml complete 
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DMEM before transfer to a 25cm
2
 flask.  After incubation at 37C for 4 hours to 
allow diffusion of residual DMSO from the cell membranes, the medium was 
replaced with 5ml of fresh complete DMEM. 
 
2.4 Laboratory-adapted HIV-1 strains and virus plasmids 
 
All the HIV-1 plasmid DNAs used in the study were obtained from Dr. M. Pizzato 
(Section of Infectious Diseases, Imperial College).  These include a full-length 
wild-type (WT) NL4.3
518
, a nef-deficient (ΔNef) NL4.3 mutant333, a gp41 
cytoplasmic tail truncated (ΔCT) NL4.3 mutant519, an env-deficient (ΔEnv) NL4.3 
virus backbone
333
 and an env-deficient (ΔEnv) HXB2 virus backbone520,521.  The 
WT and mutant NL4.3
 
were used in various neutralisation studies described in 
Chapters 3 and 5.  The ΔEnv HXB2 virus backbone was used for pseudotyping 
primary env derived from patients (section 2.16).  Methods of virus production are 
described in sections 2.16 and 2.21 – 2.24.   
 
2.5   Primary HIV-1 isolation and culture 
 
Primary PBMCs from HIV-1 patients were separated from blood and cultured 
using the same protocol described for donor PBMCs (section 2.2).  The majority 
of primary PBMCs were stored frozen (section 2.3) and the remainder (5x10
6
 
cells) was cultured with stimulated donor PBMCs (5x10
6
 cells).  To monitor virus 
replication, culture supernatant was harvested every 2 days and RT activities of 
the virus were measured by the SYBR Green I-based product enhanced reverse 
transcriptase (SG-PERT) assay
522
 (section 2.15).  Stimulated donor PBMCs 
(5x10
6
 cells) were added to the culture weekly and every addition was counted as 
1 passage.  A primary culture was defined as patient PBMCs fractionated from 
blood and subjected to no more than 3 passages or cultured for less than 30 days.     
 
2.6  Co-receptor usage determination 
 
Co-receptor phenotype of the primary isolates was determined by assay on NP2 
cell lines, engineered to express either X4 or R5 coreceptor.  The two clones of 
NP2 cells (2x10
4
) were each seeded onto 48-well tissue culture dishes the day 
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prior to infection.  Virus supernatant from the primary culture was harvested by 
low speed centrifugation at 400g for 30 minutes at 4C, then purified through a 
0.45µm filter (3M).  Aliquots (150µl) of the supernatant were added to both NP2 
cells and incubated at 37C for 2 hours, whereupon the supernatants were again 
removed from the cells.  The cells were washed twice with PBS and cultured in 
fresh complete DMEM supplemented with G418 and puromycin at 37C for a 
further 40 to 42 hours, then stained for HIV-1 p24 antigen. 
 
To stain for infection, NP2 cells were fixed with a mixture of acetone and 
methanol (1:1) (Sigma-Aldrich), incubated at 4C for 10minutes and washed in 
PBS.  Anti-p24 antibody, ARP321
523
 (diluted 1:40 in PBS containing 1% FCS) 
(National Institute for Biological Standards and Control (NIBSC), was added to 
the cells and incubated for 1 hour at room temperature.  The cells were washed 
twice with PBS before incubation with anti-mouse β-gal antibody (diluted 1:400 
in PBS containing 1% FCS) for 1 hour at room temperature.  The secondary 
antibody was removed by 2 washes with PBS and the cells were stained for β-gal 
with 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) (Calbiochem).  
The substrate (stored as a 0.12M stock in dimethylformamide (Sigma-Aldrich) 
was dissolved 1:50 in X-gal buffer (PBS with 0.01% deoxycholic acid, 0.02% 
NP40, 2mM MgCl2, 0.15% K3[Fe(CN)6], 0.21% K4[Fe(CN)6]·3H2O) immediately 
before use.  Aliquots (250µl) of this staining solution were added to the cells and 
incubated at 37°C for 2 hours.  The blue foci which indicated infected cells were 
easily observable by light microscopy.  The primary isolate was defined as R5-
using, if it exclusively infected the NP2-R5 cell line and X4-using, if it only 
infected the NP2-X4 cell line, or X4/R5-using if it infected both lines. 
 
If an isolate was determined as X4-using by the NP2 assay, it would be further 
confirmed by the commercial Trofile assay
524
 which was carried out by 
Monogram Biosciences (UK).  Trofile is a single-cycle recombinant virus assay 
employing pseudovirus consisting of full-length env gene derived from the 
primary isolate and a light-emitting Luciferase marker gene.  The pseudovirus is 
used to infect cell lines that express either the R5 or X4 co-receptor, and a positive 
infection would result in light emission.                             
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2.7  Proviral DNA extraction 
 
HIV-1 Proviral DNA was extracted directly from patients’ PBMCs or PBMCs 
from primary cultures using the QIAamp DNA blood mini kit (Qiagen).  The 
PBMCs (5x10
6
) were washed once with PBS, pelleted by centrifugation at 
10,000g, and resuspended into 200µl PBS.  Proteinase K (20µl) was added to the 
cell suspension to inactivate nucleases that might degrade the genomic DNA in 
the subsequent purification steps.  The PBMCs were lysed with 200µl buffer AL 
and incubated at 56°C for 10 minutes to maximise DNA yield.  Absolute ethanol 
(200µl) was added to the lysate to precipitate the genomic DNA.  The resulting 
mixture was transferred into a spin column and centrifuged at 10,000g for 1 
minute, during which time the DNA was bound to the membrane of the column, 
while contaminants were eluted and discarded.  Residual contaminants were 
removed by one wash with buffer AW1 (500µl) followed by another wash with 
buffer AW2 (500µl) with centrifugation at 10,000g for 1 minute each.  The flow-
through was discarded and any residual wash buffer removed by further 
centrifugation for 1 minute at 10,000g.  Bound DNA was eluted by addition of 
100-150μl buffer AE (10mM Tris-HCl, 0.5mM EDTA, pH 9.0) to the membrane, 
followed by a 1 minute centrifugation at 10,000g.  The eluted DNA was then 
diluted 1:50 in distilled water and its concentration was calculated by absorbance 
(at 260nm) using the appropriate programme on a Ultraspec 2000 
spectrophotometer (Pharmacia Biotech) and correcting for the dilution factor 
(50X). 
 
2.8  Polymerase Chain Reaction (PCR) amplification of env and rev genes 
 
Proviral DNA extracted from infected PBMCs (section 2.7) constituted the 
template for nested PCR amplification of full-length (gp160) env and rev genes.  
Outer sense primer EnvF1 (5'-GCCTTAGGCATCTCCTATGGCAGGAAGAA-
3') and outer antisense primer EnvR1 (5'-TTGTAAGTCATTGGTCTTAAAGGT 
AC-3') were used in the first round of amplification.  For the second round, the 
inner sense primer was EnvF2 (5'-GGCATCTCCTATGGCAGGAAGAAGC-3') 
and the inner antisense primer was EnvR2 (5'-CTGTATTGCTACTTGTGATTGC 
TCC-3').  A list of all the primers used in this project can be found in Table 2.2.   
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Table 2.2 – Primers used in the investigation 
 
 
 
 
 
 
Table 2.2 The primers used in the study are listed.  Citations are given for primers 
that have been previously described in the literature.  All primers were 
synthesised by Invitrogen.   
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Easy-A High Fidelity polymerase (Strategene) was employed for all PCR 
amplifications with standard reaction conditions (10X Easy A buffer with 1.5mM 
MgCl2, 20pmol of each primer, 0.25mM dNTPs and enough double-distilled 
water to make up to a final volume of 50µl).  Generally, between 100ng to 1µg of 
total DNA served as a template for the first round of PCR amplification and 1µl of 
the first round amplicon was used as a template for the second round of PCR.  The 
cycling parameters for both rounds were as follows: 1 cycle of hotstart 
polymerase activation at 95°C for 2 minutes, 35 cycles of amplification at 95°C 
(15 seconds), 55°C (15 seconds) and 72°C (4 minutes), and 1 cycle of final 
elongation at 72°C for 7 minutes.  The PCR product was separated on a 0.7% 
agarose gel and the env/rev cassette was approximately 2800 base pairs (bp) in 
size.  The DNA was purified from non-specific products by gel extraction using 
the QIAquick gel extraction kit (Qiagen) (Section 2.9).    
 
2.9  DNA purification by gel extraction 
 
To extract DNA from a gel, the required band was excised from the agarose with 
minimal exposure to ultraviolet light and weighed.  A volume of buffer QG 
(Qiagen) 3 times the weight of the gel band was added, and the mixture was 
solubilised at 50°C for 10 minutes.  To precipitate the DNA fragment, 1 volume 
of isopropanol was added to the mixture.  The resulting solution was centrifuged 
at 10,000g for 1 minute in a QIAquick spin column, during which the DNA was 
bound to the column membrane while the small contaminants were eluted and 
discarded.  The column was then washed with 750μl buffer PE by centrifugation 
for 1 minute at 10,000g.  The flow-through was discarded and any residual wash 
buffer removed by further centrifugation for 1 minute at 10,000g.  Bound DNA 
was eluted by addition of 25-40μl Buffer EB (10mM Tris-HCl, pH8.5) to the 
membrane, followed by centrifugation at 10,000g for 1 minute. 
 
2.10  TOPO cloning  
 
The purified env/rev cassette was T/A cloned into pcDNA3.1/V5-His TOPO 
vector (Invitrogen) for CMV promoter-driven expression.  The cloning reaction 
mixture was set up by incubating 2µl purified DNA with 0.5µl TOPO vector in 
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the presence of 0.5µl salt solution (1.2M NaCl, 0.06M MgCl2) for 30 minutes at 
room temperature.  Half of the reaction mixture (1.5µl) was transferred into a vial 
of One Shot TOP10 chemically competent E. coli cells and incubated on ice for 
30 minutes.  The remaining 1.5µl was stored at -20°C for future transformation, if 
necessary.  The cells were heat-shocked at 42°C for 1 minute and immediately 
returned to ice for a 2 minute incubation.  A 250µl aliquot of SOC medium (2% 
Tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM 
MgSO4, 20mM glucose) (Invitrogen) was added to the cells and the mixture was 
agitated in an Innova 4000 incubator shaker (New Brunswick Scientific) at 
250rpm for 90 minutes at 37°C.  A 150µl aliquot of the bacterial culture was 
spread on a Luria broth (LB) agar plate containing 100µg/ml ampicillin and 
incubated at 37°C overnight.  The remaining culture was stored at 4°C for future 
plating.   
 
2.11  Orientation analysis by colony PCR 
 
Since DNA was cloned into the TOPO vector bi-directionally, transformants that 
contained plasmid inserts in the correct orientation with respect to the CMV 
promoter was analysed by colony PCR.  A small fraction of the colony was placed 
into a 20µl PCR reaction containing 0.2 µl of Herculase II Fusion DNA 
polymerase (Stratagene), 1.5mM MgCl2, 0.25mM dNTPs, and 10pmol of each 
primer.  The sense primer was ColF (5’-GCTATAAGATGGGTGGCAAGTGGT 
C-3’) and the antisense primer was BGH (5'-TAGAAGGCACAGTCGAGG-3´) 
(Table 2.2), producing a 300 to 400 bp PCR product.  The cycling parameters 
were 1 cycle of initialisation at 95°C for 4 minutes, 25 cycles of amplification at 
95°C (30 seconds), 55°C (30 seconds) and 72°C (30 seconds), and 1 cycle of final 
elongation at 72°C for 7 minutes.  All correctly oriented env clones were 
expanded by small-scale plasmid preparation using the QIAprep Spin Miniprep 
kit (Qiagen) (section 2.12).  
 
2.12  Small-scale plasmid preparation from bacteria 
 
Up to 3ml aliquots of LB medium with 100μg/ml ampicillin were inoculated with 
single colonies selected from the plates and shaken at 37°C overnight.  Most of 
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this bacterial suspension (2ml) was centrifuged at 400g for 3 minutes and the 
remaining 1 ml of culture was stored with 15% glycerol (Sigma-Aldrich) at -80
o
C 
as bacterial stock.  After the supernatant was removed, the bacterial pellet was 
resuspended by vortexing briefly with 250μl buffer P1 (25mM Tris-HCl and 
10mM EDTA buffer (pH8.0) with 100μg/ml RNase A).  The bacterial suspension 
was lysed with 250μl buffer P2 (200mM NaOH, 1%SDS) and incubated at room 
temperature for 5 minutes.  Neutralisation buffer N3 (350μl) was added to the 
lysate which was then incubated for 10 minutes on ice.  Bacterial debris and 
genomic DNA was pelleted by centrifugation at 10,000g for 10 minutes.  The 
plasmid DNA contained in the supernatant fluid was transferred to the spin 
column provided and centrifuged at 10,000g for 1 minute, during which the 
plasmid DNA was bound to the column membrane while contaminants were 
eluted and discarded.  Residual nuclease activity was removed by addition of 
500μl buffer PB followed by a 1 minute centrifugation at 10,000g.  The column 
was then washed with 750μl buffer PE by centrifugation for 1 minute at 10,000g.  
The flow-through was discarded and any residual wash buffer removed by further 
centrifugation for 1 minute at 10,000g.  Bound DNA was eluted by addition of 25-
40μl buffer EB to the membrane, followed by centrifugation at 10,000g for 1 
minute.  The eluted DNA was then diluted 1:50 in distilled water and its 
concentration was calculated by absorbance (at 260nm) using the appropriate 
programme on a spectrophotometer and correcting for the dilution factor (50X). 
 
2.13  Large-scale plasmid preparation from bacteria 
 
Frozen bacterial stocks of full-length WT NL4.3 and env-deficient HXB2 
plasmids DNA were obtained from Dr. M. Pizzato (Section of Infectious 
Diseases, Imperial College).  The two bacterial stocks were expanded by large-
scale preparation using the Qiagen Plasmid Maxi Kit (Qiagen).  Approximately 
15μl of each of the bacterial stock were inoculated at 37°C overnight with 5ml 
aliquots of LB medium containing 100μg/ml ampicillin.  Most of this bacterial 
suspension (4ml) was inoculated further with 250ml of LB medium containing 
100μg/ml ampicillin at 37°C and the remaining 1 ml of culture was stored as 
bacterial stock in with 15% glycerol at -80
o
C.  After 6 to 8 hours of shaking in an 
incubator shaker, 1ml of chloramphenicol (34mg/ml in 100% ethanol) (Sigma-
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Aldrich) was added to the culture to inhibit translation and enhance plasmid DNA 
copy numbers.  The bacterial culture was then inoculated for a further 16 hours 
before being pelleted by centrifugation at 400g for 15 minutes at 4
o
C.  The 
bacterial pellet was resuspended in 10ml P1 buffer, then lysed by incubation in 
10ml lysis buffer P2 at room temperature for 5 minutes.  The suspension was 
neutralised on ice with 10ml buffer N3 for 20 minutes.  Cell debris and genomic 
DNA were removed by centrifugation at 2000g for 30 minutes at 4°C.   
 
A Qiagen column-500 was equilibrated by applying 10ml equilibration buffer 
QBT (50mM MOPS buffer (pH7.0) containing 700mM NaCl, 15% isopropanol, 
0.15% Triton™ X-100) and allowing the column to empty by gravity flow.  The 
supernatant containing plasmid DNA was added to the column and allowed to 
flow through under gravity.  The column membrane was washed twice with 30ml 
wash buffer QC (50mM MOPS buffer (pH7.0) containing 1.0M NaCl, 15% 
isopropanol).  Plasmid DNA was eluted from the column with 15ml elution buffer 
QF (50mM Tris-HCl buffer (pH8.5) containing 1.25M NaCl, 15% isopropanol), 
mixed with 10.5ml isopropanol to precipitate the DNA which was pelleted by 
centrifugation at 2,000g for 1 hour at 4°C.  The DNA pellet was washed with 5ml 
70% ethanol, centrifuged at 2,000g for 15 minutes and allowed to air- or vacuum-
dry before being resuspended in 200-500μl TE buffer (10mM Tris-HCl, pH 8.0) 
(Sigma-Aldrich).  The eluted DNA was then diluted 1:50 in distilled water and its 
concentration was calculated by absorbance (at 260nm) using the appropriate 
program on a spectrophotometer and correcting for the dilution factor (50X).  
Analysis with restriction enzymes (section 2.14) was also carried out to check for 
plasmid recombination.   
   
2.14  Analysis of DNA by restriction enzyme digestion 
 
Plasmid DNA (1-5μg) of the env-deficient HXB2 was mixed with approximately 
10 Units (U) of restriction enzyme HindIII (New England Biolabs) in the presence 
of reaction buffer 2 (10mM Tris-HCl (pH 7.9) with 50mM NaCl, 10mM MgCl2, 
1mM dithiothreitol), and enough double-distilled water was added to make up to a 
final volume of 20-50μl.  The restriction enzyme(s) accounted for less than 10% 
of the final volume.  The reaction mixture was digested at 37°C for 2 hours.  A 
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15μl aliquot of the digested DNA sample was analysed on a 0.7% agarose gel 
made up in TAE buffer (40mM Tris-Acetate, 1mM EDTA (pH8.0) and containing 
0.1μg/ml Ethidium Bromide (Sigma-Aldrich), together with a size marker, 0.5μg 
of 1Kb DNA ladder (Promega).  Electrophoresis was carried out at 80-110 volts 
for 90 minutes.  The gel was observed under an UV illuminator to confirm that the 
plasmid contained 4 fragments of approximately 600bp, 1,500bp, 3,500bp and 
6,000bp. 
 
Analysis of the WT NL4.3 plasmid was carried out under the same procedure, 
except with restriction enzymes EcoRI and XhoI (New England Biolabs) in the 
presence of reaction buffer EcoRI (100mM Tris-HCl (pH 7.5) with 50mM NaCl, 
10mM MgCl2, 0.025% Triton X-100) and 10% 1X BSA (in 20mM KPO4 (pH 7.0) 
with 50mM NaCl, 0.1mM EDTA, 5% glycerol).  The correct plasmid contained 2 
fragments of approximately 3,000bp and 11,000bp.  
 
2.15  SG-PERT assay for virus quantification 
 
To quantify virus activity, an in-house SG-PERT assay was developed
522
.  Virus 
supernatant (5µl) was lysed with an equal volume of lysis buffer (100mM Tris-
HCl (pH7.4), 0.25% Triton X-100, 50mM KCl, 40% glycerol, 0.4U/μl RNAse 
inhibitor) and incubated at room temperature for 10 to 15 minutes.  The lysate was 
diluted 10-fold with dilution buffer (20mM Tris-HCl (pH8.3), 5mM (NH4)2SO4, 
20mM KCl).  The diluted lysate (10µl) was mixed with an equal volume of PCR 
reaction mixture (40mM Tris-HCl (pH8.3), 10mM (NH4)2SO4, 40mM KCl, 
10mM MgCl2, 0.2mg/ml BSA, 1/10000 SYBR Green-I, 400μM dNTPs, 1μM 
sense primer, 1μM antisense primer, 1.2μg/ml BMV RNA, 0.2U hotstart Taq) that 
has been pre-aliquoted into the reservoir of a pre-chilled 20μl capillary (Roche 
Diagnostics).  The sense primer was SGF1 (5’-GGTCTCTTTTAGAGATTTACA 
GTG-3’) and the antisense primer was SGR1 (5’-CGTGGTTGACACGCAGACC 
TCTTAC-3’) (Table 2.2).  The capillary was centrifuged for 1 minute at 200g to 
sediment the reaction components before applying to a LightCycler 2.0 (Roche 
Diagnostics).  The cycling conditions were 1 cycle of RT reaction at 37°C for 30 
minutes, 1 cycle of polymerase activation at 95°C for 5 minutes and 45 cycles of 
amplification (denaturation at 95°C for 5 seconds, annealing at 55°C for 5 
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seconds, extension at 72°C for 15 seconds and acquisition at 83°C for 7 seconds).  
Recombinant HIV-1 RT was serially diluted 10-fold with dilution buffer and 
subjected to the SG-PERT assay to generate a standard curve.  Amplification 
curves and melting temperatures were generated by recording the fluorescence 
intensity at 530nm and analyzed using the LightCycler software 4.  The units of 
RT in the sample were calculated from the standard curve using the second 
derivative maximum method with arithmetic background correction.     
 
2.16  Production and selection of functional pseudotyped quasispecies 
 
The env clones were screened for biological function using a pseudovirus-based 
assay
528
.  Pseudovirus was produced by co-transfecting an env plasmid (0.1µg) 
along with the env-deficient HXB2 backbone (0.3µg) into 293T cells (2.5x10
4
) 
that were seeded into 24-well tissue culture dish the day prior to transfection.  The 
two plasmids were added to 4µl Fugene 6 (Roche Diagnostics) transfection 
reagent, previously diluted 1:3 in Opti-MEM I reduced-serum medium (GIBCO 
Invitrogen), and incubated for 30 minutes at room temperature.  The mixture was 
added dropwise to the 293T cells and incubated at 37°C overnight.  The 293T 
cells were washed twice with PBS to remove the transfection reagent and cultured 
with fresh DMEM.  Culture supernatant was harvested 48 hours post-transfection 
and clarified by low speed centrifugation (400g for 10 minutes), followed by 
purification through a 0.45µm filter, and the amount of pseudovirus produced was 
measured by SG-PERT assay (section 2.15).   
 
The infectious supernatant (150µl) was used to infect the TZM-bl cells (Table 1), 
which were seeded (2x10
4
 per well) into a 48-well tissue culture dish the day 
before the supernatant was harvested.  At 48 hours post-infection, β-gal staining 
was carried out; the TZM-bl cells were fixed with 0.5% glutaraldehyde (in PBS) 
(Sigma-Aldrich) for 5 minutes at room temperature followed by 2 washes with 
PBS before staining for β-gal (section 2.6).  Functional env quasispecies produced 
blue foci that were easily observable by light microscopy. 
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2.17  Neutralisation assay using TZM-bl cells 
 
Sensitivities of the functional env-pseudovirus to neutralisation by antisera and 
NAbs were assayed on TZM-bl cells.  The TZm-bl cells is a genetically 
engineered HeLa cell line that expresses CD4, X4 and R5 and contains HIV-1 tat-
inducible luciferase and β-gal reporter genes.  Pseudovirus was produced by the 
same method described in section 2.16, but on a larger scale, with 2µg of the env 
plasmid and 6µg of the env-deficient HXB2 backbone co-transfected into 293T 
cells cultured in a T-75 flask.  Viral supernatants were collected 48 hours post-
transfection, clarified by low speed centrifugation (400g), followed by 
purification through a 0.45µm filter and stored as 1mL aliquot at -80°C.  The 
virus RT activity was measured by SG-PERT assay, as well as by titration on 
TZM-bl cells.  Virus infectious units per unit of RT activity were determined for 
each pseudovirus by directly counting the number of blue foci in the infected 
monolayers 48 hours post-infection.  On average, 10 blue foci were produced by 
every mU of RT of pseudovirus.  In all neutralisation assays, virus input was 
normalised to 75mU (in a volume of 150µl) per well on a 48-well culture dish.  
 
The TZM-bl cells (2x10
4
 per well) were seeded onto a 48-well tissue culture dish 
the day prior to neutralisation.  For neutralisation with NAbs, virus was incubated 
with the NAb for 1 hour at room temperature.  The complex was added to TZM-bl 
cells and an equal volume of complete DMEM was added.  The cells were 
incubated at 37°C for 2 hours, followed by two washes with PBS before being 
cultured in fresh complete DMEM.  The cells were incubated at 37°C for a further 
40 to 42 hours before staining for β-gal (section 2.6).  In cases where replication-
competent virus was used (Chapter 5), protease inhibitor Saquinavir (1µM) 
(NIBSC) was added to limit replication to a single cycle of infection.  All 
antibodies used in the neutralisation assays are listed in Table 2.3.        
 
For neutralisation with antisera collected from HIV-1 infected patients, 
complement factors in the antisera were heat-inactivated at 56°C for 1 hour.  
Heat-inactivated serum pooled from negative donors (Sera Laboratories 
International) was used as a control to check for specificity.  The serum was 
added to the pseudovirus in dilutions of 1:20, 1:50, 1:125, 1:250 and 1:500 and 
incubated for 1 hour at room temperature before addition to the TZM-bl cells.   
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Table 2.3 – Antibodies used in neutralisation assay  
 
 
 
 
 
 
Table 2.3 The neutralising antibodies and sCD4 used in the investigation are 
listed.  B12, 2G12, 2F5 and 4E10 are recombinant monoclonal antibodies 
produced in chinese hamster ovary cells.  ARP401 is an anti-gp120 polyclonal 
antiserum raised in sheep, with a neutralising titre of 1:160.  All antibodies and 
soluble CD4 were obtained from the AIDS Reagent Programme of NIBSC.    
68 
 
The complex was added to TZM-bl cells and an equal volume of DMEM was  
added.  The cells were incubated at 37°C for 2 hours, followed by two washes 
with PBS before being cultured in fresh complete DMEM.  The cells were 
incubated at 37°C for a further 40 to 42 hours before staining for β-gal (section 
2.6).   
 
2.18  Neutralisation assay using NP2 cells 
 
Replication-competent primary HIV-1 was neutralised with NAbs and assayed on 
NP2 cells.  The cells (2 x 10
4
 per well) were seeded into a 48-well tissue culture 
dish the day prior to the assay.  Virus supernatant was incubated with 50µg/ml of 
NAb for 1 hour at room temperature before addition to the NP2 cells. The cells 
were incubated at 37°C for 2 hours, followed by two washes with PBS before 
cultured in a fresh stock of complete DMEM supplemented with G418 and 
puromycin.  The cells were incubated at 37°C for a further 40 to 42 hours before 
staining for HIV-1 p24 antigen (section 2.6).    
  
2.19  Sequence analysis of the env gene 
 
Plasmid DNA of the env clones with correct orientation (section 2.11) was used as 
the template for sequence analysis.  The V1 to V3 region of gp120 was sequenced 
using the antisense primer JAE4 (5’-ACAATTTCTGGGTCCCCTCC-3’) (Table 
2.2).  The sequencing reaction was prepared by mixing 200 to 500ng of the 
plasmid DNA with 3.2 pmol of the primer and enough water was added to bring 
the final volume to 10µl.  The gp120 sequencing mixtures were sent to the 
Genomic Core Laboratory (Medical Research Council, Imperial College) for 
analysis.  All returned data were analysed with BioEdit and MEGA4.1 softwares.   
 
2.20  Sequence analysis of the pol gene 
 
Sequencing of the PR and RT regions of the pol gene were carried out at the 
Molecular Diagnostic Laboratory (Section of Infectious Diseases, Imperial 
College) using the ViroSeq 2.0 Kit (Abbott).  Briefly, virus from 500µl of plasma 
was concentrated by centrifugation at 23,500g for 1 hour at 4°C.  Viral RNA was 
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extracted from the virus pellet by the protocol provided in the Viroseq 2.0 kit.  
The RNA was subjected to nested RT-PCR using the primers from the ABI 
Viroseq HIV-1 genotyping systems.  The amplicons (5µl) from the first round 
served as the template for the second round of PCR.  The PCR conditions for the 
second round were 1X PCR buffer II (ABI), 2.5mM MgCl2, 0.2mM of each 
dNTPs, 0.3µM of each primer and 2.5 units of Amplitaq gold (ABI).  The cycling 
parameters for both rounds were as follows: 1 cycle of polymerase activation at 
93°C for 12 minutes, 40 cycles of amplification at 93°C (20 seconds), 64°C (45 
seconds) and 66°C (3 minutes), and 1 cycle of final elongation at 72°C for 10 
minutes.  The PCR product was visualised on a 1% agarose gel.  Amplicons 
generated from the nested PCR reaction were sequenced by PCR amplification 
with primers A–C and F–H provided in the Viroseq 2.0 kit.  The PCR product was 
air-dried and resuspended in template sequencing reagent (Applied Biosystems) 
prior to separation on an ABI 310 sequencer using 60 cm capillaries (Applied 
Biosystems).  The sequencing data were analysed using BioEdit software.    
 
2.21  Production of ΔNef NL4.3  
 
The ΔNef NL4.3 construct was generated by deletion of the unique XhoI site in 
nef from wild-type (WT) NL4.3 HIV-1 plasmid.  The WT NL4.3 plasmid (10µg) 
was digested with 20U restriction enzyme, XhoI, at 37°C for 2 hours.  The 
digested plasmid was purified by gel extraction (section 2.9).  The opened plasmid 
was ligated by 40U T4 DNA Ligase (New England Biolabs) in the presence of 
reaction buffer (50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 
10 mM Dithiothreitol, pH 7.5) at 16°C overnight.  The ligated plasmid was 
purified by gel extraction before transforming into E. coli.  The ΔNef NL4.3 
plasmid (5µl) was added to a vial of DH5α competent cells (Invitrogen) and 
incubated on ice for 30 minutes.  The mixture was heat-shocked at 42°C for 1 
minute and immediately returned to ice and incubated for 2 minutes.  A 250µl 
aliquot of SOC medium was added to the cells and the mixture was agitated at 
250rpm in the incubator shaker for 60 minutes at 37°C.  A 100µl aliquot of the 
bacterial culture was spread on a LB agar plate containing 100µg/ml ampicillin 
and incubated at 37°C overnight.  Five colonies were selected and plasmid DNA 
was prepared by mini scaled preparation (section 2.12).  The resulting plasmids 
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were sent to the Genomic Core Laboratory (Medical Research Council, Imperial 
College) for molecular sequencing analysis using primer NF1 (5’-
GATGGCCTGCTGTAAG-3’) (Table 2.2).  A large-scale preparation of the 
plasmid with the correct site mutation was carried out using the method described 
in section 2.13. 
 
2.22  Production of ΔCT NL4.3  
 
Plasmid DNA of NL4.3 with truncated cytoplasmic tail (ΔCT) in gp41 was 
obtained from Dr. M. Pizzato (Section of Infectious Diseases, Imperial College).  
The truncation was carried out by replacing codon 713 of the env gene with a 
premature termination codon (TAA) generated by site-directed mutagenesis. 
 
2.23  Production of replication-competent NL4.3  
 
In some cases, the replication-competent NL4.3 virus (WT, ΔNef or ΔCT) were 
produced in cell lines or PBMCs by either transfection using Lipofectamine 2000 
(Invitrogen) or by electroporation. 
 
For transfection, cells were passaged the day prior to transfection to a density of 
1x10
6
 cells/ml and cultured in RPMI supplemented with 10% FCS without 
addition of antibiotics.  On the day of transfection, 5x10
6
 cells were pelleted by 
centrifugation at 400g for 5 minutes before resuspension in 2.5ml of RPMI 
supplemented with 10% FCS.  Plasmid DNA (5µg) was diluted in 100µl Opti-
MEM I medium and incubated for 5 minutes at room temperature.  The 
Lipofectamine 2000 transfection reagent (5µl) was added to the diluted DNA and 
incubated for 30 minutes at room temperature.  The complex was added to the 
cells and incubated at 37C for 4 to 6 hours.  The cells were washed twice with 
PBS by centrifugation at 400g for 5 minutes before cultured in fresh RMPI 
supplemented with 10% FCS.  The transfected cells were cultured at 37C for a 
further 40 to 42 hours before the virus supernatant was harvested and clarified by 
low speed centrifugation (400g for 10 minutes) followed by purification through a 
0.45µm filter.  The virus was assayed by RT activity using the SG-PERT assay 
(section 2.15). 
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For electroporation, cells were processed by the same method, except that the cell 
pellet was resuspended in 500µl of RPMI supplemented with 10% FCS and 
transferred to a 0.4cm gap electroporation cuvette (Bio-Rad Laboratories).  
Plasmid DNA (10µg) was added to the cells and incubated for 5 minutes at room 
temperature.  The cells were electroporated with 1 pulse at 250 volts and 950 
micro-Farads using a MicroPulser Electroporator (Bio-Rad Laboratories), settled 
for 5 minutes without any agitation and transferred to a T-25 flask containing 5ml 
of RMPI supplemented with 10% FCS.  The electroporated cells were cultured at 
37C for 48 hours before the virus supernatant was harvested and clarified, as 
above.  The virus was assayed by RT activity using the SG-PERT assay (section 
2.15). 
                
2.24  Production of NL4.3 chronically infected cell lines 
 
Jurkat E6.1 cell line chronically infected with either WT or ΔNef NL4.3 HIV-1, 
were produced.  Plasmid DNA of the WT and ΔNef NL4.3 were first transfected 
into 293T cells using Lipofectamine 2000 (section 2.23).  The viruses were 
harvested 48 hour post-transfection and clarified by low speed centrifugation 
(400g for 10 minutes) followed by purification through a 0.45µm filter (3M).  
After quantification using the SG-PERT assay, the two viruses were normalised 
for RT activity.   
 
The uninfected Jurkat E6.1 cells were cultured in a T-75 flask until 60-70% 
confluent.  The cells were pelleted by centrifugation at 400g for 5 minutes before 
resuspension in 1ml of complete RMPI.  The cell suspension was divided into two 
T-25 flasks (500µl in each) before addition of another 2ml of medium.  Virus 
supernatant (2.5ml) of WT NL4.3 was added to one of the T-25 flasks and ΔNef 
NL4.3 was added to another.  The cells were incubated at 37°C for 4 to 6 hours, 
then washed 2 times with PBS by centrifugation at 400g for 5 minutes to remove 
the majority of the viruses.  The cell pellets were resuspended in 10ml of fresh 
medium and placed into two new T-75 flasks and cultured at 37°C.  The cells 
were maintained in the same fashion as for uninfected cell lines (section 2.1) and 
passaged at a ratio of 1:10 when they had reached 85-90% confluence.  The 
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amount of virus in cell culture supernatant was monitored every 48 to 72 hours by 
SG-PERT (section 2.15).      
 
2.25  Virus purification and concentration by ultracentrifugation 
 
The viruses used in Western blotting (section 2.25), immunoprecipitation assay 
(section 2.26) and glycosylation analysis (section 2.27) were purified and 
concentrated by ultracentrifugation.  An aliquot (5 to 7 ml) of 20% sucrose 
solution (in PBS) was placed in a Thinwall polyallomer tube (Beckman Coulter).  
Virus supernatant was carefully overlaid onto the sucrose cushion.  The 
polyallomer tube was enclosed in a metal insert before being positioned in a 
swinging bucket rotor (Sorvall AH-629) and centrifuged at 150,000g in an Ultra 
Pro8 ultracentrifuge (Sorvall) for 90 minutes at 4C.  The supernatant and the 
sucrose solution were decanted and the virus pellet was air-dried for 10 minutes. 
 
2.26  Polyacrylamide gel electrophoresis and Western blotting 
 
The levels of Env (gp120 and gp41) and p24 incorporation into the virus were 
assayed by polyacrylamide gel electrophoresis and Western blotting.  Virus 
supernatant was first concentrated and purified by ultracentrifugation (section 
2.25) before the pellet was lysed in 20µl of 2X Laemmli loading buffer (0.125M 
Tris-HCl, 4% sodium dodecyl sulphate (SDS), 20% glycerol, 10% 2-
mercaptoethanol, 0.004% Bromophenol Blue, pH 6.8).  In some cases where the 
virus titres were exceedingly high (>1000mU RT/µl), virus supernatant was lysed 
directly with the Laemmli loading buffer without ultracentrifugation.  The lysate 
was denatured at 95C for 10 minutes before being separated on a 10% SDS-
polyacrylamide gel.  The SDS-polyacrylamide gel contained a stacking region 
(0.5M Tris-HCl (pH 6.8), 4% acrylamide/bis-acrylamide, 20% SDS, 10% 
ammonium presulfate (APS), 0.001% Tetramethylethylenediamine (TEMED)) 
and a resolving region (1.5M Tris-HCl (pH 8.8), 20% SDS, 10% acrylamide/bis-
acrylamide, 10% APS, 0.001% TEMED).  The SDS-polyacrylamide gel was 
submerged in 1X running buffer (25mM Tris-HCl, 200mM glycine, 0.1% SDS) 
and 180 volts were applied for 90 minutes.   
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For Western blotting, the separated proteins were transferred from the gel to an 
Immobilon-P Polyvinylidene Difluoride membrane (Millipore) using a Semi-Dry 
Transfer Unit (Hoefer) at 25mA for 1 hour.  Non-specific binding sites on the 
membrane were blocked by soaking the membrane in blocking buffer (PBS 
containing 0.05% Tween20 and 5% of non-fat milk) for 30 minutes.  The 
membrane was incubated with the primary antibodies, pre-diluted in blocking 
buffer, for 45 minutes, followed by 3 washes (10 minutes each) with the wash 
buffer (PBS containing 0.05% Tween20).  A list of all primary antibodies used 
can be found in Table 2.4.  Horseradish peroxidase (HRP) conjugated secondary 
antibodies were diluted 1:2000 in blocking buffer and incubated with the 
membrane for 45 minutes.  Unbound antibodies were removed by two 10-minute 
washes and one 30-minute wash with wash buffer.  Protein bands were visualized 
by incubation with Enhanced Chemiluminescent (ECL) Plus Detection reagent 
(Amersham Biosciences) for 5 minutes.  Excess ECL reagent was drained off and 
the membrane was then wrapped in Saran Wrap.  Blank autoradiography films 
(Amersham Biosciences) were placed on top of the membrane in a cassette for 
various exposure times.  The film was developed on a Kodak X-OMAT 1000 
processor and the exposure time was adjusted, as appropriate.    
 
2.27  Immunoprecipitation assay 
 
An immunoprecipitation assay was used to detect virus capture by NAbs.  
Approximately 10µl Protein A Sepharose beads (Amersham Biosciences) were 
resuspended in 500µl PBS containing 10% FCS before NAb was added to the 
suspension.  The mixture was incubated for 1 hour at room temperature with 
rocking to allow maximum NAb binding to Protein A.  The beads were washed 
twice with PBS and pelleted by centrifugation at 400g for 1 minute.  Virus 
supernatant (500µl) was added to the beads and incubated for 1 hour at room 
temperature, with rocking.  Unbound viruses were removed by 5 PBS washes with 
centrifugation at 400g for 1 minute.  The virus-bound Sepharose beads were lysed 
with 10µl SG-PERT lysis buffer (section 2.15) and incubated for 10 minutes 
before being diluted 10-fold with dilution buffer.  The diluted lysate was 
centrifuged at 800g for 1 minute to sediment the beads and 10µl of the lysate 
supernatant was used in the SG-PERT assay to quantify the virus. 
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Table 2.4 – Antibodies used in Western blots 
 
 
 
 
 
 
 
Table 2.4 The primary antibodies and the dilutions at which they were used in 
Western blots are listed above.  Primary antibodies ARP423 and ARP313 were 
obtained from the AIDS Reagents Programme of NIBSC.  The Chessie-8 antibody 
was obtained from the AIDS Research and Reference Reagent Program of the 
National Institute of Health.  Secondary antibodies, an anti-rabbit for APR423, 
anti-human for Chessie-8 and anti-mouse for ARP313, were obtained from 
Jackson ImmunoResearch Laboratories.        
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For MS, 250ml of virus supernatant was concentrated by ultracentrifugation 
(section 2.25) and the virus pellet was resuspended in 80µl 2X Laemmli loading 
buffer before being applied to a SDS-polyacrylamide gel for protein separation at 
180 volts for 90 minutes (section 2.26).  The protein bands were visualised by 
incubating the gel in GelCode Blue Stain Reagent (Pierce Biotechnology) for 1 
hour, followed by another incubation (1 hour) with distilled water.  The gp120 
bands were excised and sent to Professor A. Dell’s laboratory (Division of 
Molecular Biosciences, Imperial College) for glycomic analysis. 
 
Alternatively, for enzymatic hydrolysis reaction with the Peptide: N-Glycosidase 
F (PNGase F) enzyme (New England Biolabs), the virus supernatant was 
concentrated and purified by ultracentrifugation (section 2.25) before the pellet 
was resuspended in 40µl G7 reaction buffer (5mM NaPO4) (New England 
Biolabs).  The viral protein was denatured by heating at 100ºC for 10 minutes.  
The suspension (10µl) was then aliquoted into 4 separate 1.5ml Eppendorf tubes.  
Seven hundred U of PNGase F was added to 14µl G7 reaction buffer 
supplemented with 20% NP40.  The PNGase F mixture was serially diluted 5-fold 
and 10µl were added to the denatured viral protein aliquot.  The mixture was 
incubated at 37ºC for 20 minutes.  The 2X Laemmli loading buffer (20µl) was 
added to the mixture and protein degradation was assayed by Western blotting 
(section 2.26).      
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Chapter 3: 
 
Does the Choice of Producer Cell and Virus Platform Affect 
Neutralisation? 
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3.1 Introduction 
 
In the face of HIV-1 infection, one of the host responses is the production of 
neutralising antibodies (NAbs) capable of inactivating the 
virus
533,534,535,536,537,538,539
.  Neutralising responses are elicited against the HIV-1 
envelope glycoprotein.  The hypervariable regions (V1, V2 and V3) and the CD4-
binding domain of gp120
361,364,540,541,542,543
 , the membrane proximal external 
region (MPER) of gp41
376,377,544,545
, and the carbohydrate moieties
370,371
 have all 
been reported to contain epitopes for neutralisation.  Moreover, sera from some 
HIV-1 patients have demonstrated neutralising responses against laboratory-
adapted strains HIV-1 and, in some cases, autologous and heterologous 
isolates
350,546
.  In cases of vaccine trials, neutralising antibody responses in 
vaccinated subjects were often measured as one of the indicators for efficacy.  To 
assess neutralising antibody activities, a standardised, sensitive and validated 
neutralisation assay is needed
547,548
.   
 
Early studies on neutralising antibody responses relied on the use of T-cell lines, 
in which test sera or recombinant antibodies were used to co-culture with T-cell 
line adapted virus, and syncytium-formation, p24 and/or RT production were 
measured
549,550,551
.  However, primary isolates passaged in T-cell lines were 
abnormally sensitive to neutralisation and do not reflect their in vivo 
phenotypes
552,553
.  To mimic the in vivo situation, the T-cell assay was improved 
by using seronegative PBMCs, in which primary viruses were co-cultured with 
the test antibody or serum, and p24 or RT was measured as an indicator of viral 
replication
554,555,556
.  The PBMC-based neutralisation assay was considered to be 
the accepted standard for many years
193,557,558
, despite lacking reproducibility 
when conducted between experiments and between laboratories.   
 
Subsequently, a single-cycle virus, or pseudovirus assay was developed by 
Montefiori and others
559,560,561
.  The pseudovirus functions by incorporating env 
cloned from primary isolates into an env-deficient laboratory-adapted strain 
backbone
528
.  The ability of test antibody or serum to neutralise the pseudovirus 
was measured by reduction of infectivity on reporter cell lines, such as TZM-bl 
which contains β-gal and firefly luciferase as marker genes562,563.  Compared to 
the PBMC assay, production of pseudoviruses from plasmids allows genetically 
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identical virus to be made in each stock.  This greatly enhances the consistency, 
accuracy and reproducibility of the assay.  Due to these advantages, the 
pseudovirus assay has been recommended by the HIV Vaccine Trials
 
Network 
and Division of AIDS (NIH) as the standard assay for assessing neutralising 
antibody responses in vaccine development
547
.   
 
Nevertheless, several questions remain to be addressed before this can be 
considered the gold standard neutralisation assay
547
.  First of all, how does 
pseudotyped virus compare to wild-type replication-competent virus with respect 
to Env incorporation and sensitivity to neutralisation?  Secondly, do 
pseudoviruses produced by transfection in non-lymphoid cells differ from PBMC-
derived viruses?  In addition, how do neutralisation phenotypes compare between 
virus quasispecies?  Finally, are the genotypes of the quasispecies selected for 
neutralisation assay representative of those circulating in vivo?  The latter two 
questions will be discussed in detail in Chapter 4 while the first two questions are 
addressed in this chapter.      
 
In this study, the effects of the producer cell type and virus platform (i.e. from 
uncloned virus, infectious molecular cloned (IMC) virus, or pseudotyped virus), 
on neutralisation assays were assessed.  The choice of producer cell is critical, as 
the same virus isolate produced in different cell-lines can impact on reverse 
transcriptase activity, rate of replication, cytotoxicity, as well as post-translational 
modification of gp120
564,565
.  In addition, a single virus being presented in 
different platforms could have different envelope conformations, epitope 
accessibility and antibody binding affinity and avidity.  Hence, it is important to 
investigate whether these two parameters impact directly on neutralisation 
outcome.  The results from this study hopefully will contribute to strategies to 
standardise neutralisation assays.    
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3.2 Results 
 
3.2.1 Producer cell type affects viral infectivity and sensitivity to 
neutralisation 
 
To examine the effect of the cellular host on virus infectivity and sensitivity to 
neutralisation, NL4.3, a cloned laboratory-adapted strain of HIV-1 was produced 
by electroporation in four cell lines.  These included CD4-negative 293T and 
HeLa cells, CD4-positive Jurkat E6.1 cells and PBMCs as a control.  Using the 
same titre of virus, normalised to 75mU of RT activity, NL4.3 produced in 
PBMCs was found to be the most infectious when assayed on the TZM-bl reporter 
cell (Figure 3.1), followed by virus produced in Jurkat E6.1 cells (79%), 293T 
cells (55%) and HeLa cells (52%), respectively (Figure 3.1).   
 
In the presence of 5µg/ml 2F5, a NAb targeting gp41, virus produced in 293T 
cells was the most readily neutralisable, with 21% residual infectivity (Figure 3.2).  
Virus produced in PBMCs was the most resistant to neutralisation, with 82% 
residual infectivity.  When produced in Jurkat E6.1 cells and HeLa cells, the 
viruses displayed 64% and 34% residual infectivity, respectively, upon 
neutralisation by 2F5.  The difference in neutralisation sensitivity between viruses 
produced in non-lymphoid CD4-negative cells and PBMCs clearly indicates that 
the choice of producer cell can significantly influence the degree of neutralisation.       
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Figure 3.1 – Infectivity of NL4.3 virus in different cell lines and in PBMCs 
 
 
 
 
 
Figure 3.1 Full length molecular clone of NL4.3 virus was produced into different 
producer cell lines (x-axis) by electroporation.  Viruses were normalised for RT 
activity before infecting TZM-bl cells which contain β-gal as a marker gene.  
Infectivity (y-axis) was measured by staining for β-gal and calculated as a 
percentage relative to virus produced in PBMCs. 
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Figure 3.2 – Sensitivity to neutralisation of NL4.3 virus produced in different 
cell lines and in PBMCs 
 
 
 
 
 
Figure 3.2 NL4.3 virus produced in different cell lines (x-axis) was neutralised 
with 5µg/ml of 2F5 antibody prior to infecting TZM-bl cells.  Viruses that were 
not neutralised with 2F5 antibody served as negative controls.  The result was 
measured by calculating percent residual infectivity (y-axis) relative to the 
negative control in each case. 
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3.2.2 Pseudovirus is more neutralisable than IMC virus  
 
The current recommended
547
 neutralisation assay employing pseudovirus in a 
single-round of infection
557,558,559
 has been reported to be highly sensitive 
compared to traditional assays employing uncloned, replication-competent 
viruses
557
.  This effect, however, could simply be because the pseudovirus was 
more sensitive to neutralisation and, therefore, was not a reflection of the 
qualitative antibody response.  To examine this observation further, IMC and 
pseudotyped NL4.3 virus with the same sequence were produced (section 2.23) 
and neutralisation was carried out.  
 
The IMC and the pseudotyped NL4.3 viruses were normalised for RT activity 
before being subjected to neutralisation with NAbs: 2F5, 2G12, b12 and 4E10, at 
final concentrations ranging from 0 to 4µg/ml.  Residual infectivity was 
determined by counting the number of blue foci (β-gal) expression post-infection 
on the target cells (TZM-bl).  With all NAbs tested, pseudotyped NL4.3 was 
found to be more sensitive to neutralisation than the IMC counterpart (Figure 3.3).  
For example, when treated with 4µg/ml 2F5, pseudotyped NL4.3 was almost 
completely neutralised, while IMC NL4.3 still had 62% residual infectivity.  The 
same was observed for b12, in which pseudotyped NL4.3 was completely 
neutralised at 0.8µg/ml, while IMC NL4.3 had 69% residual infectivity.  Although 
the difference in neutralisation was not as great with 2G12 and 4E10, residual 
infectivity retained by pseudovirus was lower than that of IMC virus at any given 
concentration.  Since the infectivity of IMC virus did not reach 50% inhibition 
(IC50) within the range of antibody concentrations tested for 2F5 and 4E10, IC50 
was not calculable in these two cases.  However, the IC50 of pseudotyped NL4.3 
was 18.6-fold lower than IMC NL4.3 when neutralised with b12, and 3.2-fold 
lower when neutralised with 2G12 (Figure 3.3).   
 
To investigate whether the enhanced neutralisation sensitivity in pseudovirus was 
due to a difference in Env incorporation, pseudotyped NL4.3 and IMC NL4.3 
were subjected to neutralisation with sCD4 (Figure 3.3).  Again, the IMC virus 
retained more residual infectivity (IC50 = 0.52µg/ml) when treated with sCD4 than  
its pseudotyped counterpart (IC50 = 0.11µg/ml).  The difference in neutralisation  
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Figure 3.3 – Pseudovirus is more readily neutralised than full-length IMC 
virus 
 
 
 
 
 
 
Figure 3.3 Full-length IMC NL4.3 (blue) and pseudotyped NL4.3 (red) with the 
same protein sequence were neutralised with NAbs (x-axis): 2F5, b12, 2G12 and 
4E10, and sCD4.  Percent residual infectivity (y-axis) was calculated by 
measuring β-gal activities relative to controls with no NAb.     
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with sCD4 suggested that Env incorporation into the virion might, indeed, be 
different in the two viruses.   
 
To examine this possibility, expression of gp120, gp41 and p24 in pseudotyped 
NL4.3 and IMC NL4.3 were assayed by Western blotting (section 2.26).  
Interestingly, despite being more susceptible to neutralisation, pseudotyped NL4.3 
possessed substantially more gp120 and gp41 than the IMC NL4.3 while their p24 
levels were comparable (Figure 3.4).  This evidence suggests that the increased 
sensitivity to neutralisation of the pseudovirus was independent of the amount of 
Env present on the viral surface and was more likely due to better epitope 
accessibility or altered conformation.   
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Figure 3.4 – Env expression in IMC virus and pseudovirus by Western 
blotting 
 
 
     
 
 
 
Figure 3.4 The IMC and pseudotyped NL4.3 virus were produced in 293T cells 
and concentrated and purified by ultracentrifugation on a 20% sucrose cushion.  
Viruses, undiluted, appear on the left two lanes and 10-fold diluted viruses on the 
right two lanes.  The levels of p24 were similar in both IMC and pseudotyped 
virus, while significantly more gp120 and gp41 were detected on the pseudovirus. 
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3.2.3 Neutralisation of primary HIV-1 isolates is influenced by virus platform  
 
Since laboratory-adapted virus produced in PBMCs and full-length IMC virus 
were more difficult to neutralise, it was investigated whether the same conclusion 
can be drawn for primary isolates.   
 
A panel of six patients, designated as patient C, F, H, J, M and X, were selected 
blind from the Short Pulse AntiRetroviral Therapy At HIV seroConversion 
(SPARTAC) clinical trial.  The SPARTAC study aims to investigate whether 
application of ART during acute HIV-1 infection can preserve CD4+ T cells and 
delay disease progression (section 4.1 for a detailed discussion).  The patients 
were randomised to one of three arms: a short course of ART for 12 weeks, or a 
long course of ART for 48 weeks, or no therapy.  Primary viruses were isolated at 
two time-points: baseline and week 52.  The viruses were either cultured in 
PBMCs without cloning or constructed into pseudoviruses (in which the primary 
virus Env was introduced into a laboratory-strain, HXB2, backbone
521
) before 
being subjected to NAb and serum neutralisation.  The neutralisation profiles of 
these primary isolates are discussed in detail in Chapter 4.     
 
The viruses were incubated with a single concentration (50µg/ml) of the NAbs 
2F5, b12, or 2G12 before assaying neutralisation on either NP2 cells or TZM-bl 
cells.  Residual infectivity was measured by staining for p24 antigen (NP2 cells) 
or for β-gal (TZM-bl cells).  The neutralisation data are shown in Table 3.1.  Most 
uncloned isolates were substantially more resistant to neutralisation than the 
pseudotyped viruses.  For example, the uncloned isolate of patient C, derived 
from baseline PBMCs, was strongly resistant to 2F5 neutralisation.  Indeed, virus 
residual infectivity appeared to be substantially increased to 132% in the presence 
of 2F5.  However, the pseudovirus counterpart was neutralised to approximately 
50% by the same concentration of 2F5.  In some extreme cases, such as patient F 
at week 52, the individual’s uncloned isolate was resistant to 2F5 and b12 
neutralisation (residual infectivities = 79% and 105%, respectively) but the 
pseudotyped viruses were completely neutralised (residual infectivity = 0%).  The 
increased virus infectivity post-neutralisation was commonly observed in PBMC-
based assay and this is attributed as being a consequence of antibody-dependent 
enhancement
566,567,568
.  In this case, the virus-NAb complex interacts with the Fc  
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Table 3.1 – Quantitative difference in neutralisation resulting from using 
different virus platforms in the assay 
 
  
% Residual Infectivity with 2F5 (50μg/ml) 
Baseline 
isolates 
Uncloned 
virus 
Pseudovirus (3 clones) 
Week 52 
isolates 
Uncloned 
virus 
Pseudovirus (3 clones) 
Patient C 131.95  51.48  50.96  39.55  Patient C 126.92  0.00  0.00  0.00  
Patient F 71.33  0.00  4.49  6.93  Patient F 79.31  0.00  0.00  0.00  
Patient H 33.33  5.23  2.58  3.16  Patient H 102.69  2.76  3.71  0.54  
Patient J 76.36  12.64  10.49  6.50  Patient J 74.88  13.27  9.11  9.18  
Patient M 10.18  12.29  16.14  14.62  Patient M 130.20  15.52  9.38  14.29  
Patient X 116.28  18.50  44.36  27.41  Patient X 64.65  0.00  0.79  0.00  
  
  
% Residual Infectivity with 2G12 (50μg/ml) 
Baseline 
isolates 
Uncloned 
virus 
Pseudovirus (3 clones) 
Week 52 
isolates 
Uncloned 
virus 
Pseudovirus (3 clones) 
Patient C 100.00  52.58  30.03  37.26  Patient C 113.75  90.62  92.34  92.57  
Patient F 120.00  11.14  54.37  48.94  Patient F 82.76  3.82  5.17  0.00  
Patient H 38.10  7.41  7.22  6.87  Patient H 108.05  68.64  83.26  79.51  
Patient J 104.24  59.28  61.90  61.49  Patient J 109.48  94.69  90.40  92.82  
Patient M 33.46  62.81  51.27  60.89  Patient M 64.08  40.02  44.39  48.79  
Patient X 112.79  61.27  27.42  44.31  Patient X 74.88  96.58  94.02  85.74  
  
  % Residual Infectivity with b12 (50μg/ml) 
Baseline 
isolates 
Uncloned 
virus 
Pseudovirus (3 clones) 
Week 52 
isolates 
Uncloned 
virus 
Pseudovirus (3 clones) 
Patient C 19.08  24.81  30.12  37.99  Patient C 27.03  0.00  0.00  0.00  
Patient F 88.67  37.50  28.44  22.71  Patient F 104.60  0.00  0.00  0.00  
Patient H 143.81  47.36  59.18  57.24  Patient H 90.27  47.93  74.36  60.07  
Patient J 141.82  56.29  45.30  55.59  Patient J 92.89  33.33  42.81  35.59  
Patient M 43.27  14.57  19.29  23.04  Patient M 84.08  0.00  0.00  0.00  
Patient X 54.65  7.97  66.73  28.52  Patient X 70.70  4.53  23.18  0.00  
 
 
Table 3.1 Uncloned or pseudotyped primary isolates from six patients, C, F, H, J, 
M, and X, were neutralised with NAbs 2F5 (pink block), 2G12 (green block), or 
b12 (yellow block).  Data are presented as residual infectivity, calculated relative 
to negative control virus not treated with any NAbs.  Isolates that were more 
sensitive to neutralisation in the form of pseudotyped virus are not shaded; those 
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that were more sensitive to neutralisation as uncloned virus are shaded in green, 
and the one isolate that was equally sensitive to neutralisation using both virus 
platforms is shaded in purple. 
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receptor or the complement receptor on the cell surface; the virus then enters the 
cell either by binding to the co-receptors or by direct fusion with the cell 
membrane.   
 
In a few cases (shaded green in Table 3.1), the pseudoviruses were more resistant 
to neutralisation than the uncloned viruses.  For example, the baseline uncloned 
isolate of patient M displayed 33% residual infectivity after neutralising with 
2G12, while the pseudoviruses displayed, on average, 58% residual infectivity.  
The only time where two virus platforms yield a compatible neutralisation result 
was when the baseline isolates derived from patient M, for whom residual 
infectivity was 10% for uncloned virus and on average, 14%, for pseudoviruses.  
The disparities between the two assays make it impossible to determine which 
assay better reflects the phenotypes of these primary isolates. 
   
Furthermore, to determine whether the difference is qualitatively as well as 
quantitatively significant, changes in neutralising sensitivity from baseline to 
week 52 were compared (Table 3.2).  A qualitative difference between the assays 
is defined as occurring when the two assays failed to produce a matched 
neutralisation pattern over time.  For example, uncloned isolates derived from 
patient C displayed the same level of neutralisation to 2F5 antibody at both time 
points, with residual infectivities of 132% at baseline and 127% at week 52 (Table 
3.1).  Hence, there was no change in neutralisation sensitivity over time in this 
case.  However, the pseudotyped isolates at week 52 were considerably more 
neutralisable by 2F5 than those at baseline, with average residual infectivities of 
50% at baseline and 0% at week 52.  In this case, the neutralisation sensitivity has 
changed over time, with week 52 isolates being more neutralisable than baseline 
isolates.  Since the two assays did not yield the same neutralisation pattern, it is 
therefore, defined as having qualitative difference.  When considering this entire 
panel of patient isolates, the two assays yield the same neutralisation pattern in 
only five out of eighteen cases (highlighted in yellow in Table 3.2).  These 
discrepancies indicate that the difference in results produced by the two assays 
were both quantitative and qualitative.  
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Table 3.2 – Qualitative difference in neutralisation resulting from using 
different virus platforms in the assay 
 
 
Isolate Sensitivity to 2F5 neutralisation  
Uncloned virus Pseudovirus 
Patient C Same Week 52 > Baseline 
Patient F Same Week 52 > Baseline 
Patient H Baseline > Week 52 Same 
Patient J Same Same 
Patient M Baseline > Week 52 Same 
Patient X Week 52 > Baseline Week 52 > Baseline 
  
Isolate 
Sensitivity to 2G12 neutralisation  
Uncloned virus Pseudovirus 
Patient C Same Week 52 > Baseline 
Patient F Week 52 > Baseline Week 52 > Baseline 
Patient H Baseline > Week 52 Baseline > Week 52 
Patient J Same Baseline > Week 52 
Patient M Baseline > Week 52 Week 52 > Baseline 
Patient X Week 52 > Baseline Baseline > Week 52 
  
Isolate 
Sensitivity to b12 neutralisation  
Uncloned virus Pseudovirus 
Patient C Same Baseline > Week 52 
Patient F Same Week 52 > Baseline 
Patient H Week 52 > Baseline Same 
Patient J Week 52 > Baseline Week 52 > Baseline 
Patient M Baseline > Week 52 Week 52 > Baseline 
Patient X Same Baseline > Week 52 
 
 
Table 3.2 Neutralisation from baseline to week 52 was compared between assays 
that employ uncloned virus and pseudotyped virus.  Isolates that maintain the 
same degree of sensitivity to neutralisation over time are denoted as “same”; those 
that were more neutralisable at baseline than at week 52 are denoted as “Baseline 
> Week 52”, and vice versa.  The yellow highlight indicates where both assays 
display the same neutralisation pattern; hence, no qualitative difference.   
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3.3 Discussion 
 
Although a panel of neutralising antibodies has been established over the years, 
only a few of them are capable of neutralisation of non-B-clade viruses
374,569
.  
Individuals infected with HIV-1 develop a humoral response to the virus within 
four to six weeks
536,537,538,539
.  However, sera derived from most HIV-1 patients 
are poorly neutralising against both autologous and heterologous isolates.  
Because the search for a broadly neutralising antibody has become a critical 
objective, particularly in terms of a strategy for vaccine design, an accurate, 
sensitive, and standardised neutralisation assay is much sought after. 
 
Traditional neutralisation assays utilised virus cultured in PBMCs which serve as 
the closest model to the in vivo system; however, PBMCs are not uniformly 
alike
570
, since every batch of PBMCs comes from different donors with different 
degrees of susceptibility to HIV-1 infection due to genetic variation.  When 
PBMCs are used to support HIV-1 culture, they are first mitogenically stimulated.  
Addition of mitogens to PBMCs can lead to varying degrees of stimulation in 
cultures of different provenance, while resting PBMCs may express different 
levels of co-receptors
571
.  Moreover, not every primary virus can be isolated and 
cultured in PBMCs.  This is particularly so with non-B clade virus or when the 
viral load is low.  Due to these limitations, a new generation of neutralisation 
assay was developed, which employed pseudoviruses produced in laboratory-
adapted mammalian cell lines, such as 293T cells
528
.  This provided a consistency 
that had been lacking and has the advantage of yielding a virus titre 2-log higher 
than that produced in PBMCs
547
.  Nevertheless, virus produced in 293T cells or 
other non-lymphocytic mammalian cell lines was found in this study to have a 
lower infectivity, compared to those produced in mitogens-stimulated PBMCs.  In 
addition, virus produced in 293T cells was more sensitive to neutralisation than 
virus from PBMCs.  A similar result has been reported by Louder et al (2005)
572
.  
The observation that virus produced in T-cells and, in particular, mitogen-
stimulated PBMCs, displayed enhanced infectivity and reduced sensitivity to 
neutralisation is likely due to the fact that 293T or HeLa cells lack host membrane 
proteins, such as MHC, ICAM-1 and LFA-1, etc…, which were expressed and 
incorporated into the virus particles during assembly in and budding from T-cells 
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or PBMC
573,574,575
.  Interactions between those host proteins and their cognate 
ligands promote virus binding to target cells and thereby enhance viral infectivity 
and alter sensitivity to neutralisation.  
 
Although a previous investigation claimed that IMC virus and pseudovirus with 
the same protein sequence share similar neutralisation sensitivities
572
, the opposite 
was observed in this study.  With all the NAbs tested, pseudotyped virus was 
found to be more sensitive to neutralisation than the IMC virus and the uncloned, 
primary isolates, despite being more infectious and expressing significantly more 
envelope gp120 and gp41 on the viral surface.  Other groups have reported 
disparities between assays employing uncloned virus and those that use 
pseudovirus
576,577
, particularly with anti-gp41 antibodies, and have attributed this 
to be a consequence of extended exposure of the membrane proximal external 
region in gp41 of the pseudotyped virus
578
.  Another possible explanation of 
enhanced neutralisation in pseudoviruses could be that the large amount of 
envelope incorporation into the pseudovirus decreases the flexibility of the viral 
membrane and alters viral entry or fusion.  It is also possible that the envelope of 
the pseudovirus may be less stable and, therefore, more readily detached by 
neutralising antibodies.  In addition, the kinetic rate of envelope-antibody 
association and dissociation may be lower in pseudovirus than in uncloned virus, 
resulting in a more stable interaction and enhanced neutralisation. 
 
Although the pseudovirus-based neutralisation assay was recommended by the 
HIV Vaccine Trials
 
Network and Division of AIDS (NIH) for its stability, 
reproducibility and lower costs
547
, several issues remain be addressed if it is to 
become the standard neutralisation assay to be used worldwide.    
 
This study investigated two questions: (1) what is the effect of the producer cell 
and (2) what is the effect of the virus platform on neutralisation.  With respect to 
the first issue, the finding that virus produced in non-lymphoid cells was less 
infectious and more neutralisable is relevant.  Since virus produced in PBMCs is 
difficult to standardise, a possible solution would be to produce pseudovirus, by 
transfection or electroporation, in laboratory-adapted T cells.  This would allow 
the resulting virus to have a similar infectivity and neutralisation phenotype to 
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those produced in PBMCs, while maintaining the consistency and reproducibility 
advantages.  Our second finding was that wild type (full-length) virus is more 
resistant to neutralisation than was pseudovirus.  Antibody or serum that can 
neutralise pseudoviruses well might not display the same potency against 
uncloned viruses.  This is of particular importance in determining vaccine 
efficacy.  In the long run, it may be necessary to compare results from the two 
neutralisation assays and to correlate them with clinical outcomes, such as 
protection from infection or control of viraemia, in order to determine which 
platform best represents the in vivo situation.   
 
In conclusion, this is the first equivocal study to compare systemically two 
existing neutralisation assays.  Our investigation on the impact of producer cell 
type and virus platform provided valuable information and will facilitate 
standardisation of the current assays.   
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Chapter 4: 
 
Evolution of HIV-1 and Concomitant Antibody Responses 
in HIV-1 Seroconverters 
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4.1 Introduction 
 
Although the course of HIV-1 infection varies considerably from one patient to 
another, retrospective studies suggest that events associated with primary HIV-1 
infection (PHI) may provide critical insights for subsequent disease progression
579,580
.  Shortly following infection, there is a rapid rise in the level of plasma 
viraemia due to intensified viral replication.  Follicular dendritic cells trap HIV-1 
which is then disseminated into the lymphoid organs, thereby creating a reservoir 
for persistent infection
581,582,583
.  Immune responses specific to HIV-1 infection 
normally develop between 4 to 12 weeks; these include production of antiviral 
antibodies
539,559
 , CD4-positive (CD4
+
)
584,585,586 
and CD8-positive (CD8
+
)
587,588,589
 
cytotoxic T-lymphocyte- (CTL) mediated immunity, as well as antibody-
dependent cell-mediated cytotoxicity (ADCC)
391,392,590
 , all of which are important 
in curtailing initial plasma viraemia. 
 
Studies from both animal models and HIV-1 infected patients show that the HIV-
1 (or SIV) specific CTL response is the most effective in controlling viral 
replication, particularly in early infection
430
.  HIV-1-specific CD8
+
 T-cells possess 
a range of antiviral activities; these include direct lysis of infected immune 
cells
415,416
 and production of chemokines and cytokines, such as interferon-gamma 
(INF- γ)591, tumor-necrosis factor-alpha (TNF- α)592, macrophage inflammatory 
protein 1-alpha / beta (MIP-1α / β)431 and chemotatic cytokines ligand 5 
(CCL5)
431
.  An effective CTL response; however, cannot be achieved without a 
strong CD4
+
 T-helper cell stimulation
593,594,595
.  Furthermore, CD4
+
 T-cell help is 
crucial in controlling B-cell proliferation and production of HIV-1 specific 
antibodies
596
.  A gradual decline in CD4
+
 T-cells in HIV-1 infection results in 
prolonged production and proliferation of the virus and, hence, accelerates disease 
progression
597,598
.   
 
Conventional treatment for HIV-1 infected individuals is combination 
antiretroviral therapy (ART) when the patient’s CD4+ T-cell count falls to within 
the 200-350cells/μl range599.  The use of ART inhibits viral production and 
partially restores the number of CD4
+
 T-cells
600
.  Although HIV-1 specific CD4
+
 
T-cell responses are detectable in most patients with active infection, these 
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responses decline over time with prolonged viral suppression
601
.  Hence, some 
earlier reports on both animal and human models suggested that treatment 
immediately following PHI might be more beneficial in preserving HIV-1 specific 
immunity responses and delaying disease progression
602,603,604,605
. 
 
Based on this evidence, the Short Pulse AntiRetroviral Therapy At HIV 
seroConversion (SPARTAC) clinical trial aims to investigate whether application 
of ART for a limited duration during PHI can delay immune destruction and 
consequently prolongs time to initiation of long-term anti-HIV therapy
606
 
(Appendix I).  A total of 371 patients with PHI have been recruited to the trial 
worldwide, including Australia, Africa (South Africa and Uganda) and Europe 
(Ireland, Italy, Spain and United Kingdom).  PHI is defined as documented HIV-1 
seroconversion through one or more of the following criteria: (1) positive 
antibody test within 6 months of a negative test, (2) antibody negative, but 
proviral PCR or p24 antigen positive, (3) detuned assay with test incidence below 
0.6 and/or (4) clinical manifestations of symptomatic HIV-1 seroconversion 
illness supported by antigen positivity and by bands on Western blot.  The 
participants were randomised into one of the three arms: a short course of ART 
(SCART) for 12 weeks, a long course of ART (LCART) for 48 weeks, or no 
therapy.  Following this intervention at PHI, all participants will cease treatment 
and their disease progression followed until the closing of the trial in November 
2009.  The effect of ART at PHI on CD4
+
 T-cells preservation and the 
development of AIDS events will then be examined.   
 
In this thesis, a balanced cohort of six patients was blindly selected from the 
SPARTAC clinical trial and studied at both seroconversion (baseline) and at week 
52.  Primary viruses were isolated from these six patients at both time-points and 
neutralising antibody responses and evolution were investigated.  This study aims 
to identify any primary isolate that is readily neutralisable, or alternatively, any 
antiserum that exhibits broad neutralising activity.  Furthermore, the relationship 
between viral load, neutralisation and antigenic diversity were investigated.   
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4.2 Results 
 
4.2.1 The Genotypes and phenotypes of the primary isolates 
 
A panel of six patients with PHI was selected blind from the SPARTAC clinical 
sites in the United Kingdom.  The subjects are designated as patient C, F, H, J, M 
and X throughout this thesis.  Blood samples were collected from these patients at 
baseline and a year later (week 52).  Baseline is the first time-point when HIV-1 
infection was detected and it must be within six months of seroconversion, 
defined by at least one of the four criteria described in section 4.1.  Primary 
viruses were isolated from patients’ PBMCs and/or plasma.  A previous in-house 
study using a separate group of patients found no genetic difference between 
viruses isolated from PBMCs and those from plasma (Appendix II).   
 
The virus subtype was determined by sequencing analysis of the PR and the RT 
regions of the pol gene at baseline and week 52 (section 2.20).  All primary 
viruses were identified to be HIV-1 subtype B (Table 4.1) which is the main 
circulating subtype found in Western Europe, North America, Latin America and 
Australia
607
.          
 
Co-receptor usage of the primary isolates was determined phenotypically by 
assaying on NP2 cells (section 2.6), which were selected to express either the R5 
or the X4 co-receptor.  The R5-tropic isolates would only infect the NP2/R5 clone, 
while the X4-tropic isolates would only infect the NP2/X4 clone, while the R5X4 
isolates have the capacity to infect both clones.  Infection was determined by 
staining for p24 antigen.  Patients C, F, H, J and X, were found to have R5-tropic 
virus while patient M has X4-tropic virus (Table 4.1).  The X4-tropic isolate was 
further verified by means of the commercial Trofile assay
524
 (section 2.6).  Co-
receptor usage of the primary isolates remained unchanged at week 52.   
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Table 4.1 – The genotype and phenotype of the primary isolates 
 
 
 
 
 
Table 4.1 A group of six patients were selected for this study.  Primary viruses 
were isolated at baseline and at week 52 and the virus subtype and co-receptor 
usage were determined.  Sequencing of the pol gene revealed that all six patients 
were infected with B-clade HIV-1.  Co-receptor usage of the primary isolates was 
determined by infection of NP2 cells that express either the X4 or R5 co-receptor. 
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4.2.2 Neutralisation with NAbs using pseudovirions  
 
To study the neutralisation profiles of the primary viruses, the pseudovirus 
neutralisation assay was employed (section 2.17).  Proviral DNA was extracted 
from patient PBMCs, isolated at baseline and at week 52.  The env/rev gene 
cassettes were amplified and three clones were selected per patient for assay.  
Pseudovirus was constructed by co-transfecting the env clones with the env-
deficient backbone of the laboratory-adapted strain, HXB2, into 293T cells.   
 
All pseudoviruses were normalised to 75mU by RT activity using the SG-PERT 
assay (section 2.15).  Neutralisation was carried out with 25µg/ml of NAbs: 2F5, 
2G12 and b12, before assaying on TZM-bl cells.  Residual infectivity was 
measured by staining for β-gal activity.  The neutralisation profiles of the primary 
isolates derived from baseline are shown in Figure 4.1.  Taking patient C as an 
example, the three pseudovirus clones (each represented by different colours in 
the figure) displayed similar neutralisation susceptibility to all three NAbs, with 
approximately 40-60% residual infectivities.  It can be seen that viruses can be 
readily neutralised by one NAb but not by the others.  For instance, pseudoviruses 
from patient H were readily neutralisable by 2F5 (average residual infectivity = 
20%) and fairly neutralisable by 2G12 (average residual infectivity = 37%), but 
poorly neutralisable by b12 (average residual infectivity = 70%).  The difference 
in the neutralisation profiles among the six patients clearly indicates that the 
epitope conformation and neutralisation susceptibility between patients’ viruses 
varied significantly, despite all having subtype B envelope glycoprotein.  
Furthermore, sensitivity to neutralisation not only varied from isolate to isolate, 
but also from clone to clone.  Taking patient X for example, when neutralised by 
2F5, clone X10 displayed only 31% residual infectivity, while clone X27 
displayed 62%.  Again, when neutralised with b12, residual infectivity was 25% 
for clone X10 but 73% for clone X27.   
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Figure 4.1 – Neutralisation of baseline primary isolates 
 
 
 
 
 
Figure 4.1 Primary isolates derived from six patients at baseline were neutralised 
with 25µg/ml of NAbs: 2F5, 2G12 and b12.  Results were reported as percent 
residual infectivity (y-axis), relative to negative controls with no NAbs.  Three 
clones were studied per patient.  Each coloured bar (yellow, pink, or blue) 
represents a clone within an individual patient.    
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The neutralisation profiles of week 52 primary viruses were also studied (Figure 
4.2).  Again, sensitivity to neutralisation varies between isolates.  For example, 
pseudoviruses from patient C were well neutralised by both 2F5 and b12 (average 
residual infectivity = 5% and 3%, respectively) while pseudoviruses from patient 
H were only neutralisable by 2F5 (average residual infectivity = 15%), but not by 
b12 (average residual infectivity = 69%).  The variation in neutralisation between 
clones was much smaller when compared against the env taken from isolates at 
week 52, however.  In patient F, for example, all three clones were readily 
neutralised by 2F5, with residual infectivity of 2.5%, 3% and 4%, while all three 
clones of patient J also displayed similar sensitivity to 2F5 neutralisation, with 
residual infectivity of 24%, 17% and 17%.  The reduced variation in neutralisation 
among different clones at week 52 suggests a decrease in viral diversity. 
 
For illustrative purposes, neutralisation data were re-organised into Figure 4.3 to 
4.5, such that changes in neutralisation susceptibility over time can be easily 
visualised.  In Figure 4.3, the sensitivity of the pseudotyped primary viruses to 
2F5 neutralisation at the two time points is shown.  Primary viruses derived from 
baseline were coloured in pink and those derived from week 52 were coloured in 
green.  The week 52 isolates were either equally or more neutralisable by 2F5, 
compared to the baseline isolates.  For example, the average residual infectivity 
for patient C’s pseudoviruses was 56% at baseline but decreased to 5% at week 52.  
The same pattern was also observed in patient F (average residual infectivity = 
23% at baseline and 3% at week 52) and patient X (average residual infectivity = 
45% at baseline and 4% at week 52).  On the other hand, patient H, J and M 
maintained the same degree of neutralisation sensitivity to 2F5 at both time points.  
In patient M for example, the average residual infectivity of the three pseudovirus 
clones was 33% at baseline and 32% at week 52.  Similar result was obtained with 
patient H, where the average residual infectivity was 20% at baseline and 15% at 
week 52 and with patient J, where the average residual infectivity was 21% at 
baseline and 19% at week 52. 
 
Primary isolates derived at week 52 were more readily neutralisable by b12 than 
the baseline isolates (Figure 4.4).  For example, patient C’s baseline 
pseudoviruses displayed an average residual infectivity of 50% at baseline, but the   
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Figure 4.2 – Neutralisation of week 52 primary isolates 
 
 
 
 
 
Figure 4.2 Primary isolates derived from six patients at week 52 were neutralised 
with 25µg/ml of NAbs: 2F5, 2G12 and b12.  Results are reported as % residual 
infectivity (y-axis), relative to negative controls with no NAbs.   
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Figure 4.3 – Neutralisation of primary isolates by 2F5 
 
 
 
 
 
Figure 4.3 Pseudoviruses constructed for six patients at baseline (pink) and at 
week 52 (green) were assayed for neutralisation sensitivity by 25µg/ml 2F5.  
Three clones per patient were studied at each of the two time points.  Percent 
residual infectivity (y-axis) was measured relative to negative controls with no 
2F5. 
  
104 
 
Figure 4.4 – Neutralisation of primary isolates by b12 
 
 
 
 
 
Figure 4.4 Pseudoviruses constructed for six patient isolates at baseline (pink) 
and at week 52 (green) were assayed for neutralisation sensitivity by 25µg/ml b12.  
Three clones per patient were studied at each of the two time points.  Percent 
residual infectivity (y-axis) was measured relative to negative controls with no 
b12. 
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week 52 pseudoviruses had an average residual infectivity of 3%.  A significant 
increase in neutralisation sensitivity to b12 after one year was also observed in 
patient F (average residual infectivity = 49% at baseline and 0.2% at week 52) and 
in patient M (average residual infectivity = 37% at baseline and 5% at week 52).  
The week 52 isolates of patient J and patient X were also more neutralisable by 
b12 than their baseline counterparts but by a smaller margin.  Average residual 
infectivity decreased from 74% (baseline) to 53% (week 52) for patient J and 
from 46% (baseline) to 20% (week 52) for patient M.  Patient H was the only 
exception to this pattern; the baseline and the week 52 pseudoviruses were equally 
neutralisable by b12 (average residual infectivity = 70% at baseline and 69% at 
week 52).   
 
By contrast, primary isolates from week 52 were much more resistant to 2G12 
neutralisation than their baseline counterparts (Figure 4.5).  For example, baseline 
pseudoviruses of patient C displayed an average residual infectivity of 49%, while 
the week 52 pseudoviruses had an average residual infectivity of 97%.  Similar 
neutralisation data were obtained for other patients, with patient F being the only 
exception.  The week 52 pseudoviruses of patient F were readily neutralised by 
2G12 (average residual infectivity = 11%), compared to the baseline 
pseudoviruses (average residual infectivity = 58%).   
 
The neutralisation data suggest that the 2F5 and b12 epitopes on the primary 
viruses either have remained unchanged, or have become more accessible by 
week 52, resulting in enhanced sensitivity to neutralisation.  This is possibly 
because of a lack of selection pressure in vivo at these epitopes.  On the other 
hand, the 2G12 epitope became less accessible by week 52, possibly due to an 
evolving glycan shield, leading to decreased neutralisation susceptibility of the 
primary isolates.  
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Figure 4.5 – Neutralisation of primary isolates by 2G12 
 
 
 
 
 
Figure 4.5 Pseudoviruses constructed from six patient viruses isolated at baseline 
(pink) and at week 52 (green) were assayed for sensitivity to neutralisation by 
25µg/ml 2G12.  Three clones per patient were studied at each of the two time 
points.  Percent residual infectivity (y-axis) was measured relative to negative 
controls with no 2G12. 
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4.2.3 Neutralisation by autologous and heterologous antisera using 
pseudovirions 
 
To study neutralising antibody development in patient sera and the ability of HIV-
1 to escape these neutralising antibody responses, viruses isolated at baseline and 
at week 52 were neutralised with autologous and heterologous antisera collected 
at both time points (section 2.17).  Pseudoviruses were normalised to 75mU RT 
activity and incubated with heat-inactivated antisera at reciprocal dilutions 
ranging from 20 to 500, before being assayed on TZM-bl cells (section 2.17).  
Residual infectivity post-serum neutralisation was determined by staining for β-
gal activity.  Pooled sera from HIV-1 negative donors were used to test for 
specificity.  Indeed, this negative control was unable to neutralise any of the 
primary viruses, indicating that neutralisation by patient antisera was due to HIV-
1 specific humoral responses.   
 
Antisera collected at baseline were mostly ineffective in neutralising the baseline 
viruses (Table 4.2).  The neutralising antibody responses in baseline sera collected 
from patients F, H, J and M were below the detectable threshold.  Despite using a 
reciprocal dilution of 20 or above, sera collected from these four patients failed to 
neutralise 90% of both autologous and heterologous isolates.  However, 
neutralising antibody responses were detected in baseline sera collected from 
patient C and M.  In both cases, reciprocal dilutions between 20 and 50 were 
capable of neutralising 90% of both autologous and heterologous viruses.   
 
On the other hand, antisera collected at week 52 can effectively neutralise the 
baseline isolates, particularly the autologous ones (Table 4.2).  For example, a 
reciprocal dilution of 125 of patient C’s week 52 serum was enough to inhibit by 
90% replication of the autologous virus clones, while a reciprocal dilution of 50 
would neutralised 90% of the heterologous virus clones.  Similar results were 
observed in patient J and M.  As for patients F, H and X, a higher reciprocal 
dilution (between 50 and 125) was needed to neutralise the primary viruses.  
Nevertheless, this evidence suggests that although the humoral response 
developed slowly in vivo, neutralising antibodies were produced eventually and 
they were able to target the preceeding viruses. 
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Table 4.2 – Neutralisation of baseline primary isolates by autologous and 
heterologous sera 
 
 
Baseline 
virus 
(3 clones) 
Control 
(negative 
pooled sera) 
Baseline Sera Week 52 Sera 
C F H J M X C F H J M X 
C6 <20 50 20 20 20 50 <20 125 50 50 50 50 125 
C20 <20 50 20 20 20 <20 20 125 <50 50 50 50 50 
C28 <20 20 20 20 20 <20 20 125 50 50 50 50 50 
F4 <20 20 20 20 20 20 20 50 125 <20 50 20 50 
F6 <20 20 20 20 20 20 20 50 <50 50 50 50 50 
F8 <20 50 20 20 20 <20 20 50 50 <20 50 50 50 
H7 <20 50 20 20 20 <20 20 50 20 <50 50 50 50 
H9 <20 50 20 20 20 50 20 20 20 <50 20 50 50 
H21 <20 20 20 50 20 50 20 50 20 <50 50 20 50 
J33 <20 50 20 20 20 50 20 50 20 50 125 20 50 
J42 <20 20 20 20 20 50 20 50 50 50 125 50 50 
J50 <20 50 20 20 20 50 <20 20 50 50 <125 50 20 
M2 <20 50 20 20 20 50 20 50 <50 50 50 125 50 
M14 <20 50 20 20 20 50 20 50 50 50 50 125 50 
M17 <20 50 20 20 20 50 <20 50 50 <50 50 125 50 
X10 <20 50 20 20 20 50 20 50 20 50 50 50 <50 
X27 <20 20 20 20 20 50 20 50 50 50 50 50 <50 
X29 <20 20 20 20 20 20 20 50 50 50 50 50 <50 
 
 
Table 4.2 Reciprocal dilutions of baseline and week 52 autologous and 
heterologous sera needed to neutralise 90% of the pseudoviruses are shown in 
Table 4.2.  Boxes were filled in different colours to show the reciprocal dilution: 
pink (more than 20), purple (less than 20), green (more than 50), blue (less than 
50), yellow (more than 125), and orange (less than 125).  Pooled sera from HIV-1 
negative donors were used as negative controls.  Neutralisation was measured 
relative to pseudoviruses that were not incubated with any serum.      
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Primary viruses escape immune antiviral responses rapidly.  Antisera collected at 
both baseline and week 52 were poorly neutralising of primary isolates (Table 
4.3).  None of the baseline sera was able to inhibit 90% of the virus infection even 
when a reciprocal dilution of 20 or more was used in the assay.  Furthermore, the 
week 52 antisera were also ineffective in neutralising the isolates taken at week 52.  
For example, a reciprocal dilution of 50 or more was needed for all week 52 
antisera to neutralise 90% of the autologous viruses.  In some cases, such as in 
patient C and F, reciprocal dilution of 20 or more was required to neutralise 90% 
of heterologous viruses.  The only exception was the week 52 viruses derived 
from patient F, which were readily neutralisable (reciprocal dilution = 125) by 
heterologous sera taken from patients C, J and X at week 52.  These data suggest 
that primary viruses mutated and escaped the humoral responses efficiently and 
may contribute to the increased intra-patient viral diversity over time.     
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Table 4.3 – Neutralisation of week 52 primary isolates by autologous and 
heterologous sera 
 
 
Week 52 
virus 
(3 clones) 
Control 
(negative 
pooled sera) 
Baseline Sera Week 52 Sera 
C F H J M X C F H J M X 
C11 <20 20 20 20 20 20 20 50 20 50 20 <20 50 
C16 <20 20 20 20 20 20 20 50 <20 20 <20 50 50 
C21 <20 20 20 20 20 20 20 20 20 <20 50 20 20 
F17 <20 20 20 20 <20 <20 20 125 50 50 125 50 125 
F23 <20 20 20 20 20 20 20 50 50 50 125 20 50 
F35 <20 20 20 20 20 20 20 20 50 20 125 50 50 
H11 <20 20 20 20 20 20 20 20 20 50 <20 20 <20 
H24 <20 20 20 20 20 20 20 20 20 50 50 20 <20 
H25 <20 20 20 20 20 20 20 20 20 50 50 50 50 
J2 <20 20 20 20 20 20 20 20 20 20 50 50 50 
J16 <20 20 20 20 20 20 20 20 20 20 <20 20 <20 
J40 <20 20 20 20 20 20 20 20 20 20 50 20 50 
M5 <20 <20 20 20 20 <20 20 50 20 50 <20 50 50 
M9 <20 20 20 20 20 <20 20 50 20 <20 20 50 50 
M43 <20 20 20 20 20 20 20 50 20 <20 50 50 50 
X4 <20 20 20 20 20 20 20 50 20 50 50 50 <50 
X10 <20 20 20 20 20 20 20 50 50 <50 50 50 50 
X18 <20 20 20 20 20 20 <20 50 50 50 50 50 50 
 
 
Table 4.3 Reciprocal dilutions of baseline and week 52 autologous and 
heterologous sera needed to neutralise 90% of the week 52 pseudoviruses are 
shown in Table 4.3.  Pooled sera from HIV-1 negative donors were used as 
negative controls.  Neutralisation was measured relative to pseudoviruses that 
were not incubated with any serum.  Coloured boxes are explained in the legend 
to Table 4.2.      
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4.2.4 Viral load has no correlation with neutralisation 
 
Viral load serves as an important clinical indicator for ART efficacy.  Information 
regarding patient viral load was obtained with permission from the Clinical Trial 
Units (Medical Research Council).  Viral load was carried out at the Department 
of Diagnostic Virology (St Mary’s Hospital) using the branched DNA 
amplification method (Versant 440 Molecular System, Siemens Healthcare 
Diagnostics).  The baseline and week 52 viral loads of the six patients in this 
study are shown in Table 4.4.  The patients had various levels of viral load at 
baseline, ranging from 44,100 copies/ml to nearly half a million copies/ml.  The 
viral loads in these patients have settled down by week 52, decreased to 17,800 to 
340,000 copies/ml.  Although all patients were recruited to the trial within 6 
months of seroconversion, the time taken to diagnose HIV-1 infection 
(seroconversion) varied among individual patient.  For example, patient F was 
documented as sero-positive 33 days after he last tested negative for anti-HIV-1 
antibody, while it took 182 days for patient M to be identified as sero-positive 
following his last negative blood test.  Interestingly, when the time taken for 
diagnosis was plotted against viral load (Figure 4.6), an inverse relationship was 
observed (R
2
 = 0.914).  This suggests that the sooner a patient was diagnosed with 
HIV-1 infection, the closer to the viraemia peak the baseline sample was taken 
from, and hence, the higher the viral load.    
 
To examine if viral load correlates with neutralising response, percent residual 
infectivity post-neutralisation was plotted against viral load (Figure 4.7).  No 
association between neutralisation and viral load was observed in baseline isolates.  
For example, patient H has a low viral low (54,780 copies/ml) while patient J’s 
viral load was 6 times higher (315,764 copies/ml); however, pseudoviruses 
constructed from both patients displayed similar susceptibility to 2F5 
neutralisation (average residual infectivity = 20% and 21%, respectively).  When 
neutralised with b12, again, viruses derived from patients with low viral load had 
a similar sensitivity to neutralisation as viruses derived from patients with a high 
viral load.  Pseudoviruses constructed from patient C (viral load = 74,321 
copeis/ml) and patient F (viral load = 421,500 copies/ml) both had around 50% 
residual infectivity after neutralisation by b12.  The same was true for  
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Table 4.4 – Time to diagnose and viral load of six HIV-1 patients 
  
 
 
  
 
Table 4.4 The time taken to diagnose HIV-1 infection and the viral load at 
baseline and week 52 for patients C, F, H, J, M and X, are shown.  The time taken 
to diagnose is defined as the number of days between the last antibody negative 
test and the first antibody positive test (sero-conversion). 
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Figure 4.6 – The length of time taken to diagnose is inversely related to 
baseline viral load 
 
 
 
 
 
 
Figure 4.6 Baseline viral load is plotted against the number of days taken to 
diagnose HIV-1 infection.  A linear regression trend line is shown and the 
correlation of determination value (R
2
) is calculated to be 0.914.  
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Figure 4.7 – Neutralisation of primary viruses isolated at baseline does not 
correlate with viral load  
 
 
 
 
 
Figure 4.7 Pseudoviruses (3 clones per patient) containing primary env clones 
from viruses isolated at baseline were neutralised with 25µg/ml of NAbs: 2F5, 
2G12 and b12 on TZM-bl cells (section 2.17).  Residual infectivity was measured 
relative to virus that was not exposed to NAbs.  The percent residual infectivities 
(y-axis) of the pseudoviruses are plotted against their corresponding baseline viral 
load (x-axis).    
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neutralisation by 2G12.  Patient M’s viral load was 7-fold lower than that of 
patient J; however, their pseudoviruses were neutralised equally well by 2G12 
(average residual infectivity = 71% and 74%, respectively). 
 
For primary viruses isolated at week 52, no correlation between viral load and 
neutralisation was found (Figure 4.8).  Pseudoviruses derived from any single 
patient were readily neutralisable by 2F5 (less than 20% residual infectivity) and 
strongly resistant to 2G12 neutralisation (more than 60% residual infectivity), 
regardless of the corresponding viral load.  Furthermore, pseudoviruses derived 
from patients C, F, M and X were all neutralisable by b12 (less than 10% average 
residual infectivity).  Viruses from patient H and patient J were both resistant to 
b12 neutralisation (average residual infectivity = 69% and 53%, respectively), 
although patient H’s viral load (49,954 copies/ml) was 7-fold lower than that of 
patient J (339,135 copies/ml).  These data demonstrate that sensitivity to 
neutralisation by NAbs is independent of viral load. 
 
Correlation between viral load and the development of neutralising antibody 
responses in patient antisera was also examined (Table 4.5).  Interestingly, 
baseline antisera taken from two of the three patients (C and M) with low viral 
load appeared to have developed neutralising antibody responses against 
autologous and heterologous isolates.  On the other hand, antisera taken from 
patients (F, J and X) with high viral load had undetectable neutralising antibody 
response against virus neutralisation.  Patient H was an exception. Although the 
patient had low baseline viral load (54,780 copies/ml), NAb response was not 
detected in the individual’s serum.  It is possible that patient H’s virus was 
neutralisation-resistant and, therefore, did not readily elicit neutralising antibody 
responses in vivo.  Alternatively, patient H might have a weak immune system 
which failed to produce a timely neutralising antibody response to the infection.  
Nevertheless, the data indicate that high viral load can be an inhibitory factor in 
neutralising antibody development during acute HIV-1 infection.             
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Figure 4.8 – Neutralisation of primary viruses isolated at week 52 does not 
correlate with viral load  
 
 
 
 
 
Figure 4.8 Pseudoviruses (3 clones per patient) containing primary env clones 
from viruses isolated at baseline were neutralised with 25µg/ml of NAbs: 2F5, 
2G12 and b12, before assaying on TZM-bl cells.  Residual infectivity was 
measured relative to virus that was not exposed to NAbs.  The percent residual 
infectivity (y-axis) of each pseudovirus is plotted against its corresponding viral 
load at week 52 (x-axis).     
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Table 4.5 – Neutralising responses in antisera in relation to time to 
diagnose HIV-1 infection and viral load 
 
 
 
 
 
Table 4.5 Neutralising responses of baseline antisera to autologous and 
heterlogous primary isolates from patients C, F, H, J, M and X are shown above.  
A neutralising response is defined as one in which a 1:50 or less dilution of serum 
is required to achieve 90% virus neutralisation.      
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4.2.5 Genetic analysis of the env gene 
 
Sequences of the env region derived from primary viruses can provide important 
information on viral diversity and evolution.  Primary viruses were isolated from 
the six patients at baseline and at week 52.  A 250 amino acid region of the env 
gene encompassing V1-V3, from both functional and non-functional clones, was 
sequenced.  Phylogenetic analysis was carried out and a tree was constructed 
(Figure 4.9) and analysed using MEGA4.1 software.  The env clones derived from 
an individual patient at one time-point were grouped and represented by one 
distinct colour on a phylogenetic tree.  For example, env clones derived from 
patient X at baseline were coloured in red, while those derived at week 52 were 
coloured in green.  Several evolutionary patterns were observed: (1) the week 52 
env clones have either not evolved or have evolved very little from the baseline 
env clones.  An example of this is patient M, in which the amino acid sequences 
of the env clones from both time-points fall under the same group.  (2) The env 
clones derived from the blood samples taken at week 52 have amino acid 
sequences that are closely related to those env clones derived from baseline 
samples.  However, the week 52 env clones have evolved enough to be grouped 
under a separate branch, as seen in patient X, J, C and F.  (3) The week 52 env 
clones have diverged significantly from the baseline env clones, resulting in a 
long branching distance, as observed in patient H.  Another interesting note from 
the tree is that, the env clones of patient F have sequences similar to two of the 
reference strains (HXB2 and NL.671), suggesting a possible similarity in 
neutralisation susceptibility between patient F’s primary viruses and the 
laboratory-adapted viruses.  This may partially explain the enhanced sensitivity to 
NAbs and heterologous sera neutralisation of patient F’s pseudoviruses observed 
earlier.   
 
To examine whether viral load is related to the genetic variation of the primary 
isolates within an individual, the two parameters were plotted on a scatter graph 
(Figure 4.10).  Genetic variation is defined as the number of amino acid 
substitutions per site from averaging all sequence pairs within the patient.  
Excluding patient F and patient J (outliers), baseline env clones from the 
remaining four patients displayed a strong correlation between intra-patient  
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Figure 4.9 – Phylogenetic relationship of the primary isolates 
 
 
 
 
Figure 4.9 Primary viruses were isolated from the six patients at baseline and at 
week 52 of the SPARTAC trial.  Evolutionary histories of env derived from 
primary viruses were inferred using the Neighbour-Joining method. The optimal 
tree with the sum of branch length equals to 4.604 is shown.  The tree is drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances 
used to infer the phylogenetic tree.  The evolutionary distances were computed 
using the Poisson correction method and are in the units of the number of amino 
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acid substitutions per site.  All positions containing gaps and missing data were 
eliminated from the dataset.  Each colour represents an individual patient at one 
time-point and reference sequences are coloured in black. 
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Figure 4.10 – Correlation of viral load with evolutionary divergence within 
an individual at a single time-point 
 
 
 
Figure 4.10 Intra-patient genetic variation (y-axis) between env quasispecies 
isolated from, A) baseline and B) week 52 plotted against the corresponding viral 
load.  The scale of genetic variation shows the relative difference in amino acid 
sequence, where 1.00 is equivalent to 100% difference.  The analysis was 
conducted using the Poisson correction method in MEGA4.1 software.  
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genetic variation and the corresponding viral load, with a R
2
 value of 0.997.  
However, this correlation was not observed with the week 52 env clones.  The 
data points scatter all over the plot and no “best fit” line could be drawn.  Since 
some of the patients were treated with ART, viral diversity may have been 
suppressed and therefore, could not be compared directly to those not on 
treatment.   
 
In addition, possible correlation between baseline viral load and viral evolution 
over the timeframe was examined.  The evolutionary distance between the 
baseline and week 52 env quasispecies was calculated and plotted against viral 
load (Figure 4.11).  When the data from patient H was excluded, a direct 
relationship between the two parameters was observed, with a R
2
 value of 0.937.  
This correlation suggests that a high initial viral load might be a driving factor for 
viral diversity.  The env gene from Patient H had evolved an exceedingly long 
distance over time (distance = 0.37), compared to the env from other patients 
(distance = 0.01 to 0.16).  This is possibly due to a high immune selection 
pressure generated by error-prone virus replication.   
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Figure 4.11 – Correlation between viral load and evolutionary divergence  
 
 
 
 
 
Figure 4.11 The evolutionary distance of the primary viruses monitored from 
baseline to week 52 of an individual patient is plotted against the corresponding 
viral load taken at the same time.  The evolutionary distance (y-axis) is defined as 
the number of amino acid substitutions per site from averaging over all sequence 
pairs within the patient between baseline and week 52.  The analysis was 
conducted using the Poisson correction method in MEGA4.1 software. 
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4.2.6 Genetic analysis of the pol gene 
 
To investigate whether virus replication contributed to the viral diversity, 
sequence analysis of the pol gene was carried out.  The primary viruses were 
isolated from the six patients at baseline and at week 52.  The PR and the RT 
regions of the pol gene were amplified and sequenced using the protocol 
described in section 2.20.  The amino acid sequences between baseline and week 
52 were compared and the numbers of site substitutions in PR and in RT were 
calculated (Table 4.6).   
 
Except for patient H, the PR and the RT regions of all other patients evolved little 
over 52 weeks, with less than 5 amino acid site substitution (Table 4.6).  This 
finding correlates with the low viral divergence over time described in the 
previous section.  Mutation in the PR was not significant for patient H, with only 
6 site substitutions.  However, the amino acid sequence of the RT region differs 
significantly between viruses taken at baseline and those taken at week 52, with a 
total of 45 site substitutions.  Interestingly, while viruses derived from patient H 
have the greatest change in RT, they also displayed the greatest env divergence 
over time (Figure 4.11).  Whether or not mutations in the two genes are directly 
related will require further investigation.  However, since RT is responsible for 
transcribing viral RNA into proviral DNA, it is likely that mutations in the RT 
might promote mutations in other genes, i.e., env, for an example.    
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Table 4.6 – Sequencing analysis of the pol gene 
 
 
 
 
 
Table 4.6 The pol genes from RNA fractionated at baseline and at week 52 from 
blood samples of the six patients were sequenced.  The numbers of amino acid 
substitution in the virus PR and RT regions are shown.   
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4.3 Discussion 
 
A major obstacle in developing a HIV-1 vaccine that can elicit a broadly 
neutralising antibody response is the lack of an appropriate immunogen.  The 
extensive antigenic variation of the envelope glycoprotein driven by the RT 
infidelity
33,34,35
 leads to weak and non-group-specific neutralising antibody 
responses, which facilitate viral escape
608,609
.  When compared to laboratory-
adapted strains, primary isolates contain epitopes that are less accessible and are 
10- to 100-fold more resistant to neutralisation
459,539,559
.  Hence, employing Env 
from laboratory-adapted strains as vaccine immunogen candidates is unlikely to 
be beneficial, as any neutralising antibodies raised against these epitopes will not 
be effective against circulating primary isolates.  Thus, recent studies on 
neutralisation have been focusing on finding a primary Env structure that can 
elicit strong and group-specific neutralising antibody responses. 
 
This study randomly selected six patients, who were infected with B-clade HIV-1, 
and the subjects either received SCART or LCART or no treatment immediately 
following diagnosis at PHI.  The neutralisation phenotype of these primary viruses 
and their corresponding antisera were studied, with the aim of identifying an 
isolate that was able to elicit strong and cross-reactive humoral responses.  
Among the six subjects studied, patient M is of particular interest, as this 
individual possessed X4-tropic virus from the initial stage of infection.  Compared 
to R5-using viruses, X4-using isolates are more cytopathic and are associated with 
a substantial loss in CD4
+
 T-cells
610,611
.  Initial consensus sequencing on the C2V3 
region of patient M’s virus predicted an R5-tropism; however, the “in-house” 
phenotypic assay using NP2 cells indicated an X4 tropism, and this was later 
confirmed by the commercial Trofile assay.  The disparities between the genotype 
and phenotype result could be due to the fact that sequencing of C2V3 alone is not 
sufficient to determine tropism, as V1 and V3 are also involved in HIV-1 co-
receptor binding
612
.  It is also possible that the majority of the env quasispecies 
were R5-using but defective, while the functional quasispecies are X4-using.  
Nevertheless, the neutralisation profiles of patient M’s quasispecies did not differ 
from those that were R5-using.  Since patient M was the sole isolate that is X4-
tropic, it is difficult to conclude whether this is a common phenomenon.  A recent 
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investigation into the effect of co-receptor usage on neutralisation reported an 
increase in neutralisation sensitivity by autologous serum in two out of four early 
X4-using isolates
613
, but the small sample size render the argument inconclusive.  
A larger cohort of early X4-tropic isolates will be needed to draw a definite 
conclusion, but these samples are not easy to identify. 
 
Among the six patients in this study, patient F has the most interesting 
neutralisation phenotype.  Isolates derived from patient F at baseline displayed 
similar neutralisation susceptibility to NAbs and autologous and heterologous 
antisera, when compared to other patient isolates.  However, the week 52 isolate 
of patient F was readily neutralisable by NAbs, as well as by heterologous antisera, 
an event that was not commonly observed in primary isolates.  Interestingly, 
sequence analysis of the env genes revealed that viruses derived from patient F, 
particularly those from week 52, have sequences that are closely related to the 
laboratory-adapted strains HXB2 and NL.671.  Laboratory-adapted viruses were 
known to be readily neutralisable due to epitope exposure
552
.  It is possible that 
isolates from patient F also possess Env structures similar to HXB2 and NL.671, 
with neutralising epitopes that are easily accessible by NAbs and antisera, 
resulting in enhanced sensitivity to neutralisation.     
 
A point of particular interest from this study is the relationship between the time 
taken to diagnose HIV-1 infection and viral load.  Patients who were diagnosed 
quickly after their last negative blood test appeared to carry a higher viral load 
than those who were diagnosed later.  This was probably because the sample was 
taken at a time near to the initial viraemia burst during PHI.  Although viral load 
did not correlate with neutralisation by NAbs, it might have a predictive value in 
vivo, as high viral load appears to inhibit neutralising antibody responses in 
patient antisera taken at the acute phase of infection.  One previous study has also 
reported that low viraemia is inversely related to the level of neutralising 
antibodies in patient antisera in chronically infected individuals
614
.  It is well 
observed that neutralising antibody responses are weak during acute infection, 
whether this is due to substantial viraemia boost subsequent to initial HIV-1 
replication, however, is unknown.  Nevertheless, if the levels of viraemia are 
associated with neutralising antibody development and/or potency in acute 
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infection, then early diagnosis and administration of ART will be clinically 
relevant.  Curtailing the viral load at an early stage might be beneficial in 
preserving CD4
+
 T-cell count
602,603,604,605
, enhancing neutralising antibody 
production against autologous isolate, and protecting from superinfection
615
.  
 
Furthermore, it has been reported that patients with high viral load are infected 
with viruses that are more infectious and have a higher transmission rate
616,617
.  In 
this study, viral load was found to correlate directly with viral diversity and 
genetic evolution.  The result is supported by another cohort study on HIV-1 
patients infected the with the A/G recombinant subtype, which also reported 
correlation between viral load and intra-patient diversity, diversification rate, as 
well as divergence from baseline to week 52
618
.  It is likely that the immune 
system is more efficient in targeting the existing variants when the viral load is 
low, particularly in early infection, which leads to a decrease in viral diversity in 
circulation and in the latent reservoir.  Generally, a decrease in baseline diversity 
also translates into reduced evolutionary divergence over time.   However, the 
administration of ART in some of the patients provided an additional selective 
pressure, in which case the evolution histories of these isolates might differ from 
those that are not under any treatment, and this might explain why only baseline 
viral load, and not the week 52 viral load, correlates with virus diversity.   
 
Finally, when compared to other isolates, virus derived from patient H was found 
to have the highest number of non-synonymous amino acid changes in the pol 
gene, as well as having the longest evolutionary distance in the env gene.  It is 
possible that the incident was coincidental and there is no association between 
divergence in env and pol.  However, as pol encodes RT which is one driving 
factor behind antigenic variations because of its high error rate and lack of proof-
reading activity
33,34,35
, it is likely that mutations in RT contributed at least partially 
to the evolutionary divergence observed in env.  Furthermore, the use of RT 
inhibitors induces selection pressure and can lead to mutations in the region that 
accommodates viral escape.  Whether or not patients who are drug-resistant to RT 
inhibitors are prone to be infected with viruses that are more diverse and more 
readily transmitted will be an important question to address from both the clinical 
and public health perspectives.   
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 Appendix I 
 
The SPARTAC clinical trial (EudraCT number: 2004-000446-20) is funded by 
the Wellcome Trust and is part of an international collaboration between Imperial 
College London, Clinical Trials Unit (Medical Research Council, UK) and 
participating sites.  Informed consent was obtained from all participants, and the 
study had full ethical approval. 
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Appendix II 
 
Genetic variability of HIV-1 isolated from plasma RNA vs. proviral DNA 
 
 
 
Appendix II To determine whether HIV-1 isolated from plasma RNA and 
proviral DNA is genetically compatible, clonal sequencing was carried out and 
compared.  Specifically, we have PCR-amplified cell-free viral RNA from plasma 
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and proviral DNA from PBMCs for five recently infected patients (designated as 
patients 1 to 5) from a different patient set.  Approximately 15 to 25 clones per 
patient per sample (RNA or DNA) were selected and the V3 region of env was 
sequenced.  The data were constructed into a phylogenetic tree (above).  Clones 
isolated from plasma RNA are coloured in red, while those isolated from proviral 
DNA are coloured in blue.  There is no noticeable genetic difference between 
quasispecies and many are identical in their sequences, regardless of which source 
they were isolated from.  Based on this result, primary viruses from the six 
patients in our study were isolated from either PBMCs or plasma and their viral 
sequences should not differ one another.
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Chapter 5: 
 
The Impact of Nef on HIV-1 Neutralisation 
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5.1 Introduction 
 
Nef is a highly conserved, 27-34kDa myristolyated regulator protein encoded only 
by primate lentiviruses.  Although it was originally designated as a negative 
factor, Nef possesses multiple biological functions that are essential for viral 
pathogenicity.  Clinically, patients who are infected with HIV-1 with a defective 
nef gene fall into the category of being long-term non-progressors with low viral 
loads and delayed manifestation of AIDS
619,620,621,622
.  Although the precise 
mechanisms remain poorly understood, several distinct functions of Nef have 
been documented and these may contribute to the phenotypes observed in vivo.  
 
It has been reported that Nef enhances reverse transcription
623,624
, viral 
replication
323,625,626
 and viral infectivity
324,328,329
.  Nef is also known to down-
regulate cell surface expression of CD4 via endocytosis
313,627,628
; hence, it blocks 
superinfection and facilitates virion release by preventing aggregation of the virus 
on the membrane surface during budding
629
.  In addition, Nef selectively down-
regulates MHC-I, preferentially HLA type A and B, to escape recognition and 
killing by anti-HIV cytotoxic T lymphocytes (CTLs) and nature killer (NK) 
cells
316,318,630
.  Viral spreading is further promoted with an increased 
responsiveness to T-cell activation in the presence of Nef, as it can alter the signal 
transduction pathways immediately following T cell receptor (TCR) 
engagement
321,322 ,631,632
.  More recently, Nef has been shown to affect the 
envelope glycoprotein (Env) by enhancing incorporation
633,634
 and preventing 
CD4-induced dissociation of gp120 from gp41
635
.  In addition, sequence changes 
in the gp41 cytoplasmic tail of Nef-deficient (ΔNef) SIV has been observed in 
vivo.  This was attributed to compensate for the viral functions in the absence of 
Nef
636
. 
 
The HIV-1 envelope glycoprotein is the main surface antigen against which 
antibody responses are elicited upon infection.  The outer Env spike, gp120, is 
heavily glycosylated, with approximately 55% of its mass contributed by 
asparagine (N)-linked oligosaccharide side chains
637,638,639
.  Early studies showed 
that removal of N-linked glycans reduced the binding of gp120 to CD4
640
, 
resulting in decreased cell infectivity and cytopathicity
641,642
.  In addition, the 
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glycans form an evolving shield that acts as steric hindrance to prevent antiviral 
antibodies from binding to epitopes
643,644,645
, thereby protecting the virus from 
host immune recognition.   
 
Currently, only four monoclonal antibodies are known to display potent and cross-
reactive neutralising activities against the Env of HIV-1.  These include anti-
gp120 antibodies b12 (directed to the CD4 binding domain)
361
, anti-carbohydrate 
antibody 2G12 (high mannose oligosaccharides)
370
 and anti-gp41 antibodies, 
2F5
376
 and 4E10
377
.  Nevertheless, none of these NAbs was effective as a 
therapeutic or vaccination agent in vivo
646
.  Not all antibody-Env binding leads to 
neutralisation, however.  First of all, not all envelopes are expressed on the 
surface in the functional trimeric form.  Non-functional conformations, such as 
uncleaved gp160
647,648
, gp41 stumps depleted of gp120
649
 and/or monomeric 
gp120/gp41
650,651
 can also be expressed on the virion surface.  Neutralising 
antibodies (NAbs) differ from non-neutralising antibodies in that they only 
recognize functional trimers
652,653
.   
 
The number of envelope glycoprotein molecules expressed on the virion surface is 
associated with viral infectivity and antigenicity.  Using the three-dimensional 
electron tomogram technology, an average of 7 to 14 surface envelope spikes per 
virion was reported
654
.  Although the precise mechanism for neutralisation remain 
to be elucidated, computational studies suggest that epitope occupancy, not 
specificity, is the main determinant of neutralisation
655,656,657
.  A high occupancy 
of NAb on the surface envelope glycoprotein forms a blocking coat and prevents 
the virus from infecting the target cells.  Neutralisation is inefficient when NAb 
occupancy on the antigen is low, even if there is a high binding affinity between 
NAb and Env
656
.  Moreover, a recent study by Yang et al. (2005) suggests that 
every Env on the virion surface must be covered by at least one NAb molecule 
before neutralisation can occur
658
, as a single functional trimer per virion is 
sufficient for infection to occur.   
 
Various aspects of Env have been investigated in the past to suggest new 
strategies to enhance neutralising antibody response:  (1) Truncations of the 
cytoplasmic tail and the V3 loop lead to a conformational change in Env and 
exposure of previously conserved epitopes, thereby, increasing NAbs 
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binding
659,660,661
.  (2) In addition, modifications of the N-linked glycans on gp120 
have been reported to increase significantly the antigenicity, immunogenicity, and 
sensitivity to neutralisation of HIV-1
662,663,664
.  (3) It was suggested that the 
accessory protein, Nef, might have the ability to target Env by altering Env 
incorporation and inducing sequence changes
633,634,635,636
.  If true, HIV-1 that is 
deficient in Nef could display a different neutralisation profile from that of wild-
type (WT) virus.  This study aims to investigate the effect of Nef on HIV-1 
neutralisation.  The results might be clinically exploited for future vaccine 
strategies if, indeed, Nef can alter the humoral response. 
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5.2 Results 
 
5.2.1 Absence of Nef enhances sensitivity to neutralisation by broadly 
neutralising antibodies 
 
As suggested by previous studies, the HIV-1 accessory protein, Nef, may be able 
to modify the HIV-1 envelope phenotype
633,634,635,636
.  If true, neutralisation 
susceptibility to NAbs might be different in WT and in ∆Nef viruses.  To examine 
this possibility, WT and ∆Nef HIV-1 NL4.3 viruses were subjected to 
neutralisation by a panel of NAbs.  These included NAbs targeting the gp120 
CD4-binding site (b12), high mannose glycans (2G12) and the gp41 
transmembrane domain (2F5 and 4E10). 
 
The WT and ∆Nef HIV-1 NL4.3 viruses were produced by chronic infection in 
Jurkat E6.1 cells (section 2.24) and were normalised for RT activities using the 
SG-PERT assay (section 2.15).  The two viruses were neutralised with NAbs 
before being assayed on TZM-bl cells which carry the reporter marker gene, β-
gal.  After 2h of incubation with the virus-NAb complex, the TZM-bl cells were 
replaced with fresh culturing medium containing 1µM of the PR inhibitor, 
Saquinavir, to limit the replication competent viruses to a single round infection. 
 
After staining for β-gal activity, infected TZM-bl cells became blue in colour and 
could be visualised easily by light microscopy (section 2.6).  Residual infectivity 
was determined by counting the number of blue foci in the TZM-bl cells.  On 
average, 75mU of RT of WT NL4.3 infected approximately about 22% of the 
cells, while the same amount of ∆Nef virus infected between 2 to 3% of the cells 
(Figure 5.1).  This difference in infectivity between WT and ∆Nef viruses was 
commonly observed and was reported to be producer-cell dependent
665,666
. 
 
The normalised WT and ∆Nef NL4.3 viruses were subjected to neutralisation by 
NAbs with concentrations ranging from 0 to 20µg/ml before being assayed on 
TZM-bl cells.  In all cases, the ∆Nef NL4.3 variant was more sensitive to 
neutralisation than the WT counterparts (Figure 5.2A).  For example, when treated 
with 4µg/ml of 2F5, WT NL4.3 retained 49% residual infectivity, compared to 
just 12% in the case of the ∆Nef NL4.3.  The ∆Nef variant was also more readily 
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Figure 5.1 – Infectivity of WT and ∆Nef HIV-1 on TZM-bl cells 
 
 
 
 
 
 
 
Figure 5.1 WT and ΔNef HIV-1 (strain NL4.3) were normalised to RT activities 
before titrating on TZM-bl cells which carry the marker gene, β-gal.  The number 
of infected cells was determined by staining for β-gal activity 48h post-infection.  
Infected cells were blue in colour, as shown in the figures. 
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Figure 5.2 – Neutralisation of WT and ∆Nef HIV-1 by NAbs 
 
 
 
 
 
Figure 5.2 The WT and ∆Nef HIV-1 (strain NL4.3) were normalised for RT 
activity and neutralised with NAbs: 2F5, b12, 2G12 and 4E10 before being 
assayed on TZM-bl cells.  The x-axis represents NAb concentration while the y-
axis represents percent residual infectivity, calculated by measuring β-gal 
activities relative to control experiments with no antibody.  B) The amounts of 
NAbs required to achieve IC50 were measured from the dose-response curves in 
Figure A and these are shown in Figure B.    
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neutralised by 2G12.  For instance, at 4µg/ml, WT NL4.3 displayed 43% residual 
infectivity while ∆Nef NL4.3 only had 11% residual infectivity.  Again, the same 
was observed with 4E10 (4µg/ml), for which the residual infectivity was 62% for 
WT virus and 26% for the ∆Nef virus.  The NAb, b12, was particularly potent in 
neutralising the NL4.3 virus.  When neutralised with 0.8µg/ml of b12, WT NL4.3 
retained 47% residual infectivity, while the figure was only 20% for ∆Nef NL4.3.   
 
The NAb concentration needed to achieve 50% inhibition of infection (IC50) was 
calculated and is shown in Figure 5.2B.  The IC50 of ∆Nef NL4.3 was 13-fold less 
than that of WT when neutralised with 2F5, 7-fold lower with b12 and 4-fold 
lower with 2G12 and 4E10.  The enhanced neutralisation susceptibility in the 
∆Nef virus demonstrated that Nef, indeed, can target HIV-1 Env and protect the 
virus from being neutralised by NAbs. 
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 5.2.2 – Increased neutralisation sensitivity of ∆Nef HIV-1 is independent of 
Env incorporation 
 
A previous study by Schiavoni et al. (2004) attributed the increased neutralisation 
sensitivity of the ∆Nef virus to a decreased Env incorporation into the virion633.  
However, the published data were not confirmed in our study, despite using the 
same viral isolate.  To compare Env incorporation, WT and ∆Nef NL4.3 viruses 
were normalised for RT activity before being assayed by Western blotting 
(section 2.26).  The result is shown in Figure 5.3.  Both viruses displayed the 
same level of gp120 incorporation with compatible amounts of p24, arguing 
against the notion that the enhanced sensitivity of ∆Nef virus was a direct 
consequence of reduced surface envelope expression.   
 
Furthermore, if gp120 incorporation was less in the ∆Nef virus, then its binding to 
sCD4 should differ from that of WT virus.  Hence, neutralisation with sCD4 was 
carried out.  As expected, WT and ∆Nef NL4.3 viruses were neutralised to the 
same extent by sCD4 at every concentration tested (Figure 5.4), further suggesting 
that neither envelope incorporation nor viral infectivity contributes to the 
enhanced neutralisation susceptibility observed earlier (Figure 5.2).   
 
To examine whether Nef protects from neutralising antibodies in general, 
ARP401, an anti-Env polyclonal antiserum raised in sheep was employed.  It has 
been reported that this antiserum is responsible for high titre type-specific 
neutralising activity
529
.  Consistent with this report, HIV-1 NL4.3 was neutralised 
efficiently by ARP401 (IC50 = 0.0013µg/ml) (Figure 5.4).  Moreover, both WT 
and ΔNef NL4.3 were neutralised equally well by this antiserum at all the 
dilutions tested, indicating that the protective effect of Nef against NAbs was 
epitope-specific. 
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Figure 5.3 – HIV-1 gp120 incorporation into WT and ∆Nef viruses 
 
 
 
 
 
 
Figure 5.3 The WT and ∆Nef NL4.3 viruses were produced by chronic infection 
in Jurkat E6.1 cells (section 2.24).  The ∆Env NL4.3 virus was produced in Jurkat 
E6.1 cells by electroporation (section 2.23).  Viruses were concentrated and 
normalised for RT activity and virus pellets serially diluted 10-fold (in PBS) 
before being assayed by Western Blotting.  It can be seen from the figure that the 
same amounts of gp120 and p24 in WT and ∆Nef viruses were detected.   
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Figure 5.4 – Neutralisation of WT and ∆Nef HIV-1 by sCD4 and polyclonal 
antiserum 
 
 
 
 
 
 
 
Figure 5.4 WT and ΔNef NL4.3 viruses were normalised for RT activity and 
incubated with A) sCD4 and B) polyclonal antiserum ARP401 before assaying 
neutralisation effects on TZM-bl cells.  The x-axis shows sCD4 (A) and ARP401 
(B) dilution and the y-axis represents percent residual infectivity, relative to 
experiments in which sCD4 or ARP401 was not incubated with virus.  The two 
viruses were neutralised to the same extent by both sCD4 and ARP401.  
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5.2.3 The absence of CD4 in virus producer cells does not alter infectivity or 
neutralisation  
 
The ∆Nef HIV-1 is known to display reduced infectivity in a producer cell-
dependent manner
665,666
.  Some accredited this phenomenon to Nef-mediated CD4 
down-regulation on the host cell surface, which stimulates virus replication and 
infectivity
667,668,669,670
.   
 
To examine whether the Nef effect on neutralisation is CD4-dependent, WT and 
∆Nef NL4.3 viruses were produced by transfection in CD4-positive Jurkat E6.1 
cells as well as in CD4-negative Jurkat D1.1 cells and HSB-2 cells (Table 2.1).  
Both Jurkat D1.1 cells and HSB-2 cells were obtained from the American Type 
Culture Collection and confirmed to be CD4-negative T-cell lines.  The two 
viruses were normalised for RT activity before infecting the TZM-bl cells.  
Regardless of CD4 expression on the producer cells, the ∆Nef virus was 
infectious to the same degree in all three cell lines (Figure 5.5).  When compared 
with WT viruses (infectivity = 100%), infectivity of the ∆Nef NL4.3 was 15% 
when produced in Jurkat E6.1 cells and 10% when produced in Jurkat D1.1 cells 
or HSB-2 cells.   
 
When neutralised with 2F5, there were no difference in the neutralisation profiles 
between viruses produced in CD4-positive or CD4-negative cell lines (Figure 
5.6).  The ∆Nef virus was more readily neutralised by 2F5 compared to the WT 
virus, regardless of the host cell.  For examples, the IC50 of ∆Nef NL4.3 was 18-
fold lower than that of the WT virus (0.6µg/ml and 11.6µg/ml, respectively) when 
produced in Jurkat E6.1 cells, 17-fold lower when produced in Jurkat D1.1 cells 
and 8-fold lower when produced in HSB-2 cells.  These data suggest that the Nef-
mediated CD4 down-regulation did not directly contribute to the reduced 
infectivity or enhanced sensitivity to neutralisation of the ∆Nef virus.   
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Figure 5.5 – Reduced infectivity of ∆Nef HIV-1 is independent of CD4 
expression on the producer cell. 
 
 
 
 
 
Figure 5.5 WT and ∆Nef NL4.3 viruses were produced in CD4-positive Jurkat 
E6.1 cells, CD4-negative Jurkat D1.1 and HSB-2 cells (x-axis) by transfection 
using Lipofectamine 2000 (section 2.23).  Viruses were normalised to RT activity 
and assayed on TZM-bl cells for infectivity (section 2.16).  Infectivity of ∆Nef 
virus was calculated relative to that of the WT virus (y-axis).   
 
 
 
 
 
 
 
 
 
145 
 
Figure 5.6 – Absence of CD4 on virus producer cells has no effect on 
sensitivity to neutralisation.   
 
 
 
 
 
Figure 5.6 WT and ∆Nef NL4.3 viruses were produced by transfection in A) 
CD4-positive Jurkat E6.1 cells, B) CD4-negative Jurkat D1.1 cells, and C) CD4-
negative HSB-2 cells, and subjected to neutralisation with NAb 2F5, in 
concentrations ranging from 0 to 20µg/ml (x-axis).  Results were reported as % 
residual infectivity (y-axis) relative to experiments in which no 2F5 was included. 
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5.2.4 Truncation of the HIV-1 gp41 cytoplasmic tail and deletion of Nef 
enhance neutralisation sensitivity 
 
A study on Rhesus monkeys infected with ∆Nef SIV suggested that compensatory 
sequence changes occurred in the cytoplasmic domain of gp41 to provide 
functional activities that were normally provided by Nef
 636
.  Since changes in Nef 
and in the gp41 cytoplasmic tail are both capable of altering the neutralisation 
outcome, a combination of both might generate an additive effect.  
 
To determine the effect of Nef and CT deletions on infectivity and neutralisation, 
WT and ∆Nef HIV-1 NL4.3 viruses, with or without a truncated cytoplasmic tail 
(∆CT), were produced in Jurkat E6.1 cells and assayed on TZM-bl cells (Figure 
5.7).  Compared to the WT virus (relative infectivity = 100%), infectivity of the 
∆Nef virus was only 8%.  A truncation in the gp41 cytoplasmic tail enhances 
infectivity of the virus.  The ∆CT NL4.3 virus displayed 117% infectivity, relative 
to that of the WT virus.  The NL4.3 virus with both Nef-deletion and gp41 
cytoplasmic tail truncation (∆Nef∆CT) displayed 50% infectivity, relative to that 
of the WT virus.       
 
To examine whether Nef-deletion and gp41 cytoplasmic tail truncation together 
can generate an additive effect in enhancing neutralisation sensitivity, the four 
viruses (WT, ∆Nef, ∆CT and ∆Nef∆CT) were subjected to neutralisation by 2F5 
(Figure 5.8).  The WT virus was the least sensitive to neutralisation by 2F5, 
requiring 0.43µg/ml of NAb to achieve IC50. Consistent with the observation in 
previous sections, the ∆Nef NL4.3 virus was more sensitivity to neutralisation 
(IC50 = 0.15µg/ml), compared to that of the WT virus.  When the gp41 
cytoplasmic tail was truncated, neutralisation sensitive of the ∆CT virus was also 
enhanced, requiring only 0.11µg/ml to achieve IC50.  The ∆Nef∆CT virus is the 
most neutralisable by 2F5, with IC50 of 0.03µg/ml.   
 
To examine whether the enhanced neutralisation sensitivity observed in the ∆CT 
and ∆Nef∆CT viruses was specific for 2F5, a control experiment was carried out 
using the polyclonal antiserum, ARP401 (Figure 5.8).  Consistent with the 
previous observation (Figure 5.4), the WT and ∆Nef NL4.3 viruses were 
neutralised equally well by the antiserum (IC50 = 0.024µg/ml for both).  Viruses  
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Figure 5.7 – Infectivity of WT and ∆Nef HIV-1 with or without gp41 CT 
truncation 
 
 
 
 
 
Figure 5.7 WT and ∆Nef NL4.3 viruses, with or without a truncated CT in gp41, 
were produced in Jurkat E6.1 cells by transfection.  Viruses were normalised for 
RT activity and assayed on TZM-bl cells for infectivity, expressed as a % of WT 
infectivity. 
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Figure 5.8 Neutralisation of WT and ∆Nef HIV-1 with and without gp41 CT 
truncation.   
 
 
 
 
 
 
 
Figure 5.8 WT and ∆Nef NL4.3 viruses, with or without CT truncation in gp41, 
were subjected to neutralisation by A) anti-gp41 NAb, 2F5 and B) anti-gp120 
polyclonal serum, ARP401.  Neutralisation was assayed on TZM-bl cells (section 
2.17).  Percent residual infectivity (y-axis) was measured in relation to negative 
control experiments in which viruses were not treated with any NAb or antiserum.   
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with the gp41 truncation (∆CT and ∆Nef∆CT) also displayed a similar IC50 value 
(0.020µg/ml for both), compared to that of the WT and ∆Nef viruses.  These data 
suggest that the enhanced neutralisation sensitivity to 2F5 observed in the ∆CT 
and ∆Nef∆CT viruses was epitope-specific.   
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5.2.5 Neutralising antibodies capture ∆Nef HIV-1 more efficiently than WT 
HIV-1 
 
The enhanced neutralisation sensitivity of ∆Nef virus suggests that NAbs might 
recognise ∆Nef virus differently from WT virus.  Hence, immunoprecipitation 
assays (section 2.27) were carried out to determine if NAbs bind to ∆Nef HIV-1 
differently from the WT virus. 
 
Immunoprecipitation assays were carried out using Sepharose beads immobilised 
with Protein A.  The beads were then incubated with NAbs (2F5, b12 or 2G12) 
which would bind to the immobilised Protein A.  The WT and ∆Nef NL4.3 
viruses were normalised for RT activity and incubated with the beads bound with 
NAb.  The amount of virus captured by the by NAbs, in units of RT activity, was 
measured by SG-PERT assay (section 2.15) and shown in Figure 5.9.   
 
When 2F5 antibody was used, approximately 4-fold more ∆Nef NL4.3 virus was 
captured by the NAb, compared to the WT virus.  The other NAb, 2G12, captured 
6-fold more ∆Nef virus than the WT counterpart.  The same was also observed 
with b12 which captured 3-fold more ∆Nef virus than the WT virus.  The 
increased capture of ∆Nef virus by NAbs suggests that the NAb either has a 
stronger binding affinity to the ∆Nef HIV-1 than to the WT virus, or that the 
interaction between NAb and virus is more stable in the absence of Nef.  
Furthermore, to examine whether the increased capture of the ∆Nef virus by 
NAbs was epitope-specific, the polyclonal antiserum, ARP401, was used in the 
control experiment.  It was found that an equal amount of WT and ∆Nef NL4.3 
viruses was captured by this polyclonal antiserum, indicating that the increased 
∆Nef virus captured by NAbs was epitope-specific.    
 
To test whether the viruses captured specifically by the NAbs not by the beads’ 
matrices, a competitive immunoprecipitation assay was carried out (Figure 5.10).  
In this case, WT or ∆Nef virus was incubated with the Sepharose beads (coated 
with b12) simultaneously with excess amounts of recombinant soluble gp120 
(strain IIIB).  If the captured reaction in Figure 5.9 represents a specific 
interaction between gp120 and NAb, then the amount of virus captured would 
decrease in the presence of recombinant soluble gp120 due to competition.  On  
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Figure 5.9 – Immunoprecipitation of WT and ∆Nef NL4.3 by NAbs and 
polyclonal antiserum 
 
 
 
 
 
 
 
Figure 5.9 Immunoprecipitation assays were carried out to examine whether the 
enhanced neutralisation sensitivity in ∆Nef HIV-1 was due to a difference in NAb 
binding.  WT and ∆Nef viruses were immunoprecipitated with Protein A beads 
coated with 2F5, 2G12, b12 or ARP401 (x-axis).  Non-specific binding 
(background) was detected by immunoprecipitating the viruses with beads not 
coated with any NAb or antiserum.  The amount of virus captured (y-axis), 
defined by RT activity, was determined by the SG-PERT assay (section 2.15).  
The results shown above represent the net virus captured (total virus captured 
minus background).     
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Figure 5.10 – Competitive immunoprecipitation of WT and ∆Nef HIV-1 
 
 
 
 
 
Figure 5.10 To examine whether viruses were captured specifically by NAbs and 
not by the bead itself, a competitive immunoprecipitation assay was carried out.  
The WT and ∆Nef NL4.3 viruses were immunoprecipitated with either NAb b12 
alone (left) or with b12 in the presence excess recombinant soluble gp120 (strain 
IIIB) (right).  Non-specific binding was detected by immunoprecipitating viruses 
with beads not coated with b12.   
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the other hand, if the capture reaction was non-specific, then the amount of virus 
captured would be the same, regardless of the presence or absence of the soluble 
gp120.  In the absence of IIIB gp120, the beads that were coated with b12 
captured 2-fold more ∆Nef NL4.3 virus than the WT virus.  However, in the 
presence of recombinant soluble gp120, virus capture of both WT and ∆Nef 
NL4.3 were reduced to background level, demonstrating that the virus interacted 
specifically with the NAbs, and not non-specifically to the matrices of the beads.   
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5.2.6 Glycan composition of WT and ∆Nef viruses by mass spectrometry 
 
One possible explanation of the enhanced neutralisation sensitivity (section 5.2.1) 
and increased virus capture of ∆Nef HIV-1 (section 5.2.5) is that ∆Nef virus 
possesses different gp120 glycosylation from the WT virus.  To determine the 
sugar composition of the surface glycans on gp120 on the two viruses, mass 
spectrometry was carried out.   
 
Supernatant fluids harvested from Jurkat E6.1 cells chronically infected with WT 
or ∆Nef NL4.3 were concentrated approximately 3000-fold by ultracentrifugation 
before they were subjected to SDS-polyacrylamide gel electrophoresis (Figure 
5.11).  The NL4.3 virus deficient in Env (∆Env) was used as a negative control to 
determine the position of gp120 and to test for specificity.  Bands representing 
gp120 were excised from the gel and sent for glycomic analysis by mass 
spectrometry in Professor A. Dell’s laboratory (Division of Molecular 
Biosciences, Imperial College London).   
 
Although previous studies have analysed sugar composition of the surface 
glycans, these investigations were done on recombinant gp120 produced in a 
laboratory-adapted mammalian cell line, CHO
671,672
.  This study is the first to 
analyse carbohydrate composition in virus-associated gp120.  High mannose 
sugars were the major N-linked glycans found on surface of gp120 in both WT 
and ∆Nef virus.  Despite minor differences in the type of high mannose sugar 
between the two viruses, the overall sugar compositions were basically identical 
(Figure 5.12).  There were 17 types of complex high mannose identified in WT 
virus, 12 of which were sialylated.  For ∆Nef virus, 15 types of complex sugar 
were found, 11 of which were sialylated.  The extent of sialylation in virus-
associated gp120 was much greater than that on recombinant gp120.  Heavy 
sialylation increases the overall negative charge on the glycans and may play a 
role in the antigenic
 
properties of the virus.     
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Figure 5.11 – Polyacrylamide gel electrophoresis of WT and ∆Nef HIV-1  
 
 
 
 
 
 
 
Figure 5.11 WT, ∆Nef and ∆Env NL4.3 viruses were normalised for RT and 
concentrated by ultracentrifugation (section 2.25).  Samples were applied to an 
11% polyacrylamide gel and stained with GelCode Blue.  The ∆Env NL4.3 was 
used as a control to define the position of gp120 and to test for specificity in the 
glycomic analysis.   
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Figure 5.12 Mass spectrometry analyses on glycosylation of WT and ∆Nef 
HIV-1  
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Figure 5.12 Sugar moieties of gp120 in WT (top) and ∆Nef (bottom) virus are 
shown.  Complex sugars are constituted by the building blocks: fucose (red 
triangle), galactose (yellow circle), glucose (blue square), N-acetylneuraminic 
acid (purple rhombus), and deaminated neuraminic acid (green circle).  The x-axis 
of the chromatogram represents mass-to-charge (m/z) ratio which allows 
identification of the sugar composition and structure, and the y-axis measures the 
signal intensity. 
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5.2.7 Enzymatic hydrolysis found no structural difference in wild-type and 
∆Nef virus 
 
Since mass spectrometry could not determine the overall quantity of glycans 
present in the two viruses, further characterisation of the glycans was carried out 
by enzymatic hydrolysis with Peptide: N-Glycosidase F (PNGase F).  The 
PNGase F is an amidase that cleaves between the asparagine (N) and the 
innermost N-acetylglucosamine (GluNAc), thus releasing the N-linked glycans 
from the glycoproteins.   
 
The WT and ∆Nef NL4.3 viruses were produced by chronic infection in the Jurkat 
E6.1 cells.  Viral supernatant fluids were normalised for RT activity before 
incubation with the PNGase F enzyme (section 2.28).  PNGase F was a powerful 
enzyme capable of deglycosylating virion-associated gp120s completely in less 
than a minute.  When WT and ∆Nef viruses were treated with PNGase F over a 
range of concentrations, a gradual drop in the molecular weights of gp120s was 
observed (Figure 5.13).  Although gp120 from WT virus appeared to have more 
deglycosylated products than gp120 from ∆Nef virus when digested with 20 and 
100 units of PNGase F, the overall degradation patterns were identical in both 
viruses.  Hence, it is unlikely that that the two viruses differ in the extent of 
glycosylation quantitatively or posses different gp120 structures. 
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Figure 5.13 – Deglycosylation of WT and ∆Nef HIV-1 on a Western blot 
 
 
 
 
 
Figure 5.13 WT and ∆Nef NL4.3 viruses, concentrated and purified by 
ultracentrifugation with a 20% sucrose cushion (section 2.25), were digested with 
0, 20, 100, or 500U of PNGase F and assayed by Western blotting.  
Deglycosylation of gp120 in the presence of PNGase F is indicated by a drop in 
molecular weight. 
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5.3 Discussion 
 
The accessory protein Nef provides pleiotropic functions that are essential in 
HIV-1 infection.  In multiple studies where rhesus macaques were challenged 
with nef-deleted SIV or SHIV, the animals produced strong neutralising antibody 
responses, despite having non-detectable viral load
468,469 ,673,674,675
.  Based on these 
data, nef-deleted HIV-1 was once proposed as a candidate immunogen for live-
attenuated vaccine use.  Regrettably, the strategy failed to work for human 
subjects.  A group of eight haemophilic patients were accidentally infected with 
nef-deleted HIV-1 after blood transfusion from a single donor, and the 
immunological and virological status of these individuals was followed for over 
two decades
619,620,621,622
.  Despite delayed clinical latency associated with low 
viral loads and stable CD4 counts, some of the patients eventually contracted 
AIDS.  Nevertheless, these data suggest that antiretroviral therapy targeting nef 
might substantially delay disease progression in patients infected with HIV-1.  In 
addition, exclusion of nef (Nef) in candidate vaccines employing whole virus or 
recombinant proteins might induce stronger neutralising antibody responses.
 
 
In vitro studies have revealed that HIV-1 was substantially more sensitive to 
antibody neutralisation in the absence of Nef.  Although one group attributed this 
observation to decreased Env incorporation in ∆Nef virus633, the reported result 
was not reproducible in this study under the same experimental conditions.  The 
same amounts of gp120 and p24 were assayed in WT and ∆Nef virus; 
furthermore, the two viruses were neutralised to the same extent by sCD4.  
Although Nef is shown to increase Env incorporation
634,635,670
, the result obtained 
in this study clearly demonstrated that the Nef effect on neutralisation sensitivity 
was independent of Env incorporation.  
 
 
Since one of the many viral functions of Nef is to down-modulate CD4, it is 
possible that the enhanced sensitivity to neutralisation occurred in a CD4-
dependent manner.  Nef is an early gene product that is expressed immediately 
following infection
676,677
.  It acts by internalising the CD4 molecules presented on 
the surface of the infected cells and directs them to degradation in the lysosomes 
via endocytic pathways
313,627,628
.  While some studies reported the Nef-mediated 
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CD4 down-regulation permits higher viral infectivity and promotes Env 
incorporation into the virion
635,670,678
, others have shown that infectivity of 
progeny virus is independent of CD4
624,679,680
.  The results from this study support 
the latter argument.  Progeny WT and ∆Nef viruses displayed similar degrees of 
infectivity and have comparable sensitivities to neutralisation, whether they were 
produced in CD4-positive or CD4-negative cell lines, indicating that Nef-
mediated CD4 down-modulation has no effect on either the infectivity or the 
degree of neutralisation. 
 
From the immunoprecipitation assays performed in this study, the enhanced 
sensitivity to neutralisation in ∆Nef HIV-1 was accredited to increased NAb 
binding to their respective epitopes.  Many factors could have contributed to this 
observation.  First of all, the phenomenon could be a direct consequence of 
reduced viral fusion to the cell and decreased infectivity due to the absence of 
Nef.  However, this does not seem to be the explanation because binding to sCD4 
and polyclonal serum is the same in ∆Nef virus as in WT virus.  Secondly, it is 
possible that epitopes on Env are more accessible in ∆Nef HIV-1 due to 
glycosylation differences.  However, mass spectrometric analysis found no 
difference in the overall sugar composition, and enzymatic hydrolysis did not 
reveal any quantitative difference in the amount of glycosylation on gp120.  
Another possibility could be that, in the absence of Nef, the non-covalent 
association between gp120 and gp41 is weakened and gp120 is more readily shed 
by NAbs, leading to increased degree of neutralisation.  In addition, Nef plays a 
role in the biosynthesis and uptake of cholesterol during viral budding
681,682
 and a 
recent study reported that Nef can also alter lipid compositions of the viral 
membrane
683
.  This, in turn, has a direct effect on virus infectivity.  It could also 
influence the flexibility or the conformation of the Env protein, leading to the 
exposure of conserved antigenic epitopes and, thereby, contributing to enhanced 
NAb bindings observed in this study.   
 
The sensitivity to neutralisation of ∆Nef HIV-1 could be further enhanced when 
the gp41 cytoplasmic tail is truncated.  Previous reports have shown that 
mutations in the gp41 cytoplasmic domain can affect both viral infectivity and 
sensitivity to neutralisation
659,660
.  Meanwhile, nef-deleted SIV was found to 
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acquire polymorphic changes in the cytoplasmic domain of gp41 over time in 
order to compensate for the functional activities normally provided by Nef
 636
.  
Although there was no synergic effect in neutralisation when both nef and the 
cytoplasmic tail were absence, an additive effect was observed in our study.  
Furthermore, the neutralisation result was independent of infectivity as ΔCT virus 
was more readily neutralisable, despite being more infectious.  This observation 
provides counter-evidence for the argument that sensitivity to neutralisation is 
dependent on infectivity.   
 
For future investigation, a panel of nef mutants should be employed to investigate 
which in vitro functions of Nef contribute to the decreased neutralisation 
susceptibility of WT virus observed in this study.  In addition, a Blue-Native 
PAGE method can be used to determine whether or not Nef affects the 
stoichiometry of Env and subsequent neutralisation sensitivity.  Although the 
mechanisms underlying the enhanced sensitivity to neutralisation and increased 
NAb binding to ΔNef HIV-1 remain unclear at the moment, the results clearly 
indicate that Nef has a protective effect on anti-Env neutralisation.  The finding 
could impact on strategies to elicit strong humoral response in vaccine 
development.   
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Chapter 6: 
 
Discussion 
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Since the identification of HTLV-III (later HIV-1) as the etiological agent of 
AIDS in 1983
3
, intensive research of this virus has greatly improved our 
understanding of the virology and immunology of the infection.  Six classes of 
ART (protease inhibitors, nucleoside RT inhibitors, non-nucleoside RT inhibitors, 
integrase inhibitor, entry inhibitor and fusion inhibitors) have been produced to 
suppress HIV-1 replication and delay progression to AIDS
684
.  However, a 
preventive vaccine is still far from being discovered.  It is generally agreed that an 
effective HIV-1 vaccine should induce both cellular and humoral responses.  
Although there has been some limited success in eliciting CD8
+
 CTLs with vector 
vaccines
494,495,685
, a broadly-reactive neutralising antibody is still lacking, despite 
numerous approaches having been attempted
360
.  This thesis explores three 
aspects of the neutralising antibody response which have the potential to impact 
on future vaccine strategy.   
 
The accuracy and compatibility of current neutralising assays are investigated and 
compared in chapter 3.  The recent use of a single-round pseudovirus which 
contains the env gene derived from a primary isolate incorporated into a 
laboratory-adapted strain backbone has replaced the use of the replication-
competent primary virus in a neutralisation assay
559,560,561
.  Although this kind of 
pseudovirus allows for intra- and inter-laboratory standardisation, discrepancies in 
the neutralisation results between the pseudovirus and the replication-competent 
WT virus have been reported
374,576,677
. The only report which systematically 
compares the pseudovirus and the replication-competent WT virus is a study by 
Louder et al. (2006), which found no significant difference (less than 3-fold) in 
neutralisation between the two virus platforms
572
.  However, in this study, we 
found that the WT virus was substantially more sensitive to neutralisation (up to 
18-fold) by NAbs than the pseudovirus, which agrees with the data dervied with 
primary isolates by Binley et al. (2004)
374
.     
 
The increased neutralisation susceptibility of the pseudovirus leads to the 
suspicion that the envelope incorporation into the pseudovirus may be less than 
that into WT virus.  Since no previous characterisation has been done, we carried 
out a Western blot to assess the gp120 and gp41 expression on the two viruses 
which were normalised for RT activity.  Surprisingly, substantially more gp120 
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and gp41 were expressed in the pseudovirus than in its WT counterpart.  
Generally, the number of envelope spikes correlates with viral infectivity and 
resistance to neutralisation, and it has been proposed that a single envelope trimer 
is sufficient to mediate the infection
658
.  So why is the pseudovirus more 
neutralisable than its WT counterpart if it incorporates substantially more 
envelope glycoproteins?  One possible explanation is that most of the envelope 
glycoprotein expressed in the pseudovirus is non-functional.  During virus 
replication, the envelope precursor, gp160, is cleaved by furin at motifs R-X-R/K-
R or K-X-K-R-R, resulting in two functional trimeric products, gp120 and 
gp41
158
.  Non-functional envelope products, such as uncleaved gp160, gp41 
stumps or monomeric gp120/gp41 complex can also co-exist with functional 
envelope trimers on the virion surface
647,648,649,650,651
.  While both neutralising and 
non-neutralising antibodies can recognise and bind to non-functional envelope, 
only neutralising antibody can bind to functional trimer and neutralise the 
virus
652,653
.  Thus, it is possible that the pseudovirus expresses less functional 
trimers than the WT virus which, in turn, requires less neutralising antibody to 
block.  If pseudovirus expresses envelope differently from WT virus, then its use 
in neutralisation assay may not reflect the true antigenic nature of the virus in 
vivo.   
 
In addition, a common practice of the pseudovirus-based neutralisation assay is to 
produce the virus in non-lymphocytic cell lines for consistency and to increase 
titre
547
.  However, this study found that viruses produced in non-lymphocytic cell 
lines have lower infectivity and are more susceptible to neutralisation, compared 
with viruses produced in PBMCs or CD4
+
 T-cells.  Non-lymphocytic cells lack 
certain cellular proteins (i.e. ICAM-1 and LFA-1) which are normally 
incorporated into the virion and, therefore, have the potential to alter the 
biochemical properties of the virus
573,574,575
.  Furthermore, a virus derived from 
PBMCs is found to contain more envelope glycoproteins (12 to 19 functional 
spikes) than a virus produced from 293T cell lines (1 to 3 functional spikes) and, 
therefore, requires more NAbs to bring about neutralisation
572
.  Moreover, the 
carbohydrate repertoire varies in different cell types and, thus, the virus proteins 
undergo different post-translational modification in different cells, thus displaying 
host-specific glycosylation.   
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Although a pseudovirus-based neutralisation assay is more cost-effective, less 
time-consuming and easier to standardise than the traditional PBMC-based assay, 
several scientific questions proposed by the HIV Vaccine Trials Network and 
Division of AIDS (NIH)
547
, need to be addressed before it can be considered as 
being the “gold” standard for use.  We have addressed two issues here, on virus 
platform and producer cell types, and found that both parameters can greatly 
influence the neutralisation outcome.  Therefore, in clinical studies or vaccine 
efficacy trials, more than one neutralisation assay requires to be employed and the 
data compared to reflect better the true humoral response in vivo. 
 
The neutralisation profile and evolutionary history of six patients with PHI were 
studied in chapter 4.  Primary infection time is defined as being the first six 
months following the detection of anti-HIV antibodies.  During this time, the virus 
replicates rapidly, and an estimated 10 to 100 million CD4
+
 T-cells are killed 
daily
686
, before viraemia decreases to a steady set point.  Although both the R5- 
and X4-tropic virus can be isolated initially
687 , 688
, the R5-using virus 
predominates in early infection, possibly due to higher transmittability
689
.  One of 
the six patients in this study was found to harbour the X4-tropic virus from early 
on.  This was particularly interesting, since individuals with the X4 virus normally 
progress more rapidly along their disease course, raising the possibility that X4-
tropic virus may be more resistant to the host immune response.  To address this 
hypothesis, the neutralisation sensitivity and viral diversity of X4 and R5 primary 
viruses were compared.  In terms of neutralising antibody response, we did not 
observe any particular difference between the X4 and the R5 viruses.  The X4 
virus displays similar sensitivity to neutralisation by NAbs and autologous and 
heterologous antisera as the R5 virus.   As far as we know, there is no published 
literature which compares the neutralisation sensitivity of early X4 and R5 
primary isolates, but some studies suggest that X4 variants, isolated from chronic 
infection, are more readily neutralised than the co-existing R5 variants
613,690,691
.  
Furthermore, we found that the X4-tropic virus appears to have less clonal 
diversity and evolves more slowly than the R5-tropic virus.  Early studies by 
Wodarz and Nowak suggested that the X4-tropic virus bears a higher fitness cost 
and undergoes stronger selective pressure than the R5-tropic virus
692 , 693
.  
Assuming this theory holds, it is not surprising that the early X4 virus in this study 
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is genetically less diverse than the R5 virus.  Because early X4-tropic virus is not 
identified frequently, it is difficult to conclude whether or not the observation 
from this single case is generally applicable.  However, since neutralising 
antibodies are not developed quickly post-infection, other immune control 
mechanisms, such as CD8
+
 CTLs, probably have greater contribution than the 
neutralising antibodies to the selective pressure and slower evolution rate of the 
X4 virus during early infection. 
 
Furthermore, while HIV-1 replicates rapidly and depletes a substantial number of 
CD4
+
 T-cells within the first two to three weeks of infection
694
, neutralising 
antibodies do not appear until six to twelve weeks post-infection
539,559
 , at which 
time a persistent and latent viral reservoir has already been established.  
Nevertheless, in order to establish a functional infection, the virus must first 
amplify locally (i.e. at the mucosal surface) before it can propagate into other 
tissues (i.e. lymphoid)
695
.  Thus, the presence of neutralising antibodies at an early 
stage can potentially prevent viral expansion and subsequent transmission.   
 
The development of neutralising antibodies in HIV-1 infected patients is not rare, 
and their antisera have been shown to display antiviral activities against 
autologous viruses, particularly the preceding ones
559,696,697
.  Some patients even 
have antisera with broadly neutralising antibodies, capable of inactivating 
heterologous or even cross-clade isolates
559,696,697
.  Two of the six patients in this 
study have detectable (IC90 < 1:50 serum dilution) neutralising antibody responses 
at baseline, at which their antisera neutralise both autologous and heterologous 
viruses isolated at the same point in time.  By week 52, antisera from all patients 
were capable of neutralising preceding (baseline) autologous and heterologous 
viruses.  However, viruses evolve rapidly to evade the host immune response, and 
the week 52 isolates become resistant to neutralisation by antisera taken 
concomitantly.  Virus mutations most likely occurred at the glycosylation level, 
since neutralisation assays with NAbs indicated that the primary isolates develop 
resistance to 2G12 (anti-carbohydrate antibody) but not to b12 or 2F5 (anti-gp120 
and anti-gp41, respectively).  The same observation was made in a clinical study 
where a combination of NAbs was passively administrated in patients and their 
viruses developed resistance only to 2G12 but not to other antibodies
389
.  This is 
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perhaps not surprising since a single change in the amino acid sequence is 
sufficient to alter the glycan shields and affect neutralisation sensitivity
662,663,664
.  
These observations suggest that antibodies targeting carbohydrate epitopes may 
be more effective in neutralising viruses than those targeting gp120 or gp41 in 
vivo.  Currently, one of the vaccine immunogen design approaches is to synthesise 
molecules with epitopes recognised by anti-carbohydrate neutralising 
antibodies
698
.  Thus, identification of an antiserum which is broadly neutralising 
can provide insights for designing immunogens which can elicit neutralising 
antibody response. 
 
Finally, this chapter examined the correlation between the initial viral load and 
viral diversity.  An early study by Mellors et al. (1996) shows that the viral load 
during PHI is a strong indicator of the rate of progression to AIDS
580
.  Two recent 
clinical studies also suggest that the baseline viral load, not the CD4
+
 T-cell count, 
can better predict disease progression in the long-term
699,700
.  On the other hand, 
viral diversity is also known to correlate with disease progression.  Patients with a 
heterogeneous population of virus quasispecies develop AIDS faster than those 
with a narrow range of virus diversity
701,702
.  Early studies on chronically infected 
patients (asymptomatic or not) show that an increased immune response is 
associated with a decreased viral load but an increase in viral diversity, likely due 
to stronger selective pressure
703,704
.  However, in this study where patients are still 
in their primary stage of infection, we found that individuals who have a 
detectable neutralising antibody response have lower baseline viral load as well as 
less viral diversity.  Given that most HIV-1 infection arises from a single 
virion
705
, it is not surprising that the virus population is largely homogenous 
during PHI
706 , 707
 and becomes increasingly diverse over time under selective 
pressure and spontaneous mutation driven by RT errors.   
 
Currently, the use of ART immediately following diagnosis is increasingly being 
recommended as the standard treatment protocol for its benefits in suppressing 
viraemia, preserving CD4
+
 T-cells and prolonging the progression time to 
AIDS
602,604,605
.  Although the effect of ART on viral diversity is less clear, some 
studies have suggested that early treatment with ART can lead to a less diverse 
virus population
708,709,710
.  However, since treatment will reduce viraemia and 
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viral diversity, there will also be a reduction in immunogenicity, in which case the 
production of neutralising antibodies may be impaired.  Hence, once the 
SPARTAC study is completed, it will be very important to compare the 
neutralising antibody responses and virus diversity of patients who received 
treatment versus those who did not.   
 
Finally, in chapter 5, the impact of Nef on virus sensitivity to neutralisation is 
examined.  The Nef protein provides multiple functions for HIV-1, two of which 
were to enhance infectivity and down-regulate the CD4 receptor.  In addition, 
animal studies have shown that vaccination with nef-deleted SIV can induce a 
strong antiviral antibody response
468,469,673,674,675
.  This evidence lead us to 
hypothesise that Nef can alter the envelope phenotype and consequently, the 
neutralisation sensitivity.  Indeed, our study found that HIV-1 is 4 to 13-fold more 
sensitive to neutralisation by NAbs in the absence of Nef.  Although a study by 
Schiavoni et al. (2004) also makes the same observation, the authors accredit the 
enhanced neutralisation sensitivity of the ΔNef virus as being the result of 
decreased envelope incorporation
633
, possibly due to the increased presence of 
internalised CD4.  However, the published data does not seem to support this 
interpretation, because the ΔNef virus sample contained not only less Env but also 
less Gag and IN.  Using the same virus strain, we did not observe any effect of 
Nef on envelope incorporation, regardless of the expression of CD4.   
 
So what causes the enhanced neutralisation sensitivity in the ΔNef virus?  For 
neutralisation to occur, every functional envelope trimer must be covered or 
detached by at least one neutralisation antibody molecule
658
.  The difference in 
neutralisation sensitivity suggests that there may be differential antibody binding 
to the WT and ΔNef viruses.  Indeed, an immunoprecipitation assay showed that 
NAbs are able to capture the ΔNef virus 3 to 6-fold more efficiently than the WT 
virus.  This unexpected finding is the first direct evidence that Nef can alter the 
envelope phenotype and influence on susceptibility to neutralisation.   
 
It has been shown that changes which locally alter or mask the gp120 binding 
epitopes have a global effect on the conformation or arrangement of the envelope 
trimer and, thereby, affecting the virus’ sensitivity to neutralisation711,712.  For 
instance, the removal of a single N-linked glycosylation site can make HIV-1 
170 
 
more sensitive to neutralisation against both 2F5 and b12
713
.  Based on this 
evidence, one logical explanation of the increased antibody binding to the ΔNef 
virus is that glycosylation may be altered in the absence of Nef.  However, 
glycomic analysis by mass spectrometry and enzyme digestion did not reveal any 
quantitative or qualitative differences in sugar moieties between the WT and ΔNef 
viruses, suggesting that the increased neutralisation sensitivity is caused by other 
biological reasons.  Since Nef is known to have an effect on intervirion fusion and 
membrane lipid composition
328,332
, both of which can affect neutralisation, it is 
possible that these two phenomena contribute to the enhanced neutralisation 
sensitivity observed in the ΔNef virus.  Nevertheless, since the absence of Nef can 
better enhance neutralising antibody response, it may be more beneficial that the 
vaccine immunogen excludes Nef in order to elicit a stronger humoral response.   
 
Since this study utilised a laboratory-adapted virus strain, it will be important to 
examine the effect of Nef on neutralisation on primary isolates in vivo.  It is well 
known that the neutralising antibody response decreases over time during chronic 
infection.  Simultaneously, nef alleles isolated from late stage HIV-1 patient are 
more active in down-regulating CD4 and show augmented infectivity and virus 
replication than early nef alleles
315
.  Whether or not the evolution of nef over time 
can impact on neutralisation and/or envelope phenotype is a subject which 
remains to be investigated.  Since patients from the SPARTAC trial are all 
recruited at PHI and subsequently observed, one interesting study to conduct will 
be to isolate the nef allele from these patients at baseline and compare their 
sensitivity to neutralisation at later points in time.   
 
In conclusion, the study has examined three novel aspects of neutralisation which 
are potentially relevant for vaccine development.  Although AIDS is one of the 
most challenging diseases ever faced by the scientific community, all the research 
conducted in the past 25 years has not only resulted in a better understanding of 
HIV, but also of host-virus interaction, eukaryotic RNA processing, and vaccine 
design, all of which can be applied to the study of other diseases.   
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